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 Introduction Chapter 1
Prion diseases, or transmissible spongiform encephalopathies (TSE), are a group of rare fatal 
neurodegenerative maladies that affect humans and animals1; 2. The fundamental breakthrough in 
TSE research was the discovery of the "prion" "proteinaceous infectious particle" and the 
verification of the “protein-only” hypothesis3, which states that prions could self-propagate by 
converting the cellular prion protein (PrPC) into the scrapie form, PrPSc (or prions), and lead to 
neurodegeneration without using any nucleic acids. The concept of prions may unify 
neurodegenerative diseases under a common pathogenic mechanism4. Indeed, growing evidence 
shows that TSE may share similar pathogenesis with common neurodegenerative syndromes such 
as Alzheimer’s disease and Parkinson’s disease5; 6; a, for which there are currently no cure. Similar to 
Alzheimer's and Parkinson's diseases, TSE share two remarkable characteristics with other 
neurodegenerative diseases4: i) more than 80% of the cases are sporadic; ii) the familial (inherited) 
types of these maladies are late-onset, although many of the disease-linked mutations are expressed 
in embryogenesis. Today, PrP is one of the most studied models for protein misfolding mechanism 
and TSE serve as an excellent model for studying many other neurodegenerative diseases. 
Understanding the molecular mechanism of the PrP misfolding process may profoundly influence 
the development of diagnostics and effective therapies for neurodegenerative diseases in general. 
Investigating human (Hu) PrP TSE-linked mutations (more than 50 currently identified 
mutations, linked to ~15% of the cases) may be very instrumental in this respect, as it can provide 
hints on the molecular basis of the PrPC#PrPSc conversion. These mutations cause spontaneous 
TSE, which are likely due to modifications in the native structure of PrPC. They are located all over 
the structure. Polymorphisms (i.e. non-pathogenic, naturally occurring mutations) in the PrP gene 
have been found to influence the etiology and neuropathology of the disease in both humans8 and 
sheep9. In transgenic (Tg) mice, artificial mutations can determine the susceptibility to the infection 
of different prion strains10; 11; 12. Intriguingly, mouse (Mo) PrPb containing artificial mutations 
(denoted MoPrP chimera, hereinafter) have very different effects in vitro13: some MoPrP chimera 
were found to resist PrPSc infection, whereas some others did not; some of the resistant MoPrP 
chimeras even exhibited a protective effect (known as the dominant-negative effect) over the co-
expressed endogenous wild-type (WT) MoPrPC. Most mutations are located in the folded globular 
                                                      
a The WHO estimated ca. 7.7 million new cases of Alzheimer’s disease in the year 2010 and increasing 
numbers in the next decades due to global aging7. The European Parkinson’s Disease Association (EPDA) 
estimated ca. 6.3 million people living with Parkinson’s disease in the year 2011 (www.epda.eu.com). 
b MoPrP shares over 90% sequence identity with HuPrP. 
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domain (GD) while fewer are located in the intrinsically disordered N-terminal domain (N-term) 
(Fig. 1.1). The N-term of PrPC has been suggested to serve multiple functions in vivo, which likely 
relies on the structural flexibility of this domain14. Therefore, characterizing the structural features 
of the N-term is central for investigating not only the mutations in this domain, but also the 
physiological role of the N-term.  
 
Figure 1.1: Schematic representation of PrPC structure and the distribution of the mutations and 
polymorphisms. The intrinsically disordered N-term (residues 23-124, in HuPrP numbering) is depicted in 
dashed lines. The folded GD (residues 125-230) is shown in cartoon representation, which contains two 
antiparallel !-strands (in yellow) and three $-helices (in purple). The two signal peptides (residues 1-22 and 
231-253) that are cleaved off during the PrPC biosynthesis are not shown.  
 
The Prion Biology Lab of Prof. Legname has solved the NMR structure of HuPrPC GD 
variants in solution15. The Lab showed, along with other NMR and X-ray studies16, that Hu TSE-
linked mutations could induce structural features in the protein distinct from those in the WT 
HuPrPC. These experimental methods are very powerful yet relatively slow. Hence, determining the 
structures of more than 30 variants represents a challenge. Recently, my colleague Giulia Rossetti 
(from Prof. Carloni's Lab), along with other researches16, has shown that molecular dynamics (MD) 
simulations could predict PrPC variant structures with high accuracy whilst requiring very short 
time17. Building on this work, in this thesis we first extended the computational protocol to studying 
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the impact of all the known Hu TSE-linked mutationsc in HuPrPC GD. We next applied the same 
approach to study the GD structure of MoPrP chimeras which contain one or two residues from Hu 
or sheep PrP sequence. By studying these PrP variants, we aim to identify the structural 
determinants of the mutants that may play a role in the PrPC!PrPSc conversion. Our calculations 
discovered that these mutants exhibit different structural features from those of the WT PrP GD 
mainly in two common regions that are likely the “hot spots” in the protein misfolding process. 
These features can be classified into different types that are correlated to the types of mutants (i.e. 
pathogenic, resistant or dominant-negative), thus hinting to the molecular mechanisms of PrPSc 
formation and propagation. 
These results, although very interesting, are limited to the PrP GD. Studying the structural 
determinants in the intrinsically disordered N-term is highly challenging and indeed structural 
information is available only for short fragments in this domain, which contain 10 to 20 residues14. 
Here we have predicted the structure of the entire PrP N-term and the impact of the Hu TSE-linked 
mutations in this domain using a novel Monte Carlo-based simulation approach, PROFASI18. 
PROFASI has already shown to provide structural predictions in a disordered protein such as $-
synuclein19. Our results are consistent with available experimental data and therefore firmly allow 





                                                      
c We did not study nonsense PMs that code for truncated HuPrP. PMs that were identified after we had carried 
out the study were not included. These are I138M, D167N, N173K, V176G, D202G, V203G, V209M, E211N 
and Q212H. 
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 The prion biology Chapter 2
2.1 Prion diseases  
Hu TSE are classified according to various phenotypes: i) sporadic (spontaneous) TSE, 
including sporadic Creutzfeldt-Jakob Disease (sCJD), sporadic familial insomnia (sFI); ii) familial 
(inherited) TSE, including familial Creutzfeldt-Jakob Disease (fCJD), fatal familial insomnia (FFI), 
Gerstmann-Sträussler-Scheinker Syndrome (GSS), prion protein cerebral amyloid angiopathy (PrP-
CAA); iii) transmitted (infected) TSE, including iatrogenic Creutzfeldt-Jakob Disease (iCJD), 
variant Creutzfeldt-Jakob Disease (vCJD) and Kuru20. There are still other phenotypes of human 
TSE which are yet unclassified. In recent history, human TSE have occurred in epidemic form due 
to endocannibalism in Papua New Guinea where tribes suffered from Kuru, which is the first TSE 
shown to be transmissible21. Major public health concerns were raised by the verification that vCJD 
was caused by the same prion strain as bovine spongiform encephalopathies (BSE)22; 23 which 
infected more than 2 million UK cattle in the epizootic of the 1990s. 
2.1.1 The mysterious “toxic PrP species” 
Although the conversion of PrPC to PrPSc is clearly central to pathogenesis, the neurotoxicity 
does not correlate with PrPSc levels in the brain24; 25; 26. Moreover, the distribution of PrPSc deposits 
does not necessarily reflect the clinical signs, and PrPSc is not directly toxic to neurons, which do 
not express PrPC27; 28; 29; 30. These lines of evidence argue that the infectious PrPSc is not directly 
neurotoxic, but rather its propagation produces toxic PrP species31. The fact that GPI-anchored PrPC 
is required for neurodegeneration29; 32; 33 suggests that PrPC acts as a receptor for PrPSc and mediates 
toxic signaling34. This is further supported by a recent study35 describing two distinct phases of PrPSc 
propagation during the incubation period in mice infected with PrPSc: phase 1 where PrPSc 
propagates exponentially; and phase 2 where PrPSc remains at a plateau level until the onset of 
clinical disease. Interestingly, the propagation rate in phase 1 is not proportional to the expression 
level of PrPC, whereas the length of phase 2 is inversely proportional to PrPC expression level. 
Moreover, the PrPSc titer attained in the brain during phases 1 and 2 is independent of PrPC 
expression level. All these studies clearly demonstrate that PrPSc infectivity and propagation are 
uncoupled from the neurotoxicity in prion diseases. More and more evidence suggests that the 
neurotoxic species consist of small oligomeric forms of PrP which are off-pathway for PrPSc 
propagation, while the toxic signaling is mediated by PrPC and likely its interaction with cellular 
partners36. 
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2.2 PrPC structure and function 
2.2.1 PrP biosynthesis and trafficking 
PrP is highly conserved across mammalian species37. In fact, most in vivo and in vitro studies 
are made with mouse (Mo) and Syrian hamster (SHa) PrP, which have over 90% sequence identity 
with human (Hu) PrP (Fig. 2.1A). In this thesis the term “PrP” generally refers to mammalian PrP 
unless otherwise stated (and same for PrPC, PrPSc, etc.). The Hu prion gene PRNP encodes a 253-
residue precursor HuPrP including a 22-residue signal peptide at the N-terminus and a 23-residue 
signal peptide at the C-terminus (reviewed in ref. 38; 39; 40). The precursor HuPrP is first imported into 
the endoplasmic reticulum (ER) where the signal peptides are cleaved and the protein is 
glycosylated, modified by a C-terminal glycosylphosphatidyl inositol (GPI) anchor and properly 
folded. The protein subsequently transits in the Golgi where additional modifications are made to its 
glycans and GPI anchor before being exported to the cell surface38. The mature form of HuPrPC is a 
208-residue N-glycosylated protein attached to the cell surface by the GPI anchor (Fig. 2.1B)41.  
During co-translational translocation at the ER, four topological forms of PrP can be 
generated (Fig. 2.1C)38; 42. Most PrP nascent chains pass completely through the translocon to 
generate secretory PrP (SecPrP) and follow the traditional exocytic pathway towards the cell-
surface38. Two transmembrane forms, however, span the ER membrane lipid bilayer by a 
hydrophobic transmembrane region (TM1, residue ~113-135 d ). One form (denoted NtmPrP) 
integrates into the lipid bilayer with the N-terminus in the ER lumen and the C-terminus retained in 
the cytosol, whereas the other form (CtmPrP) integrates in the opposite orientation43. A fourth form 
fails to engage the translocon and is released in the cytosol to generate cytosolic PrP (cyPrP)44; 45 46. 
An increased production of the atypical forms, NtmPrP, CtmPrP and cyPrP, can be detrimental in vivo43; 
47; 48. CtmPrP is found in abnormally high level in the brain tissue from GSS patients carrying the 
pathogenic mutation A117V43. Expressing the equivalent mutation in Tg mice leads to increased 
CtmPrP (5–20% of total PrP, compared with ~1% in wild-type mice) and neurodegeneration47. 
Expression of artificial MpPrP mutants that generate cyPrP can cause neurodegenerative disease in 
Tg mice48. The abnormal translocation of PrP has been proposed as one of the potential toxic 
mechanisms in vitro and in vivo49; 50; 51. The translocation process is suggested to be regulated by the 
TM1 region and a preceding hydrophilic “stop transfer effector” region (STE, residue 103-111)52; 53. 
TM1 and STE act in concert to control the recognition, orientation, and integration at the translocon 
during PrP biosynthesis38; 42; 52, which interacts not only with the ER membrane but also trans-acting 
                                                      
d The residue numbers refer to HuPrP in Uniprot database (www.uniprot.org, entry ID P04156) and hereafter, 
unless otherwise stated. 
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factors in the ER membrane52 and in the cytosol54. The molecular mechanism of abnormal PrP 
topology and the related neurotoxic pathway are still elusive. 
 
Figure 2.1: A) Sequence alignment of Hu, Mo and SHa PrP excluding their signal peptides. The three 
proteins differ in 25 residues (shadowed in orange). Residues in the OR, STE and TM1 are colored in blue, 
green and red, respectively. Binding sites in MoPrPC identified for vitronectin and STI1 are underlined in 
black and blue, respectively. B) PrPC is a N-glycosylated protein attached to the cell surface by the GPI 
anchor. C) Four topology forms of PrP: SecPrP, NtmPrP, CtmPrP and cyPrP. D) Molecular structure of HuPrPC. 
The folded GD structure resolved by solution-NMR55 is shown in cartoon, while the disordered N-term and 3 
C-terminal residues are sketched in dashed lines. The two signal peptides are now shown. E) Putative “inter-
repeat” Cu2+ binding mode in the HuPrPC OR region. 
2.2.2 Mammalian PrPC structure and functional domains 
Solution-NMR studies have resolved the molecular structure of HuPrPC55; 56, MoPrPC57; 58, 
SHaPrPC59, and PrPC of many other mammalian species such as sheep (Ov)60, bovine (Bo)61; 62, etc. 
These structures have closely similar folds in the C-terminal globular domain (GD, residues 125-
230), which contains a bundle of three !-helices and two short antiparallel !-strands (Fig. 2.1D). A 
disulfide bridge between !2 and !3 helices stabilizes the GD. The NMR studies also found that the 
N-terminal domain of PrPC (N-term, residue 23-124) is largely unstructured and flexible in all these 
species.  
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PrPC is highly abundant in the developing and mature nervous system where it is expressed 
by neuronal and glial cells20. After intensive studies over the years, the physiological function of 
PrPC is still surrounded by uncertainties. As thoroughly reviewed by Aguzzi20, in vivo and in vitro 
experiments have suggested a range of possible neuroprotective functions of PrPC, such as 
antiapoptotic or antioxidative effects, neurotransmitter release in synapses, mediation of neurite 
outgrowth and survival, maintenance of the white matter, as well as functions in cell adhesion. 
Correspondingly, PrPC is hypothesized to perform its functions through interactions with its cellular 
partners. Experiments using Hu, Mo, SHa or Bo PrPC and different methods such as yeast-two 
hybrid, coimmunoprecipitations and chemical cross-linking have proposed a large number of 
interaction partners which include proteins, metal ions, membrane, lipids, nucleic acids and small 
molecules20. Many of these partners are suggested to interact with the intrinsic disordered N-term14, 
which is therefore believed to be a broad-spectrum molecular sensor which endows PrPC with 
multiple functions14.  
Chemicals which have been established to interact with PrPC N-term in vivo include 
sulphated glycosaminoglycans (GAG)63 and Cu2+ ionse; 34; 42. Sulphated GAG is detected in PrPSc 
plaques in Hu and SHa brains infected by GSS or CJD63. Solution-NMR demonstrates that herapin, 
a sulphated GAG, binds to SHaPrPC N-term at residues K23, K24, K27, K101, and histidine 
residues in the so-called octapeptide-repeat region (OR region, residues 51-90, Fig. 1B)70. Cu2+ ions, 
whose concentration in the synaptic cleft may be as high as 100-250 µM71, bind to Hu/Mo/SHa PrPC 
in vivo72; 73; 74; 75. Remarkable decreases of Cu2+ are observed in the post mortem brains of patients 
affected by TSE72 or in brains of scrapie-infected mice73; 76. Copper-poor diets were found to reduce 
the survival time of scrapie-infected mice significantly, whereas enhanced administration of copper 
significantly delayed prion disease onset76. Alterations of the Cu2+-PrPC binding process has been 
suggested to play a role in PrPC aggregation77; 78, antioxidant activity regulation73; 79; 80 and synaptic 
function81; 82, affecting PrPSc formation, amplification and the disease onset75; 77; 78; 83; 84; 85; 86; 87. On the 
other hand, it may affect cellular copper uptake and trafficking82; 88. As many as six equivalent Cu2+ 
                                                      
e Other metal ions such as Zn2+ have also been associated with Hu/Mo/SHa PrPC 64, but their relevance in vivo 
has not been firmly established. Among these, Zn2+ shows the next highest affinity for HuPrPC 65. Zn2+ ions 
bind exclusively in the OR region in the inter-repeat mode with a much lower affinity (~200 µM) than Cu2+ 66. 
The weak Zn2+ binding could still be relevant in vivo because of the high concentration of zinc in the brain 
which reaches up to 300 µM at peak levels in the synaptic cleft of glutaminergic neurons 67. Cu2+ and Zn2+ 
distribution in Mo brain is dependent on MoPrPC expression levels 68. At low Cu2+ availability, Zn2+ is able to 
modify the Cu2+ distribution among the possible Cu2+ binding modes in SHaPrPC66. On the other hand, Zn2+ is 
shown in vitro to drive the N-term of MoPrPC to interact with GD69. 
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ions can bind in PrPC N-term at physiological pH89, in the presence or absence of the GD90; f. Four of 
these binding sites are in the OR region, each containing an HGGGW motif centered at the histidine 
residue (either H60, H68, H76 or H84)95. At low Cu2+ availability, however, these four histidines 
may cooperate to bind one Cu2+ ion in a so-called “inter-repeat” binding mode (Fig. 2.1E) with Kd in 
nanomolar range (several-magnitude lower than that of a single repeat)89. The other two binding 
sites are located at residues H96 and H111 with the affinity comparable to the inter-repeat binding 
mode89. The metal coordination at H96 and H111 is highly debated, as it appears to depend on the 
length and sequence of the PrP fragments used and on the buffer and pH89; 90; 94; 96; 97; 98; 99; 100; 101. A 
recent study from our group found that these two binding sites could also cooperate to bind one 
Cu2+ ion102. Interestingly, this study also shows that a pathogenic mutation Q212P in HuPrPC GD 
could influence the Cu2+ coordination at the H96 and H111 binding sites102, implicating a role of 
abnormal Cu2+ binding in the pathology of familial Hu TSE.  
MoPrPC N-term, which has 93% sequence identical to HuPrPC N-term (Fig. 2.1A) binds to a 
variety of proteins14. Its protein partners are assumed to bind also to HuPrPC N-term14. These 
proteins include (i) vitronectin103, a secreted extracellular glycoprotein, possibly supporting axonal 
growth104. Vitronectin interacts with MoPrPC residues 104–118 (in Mo numbering, Fig. 2.1) with an 
estimated Kd of 12 nM104. (ii) The stress-inducible protein 1 (STI1)105, a secreted heat-shock protein, 
triggering neuroprotection105. STI1 binds at MoPrPC residues 114–127 (Fig. 2.1A) with an estimated 
Kd of 140 nM105. (iii) The Amyloid beta (A!) multimers that are related to Alzheimer’s diseases106; 
107; 108. A! multimers have been suggested to bind residues 95-110 of MoPrPC N-term106; 107; 108. (iv) 
The lipoprotein receptor-related protein 1 (LRP1), a transmembrane protein, which is associated 
with a clathrin-dependent internalization mechanism109. LRP1 binds to MoPrPC N-term with 
nanomolar affinity109. (v) The neural cell adhesion molecule (NCAM)110. The binding may play a 
role in the cell adhesion process. NCAM binds to both N-term and GD of MoPrPC32. The MoPrPC 
binding sites for LRP1 and NCAM have not been precisely determined14.  
Despite the enormous investigations that have provided knowledge in PrPC function and 
functional domains, the lack of structural information on the N-term has long hampered progress 
towards a full comprehension. 
                                                      
f Few studies suggest that Cu2+ can bind also to PrPC GD91; 92, for which the binding affinity is estimated to be 
~8 µM using an N-terminal truncated murine MoPrP(121-231). However, the full-length MoPrP(23-231) is 
almost saturated at 5 µM Cu2+ concentration under the same experimental conditions. The Cu2+ binding at GD 
(above 5 equivalent Cu2+) is considered to be hardly physiologically relevant 93; 94, thus it is not discussed here. 
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2.3 PrPSc strains and infectivity 
2.3.1 PrPSc strains  
The PrPC!PrPSc conversion is the result of a post-translational process whereby most !-
helical motifs in PrPC are replaced by "-structures27; 111. To date, the molecular structure of PrPSc is 
unknown112. Several structural models have been proposed (Fig. 2.2) based on MD simulations113 or 
low-resolution biophysical techniques such as X-ray fiber diffraction114, electron microscopy 
(EM)115 and Hydrogen-deuterium exchange mass spectroscopy (HX-MS)116. In fact, PrPSc exist in 
different conformations related to multiple PrPSc strains that are distinct in many aspects117; 118. In 
vivo, different strains are distinguished by differential incubation periods and distinct patterns of 
pathological phenotypes119; 120; 121. In vitro, they demonstrate distinct biochemical features, as 
distinguished by proteinase K digestion, glycosylation pattern, thermal or chemical denaturation, 
conformation-dependent immunoassay, infrared spectroscopy and metal binding122; 123; 124; 125. Indeed, 
these features are strain-specific because they are maintained when a strain passes across several 
mammalian species including humans, such as in the case of BSE strain120. Similarly, when Tg mice 
expressing a chimeric Mo/Hu hybrid PrP (denoted Mo/HuPrP chimera) are inoculated with different 
HuPrPSc strains, the biological features of each specific strain are preserved126. These findings along 
with other lines of experimental data strongly suggest that PrPSc strains derive from the capacity of 
PrPSc to adopt different conformational and aggregation states117; 118. 
 
Figure 2.2: The conformational conversion from PrPC to three proposed models of PrPSc: A) the "-helical 
model115, B) the "-spiral model113 and C) the parallel in-register extended "-sheet model116. This figure is 
adapted from ref. 112.  
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2.3.2 The “species barrier” and the “dominant-negative” effect 
Although PrP is highly conserved in mammalian species, transmission of TSE across species 
is typically far less efficient than within species127. This is known as the “species barrier”, which 
was presumed to arise from differences in the primary sequence across species. This issue has 
received wide attention since the discovery that vCJD in humans was caused by the BSE strain in 
cattle22; 23. This strain is able to transmit efficiently to a range of species while maintaining its 
biological features128. Another striking example of the prion transmission across species came from 
several studies using Tg mice expressing chimeric Mo/HuPrP10; 11; 12; 129. Expressing HuPrPC in Tg 
mice did not abbreviate the incubation time upon infection with HuPrPSc, indicating that these Tg 
mice are not more susceptible to HuPrPSc than the WT mice129. By contrast, in the same study Tg 
mice expressing a Mo/HuPrP chimera were found highly susceptible to HuPrPSc. Tg mice 
expressing MoPrP chimeras containing mutations from other species have been reported to exhibit 
both transmission barriers against certain prion strains10 and spontaneous conversion into prions11; 12. 
Investigation in Mo neuroblastoma (ScN2a) cells showed that upon MoPrPSc infection the “species 
barrier” could be raised by single-residue substitutions in MoPrP with Hu or Ov residues 13. More 
intriguingly, some of these MoPrP chimeras also acted as the so-called “dominant-negatives”g to 
protect the endogenous WT MoPrPC from being converted to MoPrPSc.  
These facts argue that the transmission barrier across species is not correlated to the 
differences in the primary sequence. In the late 1990s, Collinge already commented that “species-
strain barrier” or “transmission barrier” might be more appropriate than “species barrier” for 
describing the effects134. Accumulating experimental observations suggest that the “species barrier” 
is a conformational barrier related to distinct PrPSc conformations31; 117. Therefore, PrPSc strains and 
transmission barrier are different observations of the same origin31. Then how can one or few 
residue substitutions such as in the case of MoPrP chimeras determine the susceptibility of the host 
to a same PrPSc strain?  
It has been proposed that the loop between the "2 strand and the !2 helix in PrPC (denoted 
"2-!2 loop, residue 165-175, Fig. 2.1 and 1-2C) mediates the transmission barrier. This was first 
supported by solution-NMR studies which found that this loop could be highly flexible in some 
mammalian species including Hu55; 56 and Mo57; 58 or well structured in some other species such as 
                                                      
g The dominant-negative effects of residue substitutions on PrPC have been reported and deeply investigated 
in humans and in sheep. In humans, the naturally occurring polymorphism E219K was found to protect 
against sCJD when expressed in heterozygosis130; 131. In Ov, three polymorphisms are acutely linked to the 
occurrence of Ov scrapie: A136V, R154H and Q171R/H. These generate five commonly observed alleles: 
ARQ, ARR, AHQ, ARH and VRQ. ARR and AHQ are associated with resistance to Ov scrapie, while ARQ, 
ARH and VRQ are associated with susceptibility132; 133. 
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SHa135, elk136, bank vole137, wallaby138, rabbit139 and horse140. Moreover, the C-terminal part of !3 
helix (residue 215-228) might modulate the "2-!2 loop conformation by long-range interactions138. 
Single-residue substitutions within these two regions of MoPrPC could cause the otherwise flexible 
"2-!2 loop to adopt rigid structures137; 138; 141. Remarkably, Tg mice denoted tg1020 which 
overexpress MoPrP containing two of these substitutions, S170N and N174T, developed 
spontaneous and progressive prion-like disease11. This de novo generated disease in tg1020 mice 
could be transmitted to Tg mice overexpressing WT MoPrP and then to WT mice in a second 
passage. By contrast, tg1020 mice exhibited a very prolonged incubation time when infected with 
WT MoPrPSc strain, RML11, arguing that the artificial mutations generated transmission barrier for 
the RML strain. Later studies where the tg1020 mice were challenged with PrPSc from five different 
species (Mo, SHa, Bo, Ov and deer) demonstrated altered transmission barriers compared to Tg 
mice overexpressing WT MoPrP10; 142. These in vivo studies further support the hypothesis that the 
"2-!2 loop is involved in the conformational selection for PrPSc strains. 
The finding that expressing HuPrP does not render Tg mice more susceptible to HuPrPSc 129 
suggests that other factors might be involved in the PrPC!PrPSc conversion. To explain this 
phenomenon, the concept of “protein X”, an unknown factor that mediates the PrPC!PrPSc 
conversion, was proposed. Although many interaction factors have been suggested for PrPSc, the 
existence of protein X has never been proved20. Nevertheless, more and more evidence indicates 
that PrPSc does not replicate by directly imposing its structure onto PrPC36. More future researches 
are required to reveal the complicated picture of PrPSc propagation.  
2.4 Mutations and polymorphism in the human PRNP gene 
The familial types of Hu TSE (including fCJD, GSS, FFI and PrP-CAA) account for about 
15% of the cases, which are caused by pathogenic mutations (PMs) in the PRNP gene15; 143 (Fig. 
2.3).  
Most of the currently identified PMs are missense mutations coding for a single-residue 
substitution. As many as 33 missense PMs are located in HuPrPC GD. In vitro, they may accelerate 
the protein misfolding process144; 145; 146. Regarding the structural role of these PMs, NMR147; 148; 149 
and MD16; 17; 150; 151; 152 studies on HuPrPC or MoPrPC have revealed that PMs affect secondary 
structure elements of the GD and render the GD more flexible than that in the WT. This increases 
the propensity of the protein for misfolding, consistent with experimental evidence145; 146; 153. Seven 
missense PMs are instead located in the N-term of HuPrPC: Q42P is likely associated with fCJD154; 
G114V is reported with both fCJD- and GSS-like phenotypes155; 156, whereas P102Lh, P105L/S/T, 
                                                      
h The correspondent mutation of P102L in MoPrPC alters the incubation time in transgenic mice upon 
infection by PrPSc from Hu, SHa, Ov or murine sources in a strain-dependent manner157; 158. 
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and A117V are associated with GSS159. They cause the disease without affecting the kinetics of the 
HuPrPC!HuPrPSc conversion in vitro145; 146; 160. This hints at the presence of processes in vivo that 
lead these mutations indirectly to the formation of HuPrPSc, the hallmark of Hu TSE. However, 
structural information on the effects of these mutations is currently lacking. GSS patients carrying 
A117V have an abnormally high level of CtmPrP in the brain43. P102L and G114V have also been 
shown to increase the formation of CtmPrP in vitro161; 162. As mentioned in section 1.2, HuPrPC N-
term on the one hand contains the TM1 and STE regions, which regulate the protein topology; on 
the other hand it interacts with a broad range of cellular partners such as Cu2+, sulphated GAG and 
likely several protein partners. Therefore, the PMs in HuPrPC N-term might affect the protein 
topology and/or alter the interaction with cellular partners, thus affecting the protein function. 
Another 3 missense PMs located in the C-terminal signal peptide are not discussed here, since the 
signal peptide is cleaved off during HuPrPC biosynthesis.  
Five PMs are nonsense mutations, Y145stop, Q160stop, Y163stop, Y225stop and Y226stop, 
which code to prematurely terminate the protein sequence at the mutation position163; 164. Although 
these PMs are rare, they all cause peculiar vascular amyloid fibril deposits generally defined 
cerebral amyloid angiopathy (CAA) that also occurs in other neurodegenerative disorders including 
Alzheimer’s disease164.  
In the OR region, from one to nine OR insertions have been reported. Most of the OR 
insertions lead to fCJD, except for an 8-OR insertion whose phenotype is unclassified. A 2-OR 
deletion in this region might cause fCJD165, albeit OR deletions are not yet firmly associated to Hu 
TSE.  
A methionine/valine polymorphism at codon 129 (129M/V) appears to influence Hu TSE 
phenotype when coupled with certain PMs, although the polymorphism itself does not promote the 
disease159. Another polymorphism, E219K, present in ~6% of the Japanese population appears to be 
protective against sCJD131. A polymorphism at codon 127 (G127V) reported only in the natives of 
Papua New Guinea is protective against Kuru166. Other mutations have been reported in PRNP that 




Figure 2.3: Polymorphism and pathogenic mutations in Hu PRNP gene. Mutations associated with fCJD, 
GSS, FFI and PrP-CAA are colored in blue, red, green, and black (italic), respectively. Polymorphisms are 
underlined. Mutations with unclassified disease phenotypes are colored in gray.  
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 Materials and methods Chapter 3
3.1 Molecular simulation of proteins 
Proteins are central to the health and function of cellular life. These complex macromolecules 
serve a fascinating variety of functions, which lie in their diverse molecular structures. Researchers 
have sought to uncover the structure–function relationships of proteins at atomic level using 
techniques such as high-resolution X-ray crystallography and NMR spectroscopy. Nevertheless, 
proteins are characterized by their dynamic features rather than static structures167. A large part of 
the properties of a protein or a biomolecular system is beyond the access of experimental 
measurements that in general correspond to averages of a quantity over space and time. Moreover, a 
rapidly increasing number of proteins are being identified as (at least partially) “intrinsically 
disordered”, which lack stable tertiary structures in vitro168. These intrinsically disordered proteins 
perform essential functions by virtue of their flexibility168. However, they represent a major 
challenge to structural biology. The science and art of molecular simulations has revolutionized the 
understanding in protein dynamics and function. Through model building and computation, 
molecular simulations have brought to reality the dream to 'watch' proteins in action at atomic 
resolution169. On the one hand, computer simulations can determine not only averages but also 
distributions and often time series of any definable quantity. Thus, they represent an indispensable 
tool to interpret experimental data by providing insights into the experimental observations. On the 
other hand, computer simulations are widely used to predict protein structures and properties that 
are difficult or expensive to realize under environmental conditions.  
Protein simulations encompass ab initio and semi-empirical quantum mechanics, empirical 
molecular mechanics (MM) and many other established procedures and methods. Here, only all-
atom MM simulations will be described, which are the methods employed in this thesis. The term 
MM refers to the use of classical potential energy functions (e.g., harmonic oscillator or Coulombic 
potentials) to model molecular systems170. The potential energy of a system in MM is calculated 
using force fields. In all-atom MM methods, the system typically consists of spherical atoms each 
assigned with a radius (usually the van der Waals radius), polarizability, and a constant net charge. 
The bonded interactions are represented by springs connecting the atoms, and the non-bonded 
atoms might be treated as inelastic hard spheres or may interact according to a Lennard-Jones 
potential. Each force field is parameterized to be internally consistent, typically through agreement 
with some experimental values and theoretically calculated results. MM approaches are widely 
applied in molecular dynamics simulations, Monte Carlo simulations, and ligand-docking 
simulations.  
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The development of protein simulation has been continuously driven by the steady growth of 
computing power as well as the advancement in force fields, algorithms and experimental 
techniques171. Protein modeling and simulation has expanded in both quality and scope, albeit 
caveats and inherent approximations are clearly recognized in the field169. Today, protein 
simulations are capable of handling more and more complex biomolecular systems and achieving 
profound comprehension of intriguing questions in biological systems. These questions range from 
resolving the equilibrium structure of a small peptide to the kinetics of protein folding and the 
functioning of a supramolecular aggregate; from the energetics of hydrogen-bond formation in 
proteins to the binding affinities of ligands/drugs to their target. Combined with constantly evolving 
experimental techniques, computer simulations are indispensable tools to pursue many fundamental 
questions concerning the biological motions and functions of complex systems such as enzyme-
substrate complexes, ion channels, transmembrane receptors and ribosomes169.  
3.2 Classical molecular dynamics simulation 
3.2.1 Introduction 
In statistical mechanics, experimental observables are described in terms of ensemblei 
averages taken over a large number of microscopic states of the system considered simultaneously. 
Molecular dynamics (MD) simulations generate a sequence of microscopic states of the system in 
phase space as a function of time. These states correspond to different configurations belonging to 
the same ensemble and satisfy the conditions of a particular thermodynamic state. MD simulations, 
in the most widely used versions, determine the trajectories of atoms and molecules by numerically 
solving the Newton's equations of motion for a system of N interacting particles. Internal forces 
between the particles and potential energy of the system are defined by force fields. The results of 
MD simulations can be used to quantify macroscopic thermodynamic properties of the system 
assuming the ergodic hypothesis is valid for it: if the system is allowed to evolve in time 
indefinitely, it will eventually pass through all possible states and the time averages of the system 
are equal to the statistical ensemble averages. An ensemble average is given by 
A ensemble = dpN drNA pN ,rN( )! pN ,rN( )"" ,  (3.1) 
where A pN , rN( ) is the observable of interest, and is expressed as a function of the momenta, 
pN = p1, p2,...pN( ) , and the positions, rN = r1, r2,...rN( ) , of the N particles. Consider a canonical 
ensemble that describes the statistical distribution in a system that can exchange energy via very 
weak contact with a temperature bath and eventually come to equilibrium. It is generally the most 
                                                      
i An ensemble is a collection of different microscopic states of a system with the probability distribution that 
corresponds to the macroscopic properties of the system. 
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useful ensemble in practice since we most often deal with systems in thermal equilibrium (constant 
T) with their surroundings. The probability density of the canonical ensemble is given by 
! pN , rN( ) = 1Z exp !H p
N , rN( ) kBT"# $%,  (3.2) 
where H is the Hamiltonian, T is the temperature, kB is Boltzmann’s constant and Z is the partition 
function 
Z = dpN drN exp !H pN , rN( ) kBT"# $%&& ,  (3.3) 
where the integral is generally very difficult to calculate because all possible microstates of the 
system must be considered. Alternatively in MD simulations, the microstates in the ensemble are 
calculated sequentially in time, which gives the time average of the observable A: 
A time = lim!"+#
1
!









& ,  (3.4) 
where ! is the simulation time, M is the number of frames in the simulation and A pN , rN( )  is the 
instantaneous value of A. The right-end side of Eq. (3.4) accurately approximates the ensemble 
average only if MD simulations sample a sufficient amount of phase space (and this has to be done 
using a feasible amount of computer resources), i.e. the ergodicity is satisfied. 
MD simulations have the peerless advantage (with respect to other sampling methods like the 
Monte Carlo method) that they can thoroughly describe protein dynamics167. Provided a high-
resolution structure as a starting point, the precise position of each atom at any instant of time can 
be followed, along with the corresponding energies. It can describe the motions of individual 
particles as a function of time and disentangle the correlations between motions, which are obscured 
in ensemble-average experiments. MD simulations provide fine details of a system at a precision 
and on a time scale that are otherwise inaccessible167. They serve to extend our understanding of the 
modeled systems and inspire new experiments. Since the first simulation of a protein in 
1976172, MD simulations, along with a range of complementary computational approaches, have 
become valuable tools for solving the puzzle of protein structures and functions170. They are widely 
applied to various studies such as molecular design, structure determination and refinement, protein 
folding, investigation in molecular stability, conformational and allosteric properties, molecular 
recognition and the properties of complexes169. The last few years have seen challenging 
applications of MD simulations such as those involving complex systems like membrane-embedded 
receptors in dimer bound with ligand173, and those that extensively probe into protein folding 
process at microsecond scale174. 
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3.2.2 Force fields  
An MD simulation consists of the numerical, step-by-step solution of the Newton’s equations 
of motion 
mi!!ri = Fi ,  (3.5) 
where Fi is the force exerted on particle i, mi and ri are the mass and coordinate of atom i, 
respectively. The force acting on atom i can be expressed as the derivative of the potential energy U 




U.  (3.6) 





.  (3.7) 
The core of any force field is the functional form of U with respect to the coordinates, rN. The 
combination of the potential energy function with the parameters used in that function constitute a 
force field. Biomolecular systems are commonly well described by empirical force fields175 using an 
additive potential energy function formed by a collection of simple functions that represent the 
intramolecular and intermolecular interactions: 
U rN( ) =Ubonded rN( )+Unon-bonded rN( ),
Ubonded rN( ) = Kb b! b0( )
2
bonds
" + K! ! !!0( )
2
angles
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In the bonded terms, bonds, angles and out-of-plane distortions (improper dihedral angles) are 
treated harmonically, and dihedral rotations are described by a sinusoidal term. The non-bonded 
interactions include a Lennard-Jones (LJ) 6-12 potential, that is typically used to describe the atom-
atom van der Waals (vdW) interactions, and a Coulomb potential, which describes electrostatic 
interactions. In Eq. (3.8), b is the bond length, " is the valence angle, # is the dihedral angle, $ is 
the improper angle, and rij is the distance between atoms i and j. The parameters in Eq. (3.8) 
represent the actual force field. Parameters in the bonded terms include: the bond force constant and 
equilibrium distance, Kb and b0, respectively; the valence angle force constant and equilibrium 
angle, K", and "0, respectively; the dihedral force constant, multiplicity and phase angle, K%, n, and 
&, respectively; and the improper force constant and equilibrium improper angle, Kimp and $0, 
respectively. Parameters in the non-bonded interactions between atoms i and j include: the LJ well 
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depth, 'ij, and the minimum interaction radius, Rminij , which are used to treat the vdW repulsion and 
dispersion interactions; and the partial atomic charges, qi, qj, and the dielectric constant, ', which 
are used in the Coulomb term. Typically, 'i and Rmini  are obtained for individual atom types and 
then combined to yield 'ij and Rminij . The terms in Eq. (3.8) are common to the majority of 
biomolecular force fields, such as the widely used all-atom protein force fields AMBER176, 
CHARMM177 and OPLS178. In fact, this simple form for the potential energy function is good 
enough to allow for studies on systems of 100,000 or more atoms with the current computational 
capabilities.  
The potential energy function along with the parameters allow for the energies and forces of 
the selected molecules to be evaluated. The approaches employed to calculate the parameters of the 
force fields ultimately determine their applicability and quality. For a variety of force fields the 
parameter optimization is based on fitting and comparisons with quantum mechanical results for 
model compounds representative of the biomolecules of interest. For example, the alanine dipeptide 
is the quintessential model for optimization of the protein backbone parameters, often being 
supplemented with data from the glycine and proline dipeptides (Fig. 2.1), as these represent the 
amino acids in which the covalent structure of the backbone differs from the remaining 18 natural 
amino acids.  
Additional adjustment or alternate terms beyond Eq. (3.8) are often introduced to yield higher 
accuracy, such as higher order terms to treat the bond and angle terms and/or cross terms between 
bonds and angles or angles and dihedrals175. 
 
Figure 2.1: A) Alanine, B) proline, and C) glycine dipeptides often used for parameter development of 
protein backbone. Shown in the figures are the !, ( dihedral angles that define the Ramachandran plot179. 
3.2.3 The integration algorithms 













Among the many possible methods to perform step-by-step numerical integration of these 
equations, the favorable ones should take into account the following characteristics: i) there may be 
short and long timescales, and the algorithm must cope with both; ii) calculating the forces typically 
involves a sum over pairs of atoms, which is computationally intensive and should be performed as 
infrequently as possible; and iii) the trajectory of coordinates should stay on the constant-energy 
hypersurface over long timescales (much longer than typical correlation times of the dynamical 
properties of interest), in order to sample the correct ensemble. Consistent with these features, the 
most common simulation algorithms are of low order, i.e. without involving high-order derivatives 
of positions, which are faster and allow larger time steps without jeopardizing energy conservation. 
In particular, the old Verlet algorithm180, which requires only one evaluation of the forces at each 
time step, fulfills all these requirements and due to its simplicity is one of the most employed 
nowadays. The Verlet algorithm exists in various, essentially equivalent versions. The leapfrog181 
version of the Verlet algorithm is described below, which is the default algorithm in the Gromacs 4 
simulation package182 used in this thesis. Leapfrog uses positions ri at time t and velocities v at time 
t-#)t, and updates r and v using the forces F(t) determined by ri at time t: 













































It produces trajectories that are identical to the original Verlet algorithm180: 
ri t +!t( ) = 2ri t( )" ri t "!t( )+
1
m
F t( )!t 2 +O !t 4( ).  
  
(3.12) 
Therefore, the leapfrog algorithm is (locally) a third order method and it is time-reversible. The 
advantage of leapfrog with respect to the original Verlet algorithm is that the velocities are 
calculated explicitly. The disadvantage is that velocities are not calculated at the same time as 
positions, therefore it cannot calculate kinetic energy contribution to the total energy at the same 
time as the positions are defined. The equations of motion are modified for temperature coupling 
and pressure coupling, and extended to include the conservation of constraints, all of which will be 
described in later sections.  
3.2.4 Periodic boundary conditions and neighbor list 
Biomolecular MD simulations are typically performed in small-sized systems, which means 
that atoms on the outer surface can have large artificial effects on the measured properties. Periodic 
boundary conditions (PBC) are usually employed to eliminate the surface effects, unless the 
behaviors near the surface are of particular interest. In PBC, a so-called “primary box” is generated 
 30 
which contains the molecules of interest and the bulk material. The primary box is replicated 
infinitely in all directions to give a periodic array. Thus the primary box is surrounded by images of 
itself with the same size, shape and content (Fig. 2.2A). The shape of the boxes is space-filling and 
all the boxes are separated by open boundaries so that particles can freely enter or leave any box. In 
the course of the simulation, if atoms leave the box, their images simultaneously enter the box 
through the opposite side. PBC enables a simulation to be performed using a relatively small 
number of atoms in such a way that the atoms experience forces as if they were in a bulk solution. 
Assuming the interactions are of short-range (treatment of long-range interactions will be discussed 
in a later section), the “minimum-image convention” is applied. In fact, with short-range 
interactions a cutoff distance, rcut, can be introduced to save computational resources, so that 
interactions beyond the cutoff range (rij > rcut) are not calculated. If the cutoff is not longer than half 
of the shortest box vector, then in order to calculate the interaction of an individual particle i with 
all the replicas of another particle j it is sufficient to consider only the closest image among the 
particles j to i. 
In principle, computing the non-bonded terms in Eq. (3.7) involves the evaluation of a large 
number of pairwise interactions between each atom i and all interacting atoms j. Although the use 
of cutoff avoids expensive calculations, it is still time consuming to examine and calculate all 
distinct pairs, which are #N(N-1) in a system of N atoms. The “neighbor list” technique was 
introduced by Verlet to improve the computing speed. The cutoff range rcut gives a sphere of radius 
rcut around an atom i within which we can find all the atoms j that can interact with i. A larger range 
rlist is defined to identify a larger sphere around atom i for determining a list of neighbor atoms (Fig. 
2.2B) as possible interacting atoms. At the first step in a simulation, for each atom i a list of all the 
neighbors j is constructed (for which rij < rlist). Over the next few MD time steps, only pairs between 
i and the atoms appearing in the corresponding neighbor list are examined for the force 
computation. The neighbor lists have to be reconstructed rather frequently, before an unlisted atom 
can enter the interaction range rcut of the corresponding atom. Therefore, the choice for the best 
value of rlist has to take into account both the value of the updating frequency of the neighbor list 
and the computing time needed to evaluate the interactions of all the pairs defined by rlist. 
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Figure 2.2: A) 2D illustration of periodic boundary conditions applied on a cubic primary box. When an atom 
moves out of the simulation box, an image particle moves in from the opposite side to replace it. B) 2D 
illustration of the neighbor list on its (re)construction (left) and a few MD time steps later (middle). 
Interacting atoms (white circles) and atoms in the neighbor list (gray filled circles) of atom i are indicated. 
The neighbor list must be reconstructed before any unlisted atoms (black filled circles) have entered the range 
of rcut, as shown on the right. 
3.2.5 Constrains 
In biomolecular simulations, it is common practice to constrain intramolecular bonds with 
very high vibration frequencies in order to improve the computational efficiency. For instance, 
bonds involving hydrogen atoms require a time step of 0.5 fs in order to conserve energy. Instead of 
treating these bonds by terms in the potential function, they can be constrained to have a fixed 
length. This allows for larger time steps up to 2 fs and significantly reduces the computing costs of 
simulations of given timescales.  
3.2.5.1 The SHAKE algorithm 
The SHAKE algorithm183 was the first one developed to satisfy bond geometry in MD 
simulations. Using a set of coordinates (ri) and a set of new unconstrained coordinates (ri") 
generated at the next time step, SHAKE changes ri" to a set of coordinates ri"" that fulfills a list of 
distance constraints. For the original Verlet algorithm, SHAKE determines the constraint forces in 
such a way that the constraints are satisfied at the end of each time step.  
Let us take a fixed bond length b between atoms 1 and 2 as an example. A constraint 
equation and the time derivative of the constraint can be written as 
! r1, r2( ) = r1 ! r2( )2 ! b2 = 0,  
  
(3.13) 
!! r1, r2( ) = 2 v1 = v2( ) r1 ! r2( ) = 0.  
  
(3.14) 
Assuming the equations of motion must fulfill n holonomic constraints: 
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! k r1...r2( ) = 0; k =1...n,  
  
(3.15) 
the constraints are added as zero terms to the potential U(r), multiplied by Lagrange multiplier 
!k t( ) , and consequently the forces are now given by 
F t( ) = ! "
"ri












where !k  must be solved to fulfill the constraint equations Eq. (3.15). The second part of the right 
hand side determines the constraint forces Gi 




# .  
  
(3.17) 
In the Verlet or leapfrog algorithm, the evolution of the unconstrained coordinates ri" and the 
constrained coordinates ri"" (on which are applied the constraint forces Gi) are respectively: 
!ri t +"t( ) = 2 !ri t( )# !ri t #"t( )+
!F t( )
m
"t 2 ,  
  
(3.18) 




= 2 !!ri t( )# !!ri t #"t( )+
!F t( )+G t( )
m
"t 2.
   
(3.19) 
SHAKE solves the Lagrange multipliers (and hence the displacements Gi(t)?t2/m) by solving a set 
of coupled constraint equations iteratively to satisfy each constraint equation in turn until 
convergence to a given tolerance.  
However, SHAKE has the drawback that no solutions may be found when displacements are 
large184. This is because the coupled bonds are handled one by one and correcting one bond may tilt 
a coupled bond up to a point that the method does not converge. 
3.2.5.2 The LINCS algorithm 
The MD simulations in this thesis employ the LINCS (Linear Constraint Solver) algorithm184 
which is the default constraint method in Gromacs 4. LINCS is faster and more stable than SHAKE, 
although it can only be used with bond constraints and isolated angle constraints, such as the proton 
angle in OH. Similar to SHAKE, LINCS resets new bonds to their correct lengths after an 
unconstrained update. The method is non-iterative, as it always uses two steps (Fig. 2.3). The first 
step sets the projection of the new bonds onto the directions of the old bonds. The second step 
corrects the bond lengths to the prescribed lengths.  
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Figure 2.3: Schematic illustration of the two-step reset of constrained bonds by LINCS after an unconstrained 
update for one time step. The old bonds are shown in dashed line and the new bonds in solid lines. l = d cos?
and p = 2d 2 ! l2 . 
 






where r is the 3N coordination vector, F is the 3N force vector and M is a 3N $ 3N diagonal matrix 





"r U + #$( ),  
  
(3.21) 
Introducing a new notation for the gradient matrix of the constraint equations Bhk = !"! h "rk ,  





+BT" +F = 0.  
  
(3.22) 
Because the constraint equations equal zero, the first and second time derivatives of the constraints 


















= 0.  
  
(3.24) 





!1BT" +BM!1F = 0.    
(3.25) 
Thus the constraint forces are 
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which can be substituted into Eq. (3.22) to give the constrained equations of motion. Defining an 
abbreviation T =M!1BT BM!1BT( )!1, the equations of motion become 
d 2r
dt 2






I-TB is a projection matrix that sets the constrained coordinates to zero, BM-1F is an n vector of 
second derivatives of the bond lengths in the direction of the bonds, and T is a 3N $ n?matrix that 
transforms motions in the constrained coordinates into motions in Cartesian coordinates without 
changing the equations of motion of the unconstrained coordinates. The last term in Eq. (3.27) 
represents centripetal forces caused by rotating the bonds.  
3.2.6 Long-range interactions  
Non-bonded interactions are extremely important for understanding the properties of 
biomolecules. They can be divided into short-range and long-range interactions. In a 3D system, a 
force is defined to be short ranged if it decreases with distance quicker than r3. As mentioned 
earlier, short-range interactions are commonly handled by imposing a cutoff, rcut, to the potential, 
beyond which the potential is set to 0. Long-range interactions, however, present a more 
complicated problem because a cutoff could introduce a considerable energetic discontinuity into 
the system, which leads to unstable simulations. The determination of these interactions (which 
have to be treated as infinite-ranged) represents the most computationally expensive part of 
empirical force field calculations: the simulation cell and all its periodic images must be considered. 
The neighboring-list technique would diminish the effect of cutting off the potential over a range of 
several tens or hundreds of nanometers, while current biomolecular simulations typically have box 
lengths of the order of few nanometers. Thus, to account for long-range interactions, one must 
consider the effect of the periodic images. 
With respect to the long-range LJ term, the region beyond the cutoff distance is typically 
treated as being homogenous (i.e., an “average” over all LJ atom types in the system)185; 186. This is 
realized by introducing corrections to account for the truncated LJ contribution185; 186. It is often 
assumed that the LJ contribution at longer distances is insignificant due to the r6 distance 
dependence. However, it should be emphasized that the summation over all the truncated 
contributions becomes significant, especially in systems dominated by aliphatic groups, as in lipids. 
For the electrostatic interactions, the Ewald summation method introduced by Ewald in 1921187 is of 
particular importance in this field. It takes advantage of crystal symmetry combined with reciprocal 
space to treat the long-range electrostatic interactions of systems satisfying periodic boundary 
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conditions. A modified, numerically more efficient version, the particle mesh Ewald (PME) 
method188, has been implemented in a number of widely used simulation packages. Both the Ewald 
summation method and the PME method are described in detail below.  
3.2.6.1 Standard Ewald summation 
Consider a neutral system in a lattice made up of N particles with charges ql, q2,…, qN at 
positions rl, r2, …, rN. The real space lattice vectors are a1, a2 and a3, which need not be orthogonal. 
All the particles are assumed to be spherically homogeneous (point-like in biomolecular systems). 
The problem is to calculate the electrostatic potential experienced by particle i in the presence of all 
the other particles in the system. Under PBC, The electrostatic energy of the system is defined by 
  (3.28) 
 where the sum over n is the a sum over lattice vectors , and ! ri( )  is the 
electrostatic potential. The prime in Eq. (3.28) indicates that the term for which  is 
neglected. Hence, the potential ! ri( )  does not include the infinite "self-energy" of the point 
charges, and is not a solution of Poisson's equation.  
The Ewald summation introduces a localized "screening" charge density in spherical 
Gaussian distributionj, which is centered at each point charge of equal magnitude and opposite sign. 
The screening charge density !S r( ) is a sum of the local densities.  



















( ,   (3.29) 
where ! is a positive parameter that determines the width of the Gaussians. The potential ! ri( )  in 
Eq. (3.28) can be written 
! ri( ) = ! ri( )+!S ri( )( )!!S ri( ) =!real ri( )+!recip ri( ),   (3.30) 
where ! ri( ) is the potential contributed by a Gaussian distribution of charges centered at each 
particle site, with the same total charge as those of the real particles; !S ri( )  is the potential of the 
screening charges with an additional Gaussian distribution of opposite sign at each point charge. 
Since the charge distribution on a reference charge point is not considered to contribute to the 
                                                      














# = 12 qi! ri( )i=1
N
# ,
n = n1a1 + n2a2 + n3a3
rij +n = 0
 36 
potential ! ri( ) , by taking the sum of ! ri( ) and !S ri( )  the Gaussian distributions counteract, so 
that the rapid convergence of the sum can be achieved by choosing a suitable width of the Gaussian 
distributions without affecting the total energy. This yields the real-space sum, !recip ri( ) , which is a 
sum of short-range potentials. The reciprocal sum, !recip ri( ) , is the long-range potential associated 
with the periodic charge density !!S r( )  which converges smoothly in the real space and it had 
long been a challenge for the MD community.  
The reciprocal potential !recip ri( )  in Eq. (3.30) can be calculated by solvating Poisson 
equation in Fourier space. The Poisson equation reads 
!2!recip ri( ) = "4!"S r( ),  
  
(3.31) 
Expanding !recip ri( )  and!S r( ) in Fourier series 
!recip ri( ) = !ˆ recip m( )exp imri( )
m
! ,   (3.30) 
!S r( ) = !ˆS m( )exp imr j( )
m
! ,   (3.31) 
where m is the reciprocal lattice vector m =m1a*1 +m2a*2 +m3a*3 with m1, m2, m3 integers not all zero. 
Substituting Eq. (3.30), (3.31) into Eq. (3.31), we obtain 
!ˆrecip m( ) =
4!
m2
!ˆS m( ).  
  
(3.32) 
































*exp 2"im +r( ),
   
(3.34) 
where V is the volume of the lattice. 
The potential !real ri( )  is produced by the fraction of point charges that are not screened and it is 
evaluated at the reference point 
!real ri( ) = 'qj








qj ,  
  
(3.35) 
where erfc(x) is the complementary error function. 
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.   
(3.36) 
 Finally, the analytic expression for the electrostatic energy is 




qi !real ri( )+!recip ri( )"# $%
i=1
N


































































& + J D,P, !!( ).  
  
(3.37) 
The last term J D,P, !!( ) in Eq. (3.37) corrects for the non-uniform field associated with a 
macroscopic (but finite) crystal in a dielectric continuum190. It depends on the dipole moment D of 
the unit cell, the shape P of the macroscopic boundary conditions, and the external dielectric 
constant "'. 
E in Eq. (3.35) can be recast in the Fourier space to be more efficient convergent, which is 
known as the Fast Fourier Poisson method190. This method replaces the interaction of each point 
charge with !recip r( ) by the interaction of the introduced charge density having the same net charge 












! "r( )+ !S "r( )$% &'!recip "r( )d 3 "r# (
1
2
!S "r( )!recip "r( )d 3 "r# ,
   
(3.38) 
where ! r( )  is the point charge density 
! r( ) = qi! r ! ri( )
i=1
N
" .  
  
(3.39) 
The first integral in Eq. (3.38) is canceled out by the real-space sum leaving only the second 
integral of order N, which can be numerically estimated in a much more efficient way. 
 
3.2.6.2 The PME method 
Inspired by the particle-mesh method of Hackney and Eastwood191, Darden et al.188 
investigated the use of the fast Fourier transform (FFT) algorithm to speed up the calculation of the 
reciprocal sum in the Ewald summation. In computing the direct sum, the Ewald parameter # is 
erfc x( ) = 2
!




chosen to reduce the real-space sum from O(N2) to O(N) problem by employing a cutoff approach 
to numerically estimate it, The reciprocal sum is approximated by using 3D-FFT with convolutions 
on a grid where particle charges are interpolated on.  
The reciprocal term in Eq. (3.37) can be simplified to be more efficiently convergent. 
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Here, introducing the structure factor192 known in protein crystallography 
S m( ) = qk
k=1
N
! exp 2!imrk( ),  
  
(3.42) 




























) S m( )
2
.
   
(3.43) 
Therefore, the sum over i and j of order N2 in Erecip are transformed into two sums of order N in Eq. 
(3.41) and finally into a single sum of order N in Eq. (3.43).  
In the PME approach , the structure factor S(m) in Eq. (3.43) is approximated by 




























where Q is the charge matrix containing charge values obtained by interpolating the point charges 
to a uniform grid of dimensions that fills the simulation box. is the 3D-FFT of Q. 
Combining Eq. (3.43) with Eq. (3.44), the reciprocal energy can be also approximated by 















)F Q( ) m( )F Q( ) #m( ).  
  
(3.45) 

















where !recip is the reciprocal pair potential and "*" indicates a convolution. The Q matrix is first 
computed over a 3D uniform grid, and then it is transformed using inverse 3D-FFT to obtain the 
structure factors. The reciprocal energy is then calculated using Eq. (3.46) with the aid of FFT to 
compute the convolution !recip * Q.  
3.2.7 MD in NPT Ensemble  
The NPT ensemble is an isothermal-isobaric ensemble where the number of particles (N), the 
pressure (P) and the temperature (T) are conserved. It corresponds most closely to laboratory 
conditions with a system open to ambient temperature and pressure. Therefore, MD simulations are 
commonly performed in NPT ensemble, which is realized by applying a thermostat and a barostat 
algorithm to the equations of motion. Below I describe the most widely employed thermostat and 
barostat approaches including those used in this thesis. 
3.2.7.1 Nosé thermostat and Nosé-Hoover thermostat  
Various methods have been developed to control the temperature, which allow for sampling 
the canonical (or “NVT”) ensemble. In canonical ensemble, the number of particles, the volume and 
the temperature are fixed to the prescribed values. Among these methods, the Nosé thermostat193 has 
received a great amount of attention because it is deterministic, reversible and not restricted to 
systems with a large number of particles. A modified version of this method, the Nosé-Hoover 
thermostat194, has become one of the most widely used methods to produce a simulation that 
samples the canonical ensemble.  
 
An extended system 
Given a system of N particles with coordinates rN in a fixed volume V, and potential energy 
U(rN), the basic idea in the Nosé thermostat193 is to introduce an additional degree of freedom s, 
which represents an external system for the physical system and acts as an heat reservoir. The 
thermal interaction between the heat reservoir and the physical system is an exchange of kinetic 
energy between them, which is expressed via the scaling of the real velocities of the particles 
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vi = s!ri ,  
  
(3.47) 
and this results in the temperature fluctuating around a target value Teq . A potential energy gkBTeq ln s
is associated with s, where g = f+1 (f being the number of degrees of freedom in the system) and kB 
is the Boltzmann’s constant. This choice of potential energy is essential for producing the canonical 
ensemble, as it will be shown later.  
The Lagrangian and Hamiltonian of the extended system of particles and s can be written as 






! "U r( )+Q2 !s
2 " gkBTeq ln s,  
  
(3.48) 






! +U r( )+ ps
2
2Q
+ gkBTeq ln s
= Hr pi", "r( )+ ps
2
2Q




where Hr is the Hamiltonian of the real system 
 
Hr pi!, !r( ) = pi!
2
2mii
" +U !r( ),  
  
(3.50) 
















In the extended system the total Hamiltonian He is conserved.  
The Nosé method produces the canonical ensemble. In fact, if He is the only conserved 
quantity, the microcanonical ensemble for the extended system is described by the partition function 
Z = C0
N !
dps! ds! dp! dr! ! He " E( ),  
  
(3.53) 
where C0 is a normalization constant, E is the (constant) extended-system energy, $(x) is the Dirac 
delta function, dp = dp1dp2...dpN , dr = dr1dr2...drN  Transforming pi and ri into the real variables, the 
volume element becomes dpdr = s f d !p d !r . Therefore, 
Z = C0
N !
dps! ds! d "p d "r!! s f! Hr pi", "r( )+ ps
2
2Q









.    
(3.54) 
Using the equivalence relation! g s( )!" #$= ! s% s0( ) / &g s( )  where s0 is the root of g(s)=0,  
pi! = pi / s r! = r
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+ gkBTeq ln s0 " E = 0,  
  
(3.55) 
s0 = exp !
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(3.58) 




d !p" d !r" exp #Hr pi!, !r( ) kBTeq$%& '().  
  
(3.59) 
This demonstrates that by choosing the potential energy for s as f +1( )kBTeq ln s , the partition 
function of the extended system is equivalent to that of the canonical ensemble except for a constant 
factor C. Under the ergodic hypothesis, the time average of time-independent quantities, which are 










A p s r dt A p s r A p r
t!"





denote the average in the canonical ensemble. During simulations, canonical trajectories 
in the real molecular systems are generated by sampling the microcanonical ensemble for the 
extended system. 
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It is worth pointing out that the above result is derived from the assumption that the extended 
system has no conserved qualities other than He. In fact, the total momentum pi
i
! and angular 
momentum ri
i
! " pi are also conserved, which gives rise to slight deviations from the canonical 
ensemble. 

























































.    
(3.64) 






















.    
(3.65) 
Eq. (3.65) indicates that the change of s with time makes the kinetic energy oscillate about the value 
gkBTeq / 2. When the kinetic energy is larger than gkBTeq / 2, the quantity in the bracket is positive, s 
experiences a positive acceleration and tends to be larger. This tends to make the kinetic energy 
smaller. On the contrary, when the kinetic energy is smaller than gkBTeq / 2, s tends to get smaller 
and make the kinetic energy become larger. Under equilibrium state, the time average of d 2s dt 2
vanishes, hence the time average of the kinetic energy coincides with the externally set temperature 
Teq . The parameter Q controls the time scale of the temperature fluctuation. A small Q gives rapid 
response to the temperature change while a large Q leads to slow temperature fluctuations. 
 
Real time sampling and Nosé-Hoover thermostat 
In the previous section, Eq. (3.57) is achieved by sampling data points at integer multiples of 
virtual time unit *t. Nosé called this sampling as “virtual time sampling” in which the real time 
interval is unequal. The relation of real time and virtual time is s = dt
d !t
, so s can be thought of as a 
time scaling factor. Real time sampling can be carried out by using equal intervals in real time with 
t1 = dt / s0
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(3.66) 
To produce canonical ensemble, this average should be identical to A !p , !r( )
c





A p / s,r( ) dts0










which can be achieved by choosing g = f .  
Nosé193 transformed the equations of motion Eq.(3.61)~(3.64) into equations for the real 
variables  !ri = r ,  !pi = pi / s ,  
!t = dt















































.    
(3.71) 
The equations become complex but can be solved in real time by setting g = f. Hoover194 simplified 
the above equations by introducing a new variable! ! "ps /Q . The equations of motion are then 




































It is evident that! controls the kinetic energy oscillating around the value gkBTeq /2. These equations 
describe the Nosé-Hoover thermostat, which is more suitable for production runs and it has been 
widely used for constant-temperature simulations. 
3.2.7.2 The Andersen barostat and the Parrinello-Rahman barostat  
Among the many classes of pressure control methods, the Berendsen barostat, the Andersen 
barostat and the constraint methods have been the most used over past decades. Here I discuss the 
Andersen barostat195 and an extended version of it, the Parrinello-Rahman barostat196 which was 
used in the work of this thesis. 
 
The Andersen barostat 
The Andersen barostat195 considers a system of N particles in a cubic PBC box of volume V. 
V is set to be a dynamical variable rather than a fixed quantity in order to describe the volume 
fluctuations at constant pressure. The coordinates r1,r2...rN of the particles were then replaced by 
scaled coordinates, !1,!2...!N ,  
!i = ri V
1
3 , i =1,2,...,N ,  
  
(3.75) 
where each component of is a dimensionless number between 0 and 1. The Lagrangian of this 
scaled system is  



















!V 2 "!V .    
(3.76) 
The last two terms represent the kinetic energy term and the potential energy term associated with 
V, respectively; M and + are constants. The Lagrangian can be interpreted as follows: suppose the 
particles are in a container whose volume can be compressed by a piston, the variable V represents 
the coordinate of the piston, thus, M is the mass of the piston and + is the external pressure acting 
on the piston. The Hamiltonian of the scaled system is 
   
(3.77) 






3 !!i , pV =
!LA
! !V
=M !V    
(3.78) 
The equations of motion are therefore: 
!i
 









































































































.    
(3.83) 
P is the instantaneous pressure defined by 
P = 2
3V
























where W is the internal virial. 
It can be proved that under the ergodic hypothesis, the time average of any function 
 of the scaled system is equal to the averages of X over an isoenthalpic-isobaric (NPH) 
ensemble in which the pressure is +, except for negligible errors195. In fact, the partition function of 




d!! dV! dp! dpV! " HA " E( ),  
  
(3.85) 
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(3.86) 
Transforming the scaled variables into real ones , ,  
X !,V , p, pV( )
!i = ri V
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(3.87) 








then Eq. (3.87) can be written as 
 
X =






































   
(3.89) 
which is closely related to the isoenthalpic-isobaric ensemble average of X except for the pv 
integration. To eliminate this difference, Andersen expanded XNPH  
 








= X NPH N ,! , E( )" pV
2
2M
)X NPH N ,! , E( )
)H
+O N "2( ),    (3.90) 
and substituted it into Eq. (3.87) to get 
 
X = X NPH N ,! , E( )
"
#X NPH N ,! , E( )
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= X NPH N ,! , E( )" pV
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+O N "2( )











   
(3.91) 
where O(N-2) is the error term proportional to !
2 X NPH !H
2 for an intensive property X (for an 
extensive X, it should be of order N-1).  
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The above result indicates that the Andersen barostat trajectory gives time averages equal to 
those of the NPH ensemble with P = + andH = E ! pV2 2M . As Andersen pointed out, the value 
of pV2 2M is proportional to the temperature T fixed by the chosen E of the scaled system (
pV
2 2M = kT 2 ) and it is therefore independent of M. From Eq. (1.10) we can see that the mass 
of the piston, M, determines a response time of the pressure fluctuations caused by the box size 
oscillations, thus, an appropriate value of M must be chosen to ensure the response time is short 
enough for the pressure to be approximately constant. Andersen recommends that M be chosen to 
make the response time approximately equal to that for a sound wave to cross the simulation box. 
 
The Parrinello-Rahman barostat 
The Andersen barostat does not allow the simulation box to change its shape. To overcome 
this problem, Parrinello and Rahman196 extended the Andersen method to enable a variable 
simulation box shape. In the Parrinello-Rahman barostat, a time-dependent metric tensor is 
introduced which allows the volume and the shape of the simulation box to vary with time. 
Basically, the box vectors are set to follow an equation of motion, and the equations of motion of 
the particles are also changed as in the Andersen barostat. 
The simulation box can have an arbitrary shape described by three vectors, a, b and c. The 
vectors can have different lengths and arbitrary mutual orientations. Define a 3 % 3 matrix, h, whose 
columns are these three vectors. The box volume is given by  
V = deth = a ! b! c( ),  
  
(3.92) 
The position ri of a particle can be written in terms of h and a column vector si, with components %i, 
&i and 'i as 
ri = hsi = !ia+!ib+! ic,  
  
(3.93) 
with 0& %i, &i, 'i & 1. The square of the distance between particle i and j is given by 
rij
2 = sij
TGsij ,  
  
(3.94) 
where the metric tensor G is G=hT h. Using the latter notation, the Lagrangian of the scaled system 




TG!si ! U rij( )!!! + 12MTr




Derivation of the equations of motion for the Parrinello-Rahman barostat system is similar to the 
case of the Andersen barostat. 
3.2.8 Solvation effects: implicit and explicit models  
Most proteins exist within an aqueous environmentk. When simulating such proteins, it is 
common to assume that the protein is fully solvated in pure or ion-containing water. An explicit 
representation of the surrounding solvent can provide an accurate treatment of solute-solvent 
interactions. Although the discrete nature of water plays an important role in protein 
thermodynamics and functions, it typically increases the system size by about one order of 
magnitude compared to the size of the solute alone. In addition, a long simulation timescale is 
needed to average instantaneous solute-solvent interactions in order to obtain meaningful results 
concerning the solute structure, dynamics or energetics. Implicit solvent models represent the 
solvent as a continuous medium instead of individual explicit solvent molecules. Although implicit 
models largely improve the computational efficiency, they are associated with many limitations 
such as the lacking in the treatment of ionization effects and of specific interactions between 
biomolecules and solvent. Therefore, caution must be taken in choosing the appropriate solvent 
models in biomolecular simulations.  
3.2.8.1 Implicit solvent models 
Implicit solvent models reduce explicit solute-solvent interactions to their mean field 
characteristics, which are expressed as a function of the solute configuration alone. In many cases 
of protein simulations, the properties of interest are not largely affected by the detailed atomistic 
behavior of solvent molecules. In such cases, averaging over unimportant atomistic details of 
solvent greatly decreases the number of degrees of freedom in the system and generally yields 
significant computational efficiency. They allow for better direct estimations of free energies of 
solvation than explicit solvent models197. Therefore, implicit solvent methods are often applied to 
estimate free energy of solute-solvent interactions processes such as folding or conformational 
transitions of biomolecules, protein-protein or protein-ligand association, or transport of drugs 
across biological membranes.  
There are two basic types of implicit solvent methods: models based on solvent-accessible 
surface areas (SASA), and the more recent continuum dielectric models based on the Poisson 
Boltzmann equation198. Various modifications and combinations of the different methods exist198 
and many successful applications have been reported199. However, implicit solvent models alone are 
not adequate to mimic all aspects of the solvent environment. A number of studies have shown that 
when the properties of the water molecules are substantially different from those of the bulk 
                                                      
k Other proteins such as transmembrane ones are not discussed here. 
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solvent, implicit solvent models could produce large artifacts compared to explicit solvent models. 
These include water near a membrane bilayer200, ion dynamics in gramicidin channels201, as well as 
the role of solvent in proton binding free energies for proteins202.  
3.2.8.2 Explicit solvent models 
In explicit solvent models, water is represented by all-atom force fields. Explicit solvent 
models contribute specific interactions in addition to the dielectric screening effects, which are 
often important for mediating protein structure or function203. For instance, i) water molecules often 
mediate protein-protein or protein-ligand interactions; ii) explicit solvents play an important role in 
simulations for the accurate consideration of electrostatic effects and for the valid decomposition of 
free energies204; iii) explicit solvents are often required to study the detailed role of solvent in 
mediating interactions during protein folding205. 
For cases when explicit solvents are necessary, there is a wide range of explicit water models 
available170. The most popular models being used in biomolecular simulations include TIP3P206, 
TIP4P206, TIP5P207, SPC208, and SPC/E208. Each of these models is optimized to one or more physical 
properties of water, such as the radial distribution function, diffusivity, density etc. But none of 
these models can simultaneously reproduce all the properties of water. Commonly, the parameters 
in the water models are adjusted so that the enthalpy of vaporization and the density of water are 
reproduced in simulations209. All of the above models have a dipole moment of about 2.3 D instead 
of the experimental gas-phase value of 1.85 D210. The temperature dependence of the density of 
water is not described well by any of these models perhaps except the TIP5P model211. These most 
popular models treat the molecules as completely rigid, thus thet are all consistent with the SHAKE 
and LINCS constraints discussed above.  
3.3 Classical Monte Carlo simulations 
Monte Carlo (MC) simulations represent a significant alternative to MD simulations for 
investigating structural and thermodynamic properties of a system212. The term MC generally refers 
to simulations that use a stochastic approach to generate a set of representative configurations under 
given thermodynamic conditions such as temperature and volume. Classical MC simulations 
perform importance sampling of systems at equilibrium. The configurations are drawn from a 
probability distribution, often the classical Boltzmann distribution, to obtain thermodynamic 
properties or minimum-energy structures.  
In its general form, a MC simulation proceeds as follows: starting from an initial 
configuration of particles in a system, a MC move is attempted that changes the configuration. This 
move is accepted or rejected based on an acceptance criterion which guarantees that the 
configurations are sampled in the desired ensemble distribution, and with the correct weight. After 
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the acceptance or rejection of a move, the value of a property of interest is calculated. The results of 
many such steps are collated. Once sufficient sampling has been achieved, an accurate average 
value of this property can be obtained. With the application of statistical mechanics, it is possible to 
calculate the equilibrium thermodynamic properties of the system. Therefore, the ergodic 
hypothesis is one important necessary condition for MC simulations.  
One attractive aspect of classical MC simulations is that only the potential energy is normally 
used in stepping through configurations. Unlike molecular dynamics simulations, MC simulations 
are free from solving Newton’s equations of motion and calculation of forces (although some biased 
MC approaches do utilize force data). This allows for much more efficient calculations, which can 
lead to great speedups of up to 10 orders or more in the sampling of equilibrium properties170. 
Specific MD moves can also be combined in a simulation, allowing the modeler great flexibility in 
the approach to a specific problem212. In addition, Monte Carlo methods are generally easily 
parallelizable, with some techniques ideal for large CPU clusters. 
However, there are a number of issues that hamper the use of MC simulations with large 
biomolecules. One issue is that it is difficult to define efficient moves for macromolecules "moves 
that change the configuration in a sufficiently large magnitude but also avoid generating 
energetically infeasible configurations. Conventional MC methods are inefficient for exploring the 
configurational space of large biomolecules when compared to MD simulations213. However, some 
work has eased this issue for proteins214; 215; 216. Another main issue is MC simulations of proteins in 
explicit solvent. It is difficult to conduct large-scale moves. Any move that significantly alters the 
internal coordinates of the protein without also moving the solvent molecules will likely result in a 
large overlap of atoms and thus, the rejection of the move. MC simulations using implicit solvent do 
not suffer from these drawbacks. Therefore, MC simulations of proteins are commonly conducted 
with coarse-grained models217. In addition, MC methods give no dynamical information about the 
time evolution of structural events. Last but not least, there is a lack of general, good, freely 
available programs for MC simulations of proteins because the choice of MC moves and acceptance 
criteria vary for one specific problem to another. It is worth noticing that a MC module has been 
added to CHARMM218. Another MC simulation program package, PROFASI (PROtein Folding and 
Aggregation Simulator)18 has been made freely accessible for studying protein folding and 
aggregation. PROFASI has been employed in the preparation of this thesis and details of PROFASI 
will be described in a latter section. 
3.4 Classical Monte Carlo simulations 
Monte Carlo (MC) simulations represent a significant alternative to MD simulations for 
investigating structural and thermodynamic properties of a system212. The term MC generally refers 
to simulations that use a stochastic approach to generate a set of representative configurations under 
 51 
given thermodynamic conditions such as temperature and volume. Classical MC simulations 
perform importance sampling of systems at equilibrium. The configurations are drawn from a 
probability distribution, often the classical Boltzmann distribution, to obtain thermodynamic 
properties or minimum-energy structures.  
In its general form, a MC simulation proceeds as follows: starting from an initial 
configuration of particles in a system, a MC move is attempted that changes the configuration. This 
move is accepted or rejected based on an acceptance criterion that guarantees the configurations are 
sampled in the desired ensemble distribution with the correct weight. After the acceptance or 
rejection of a move, the value of a property of interest is calculated. The results of many such steps 
are collated. Once sufficient sampling has been achieved, an accurate average value of this property 
can be obtained.  
One attractive aspect of classical MC simulations is that only the potential energy is normally 
used in stepping through configurations. Unlike molecular dynamics simulations, MC simulations 
do not solve Newton’s equations of motion and do not need to calculate forces (although some 
biased MC approaches do utilize force data). This allows for much more efficient calculations, 
which can lead to great speedups of orders of magnitude in the sampling of equilibrium properties 
170. Specific MD moves can also be combined in a simulation, allowing the modeler great flexibility 
in the approach to a specific problem212. In addition, Monte Carlo methods are generally easily 
parallelizable, with some techniques ideal for large CPU clusters. 
However, there are a number of issues that hamper the use of MC simulations with large 
biomolecules. One issue is that it is difficult to define efficient moves for macromolecules" moves 
that change the configuration in a sufficiently large magnitude but also avoid generating 
energetically infeasible configurations. Conventional MC methods are inefficient for exploring the 
configurational space of large biomolecules when compared to MD simulations213. However, some 
work has eased this issue for proteins214; 215; 216. Another main issue is performing MC simulations of 
proteins in explicit solvent. It is difficult in general to conduct large-scale moves. Any move that 
significantly alters the internal coordinates of the protein without also moving the solvent molecules 
will likely result in a large overlap of atoms and thus, the rejection of the move. This implies that in 
these condition the sampling will be inefficient. MC simulations using implicit solvent do not suffer 
from these drawbacks. In addition, MC methods give no dynamical information about the time 
evolution of structural events. Last but not least, there is a lack of general, good, freely available 
programs for MC simulations of proteins because the choice of MC moves and acceptance criteria 
vary for one specific problem to another. It is worth noticing that a MC module has been added to 
CHARMM218. Another MC simulation program package, PROFASI (PROtein Folding and 
Aggregation Simulator)18 has been made freely accessible for studying protein folding and 
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aggregation. PROFASI has been employed in the work of this thesis and details of PROFASI will 
be described here in a latter section. 
3.4.1 The Metropolis method 
The Metropolis algorithm introduced by Metropolis et al.219 is a Markov chain technique 
which is by far the most common MC simulation scheme217. In this scheme, a problem is described 
in terms of a thermodynamic system at potential energy, E, and temperature, T. With a constant T, 
the initial configuration is perturbed and the change in energy dE is computed. If dE is negative, the 
new configuration is accepted. If dE is positive, it is accepted with a probability given by a 
Boltzmann factor. This algorithm can be summarized in the following steps: 
Step 1. Pick the configuration Cn (the initial configuration n=0 can be any configuration of 
the system).  
Step 2. Generate a trial configuration Ct (usually a configuration similar to Cn  obtained by 
performing some change or move on it) and compute the probability ratio R= P(Ct)/P(Cn).  
Step 3. Pick a random number p with value between 0 and 1. Make Cn+1= Ct, if p & R. 
Otherwise, make Cn+1= Cn.  
Note that the probability of accepting a trial configuration Ct is 
   
(3.96) 
Step 2 and step 3 are iterated to obtain a set of N configurations, C1, C2, …, CN, where N is a 
sufficiently large number. It can be proved (below) that such an algorithm indeed produces an 




where NC is the number of time the configurations C of the system has been visited in the MC run, 
and P(C) is the Boltzmann distribution,  
To prove that the algorithm produces an ensemble of configurations that satisfies Eq. (3.97), 
it needs to be shown that any initial distribution NC/N evolves towards the distribution P(C), and 
once such a distribution is reached it remains at equilibrium. According to steps 2 and 3, for any 
pair of states C and C', the number of configurations generated in state C' by applying the algorithm 
to the N(C) configurations in state C is N(C)PC,C', where PC,C' is the probability of accepting the trial 
configuration C' when Cn = C. In addition, the number of configurations generated in state C' by 
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number Ntot(C') of configurations in state C' after the application of the algorithm to configuration C 
and C' is 
   
(3.98) 
where is the net change in the number of configurations in state C', 
relative to N(C'). According to Eqs. (3.96) and (3.98), 
   
(3.99) 
when P(C') > P(C) and 
  
(3.100) 
when P(C') < P(C). Therefore, according to Eqs. (3.99) and (3.100), (N(C')> 0 when N(C')/N< 
P(C') and (N(C')< 0 when N(C')/N> P(C'). The algorithm evolves any arbitrary distribution 
towards the equilibrium distribution where NC/N= P(C). In addition, Eqs. (3.99) and (3.100) indicate 
that (N(C')= 0 when both N(C)/N= P(C) and N(C')/N= P(C') are satisfied, i.e. the algorithm does 
not alter the relative population of the states when the ensemble distribution is equal to the 
equilibrium distribution. 
The most important aspect of the method is that the algorithm is able generate an ensemble of 
configurations with the probability distribution simply by computing the probability ratios 
P(C')/P(C).  
Under ergodic hypothesis, the Boltzmann average for any observable property can be 




where A(C) is the value of the observable A for state C and  is the Monte Carlo estimator of  
associated with the finite number of configurations N.  
3.4.2 PROFASI: PROtein Folding and Aggregation Simulator 
3.4.2.1 The force field in PROFASI 
PROFASI uses an effective all-atom potential220 to simulate protein folding and aggregation. 
The model contains all atoms of the protein chains, including hydrogen atoms, but no explicit water 
molecules. It assumes fixed bond lengths, bond angles, and peptide torsion angles (180°), so that 
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each amino acid has the Ramachandran dihedral angles, $ and (, as well as a number of side-chain 
torsion angles as its degrees of freedom. The interaction potential is composed of four terms 
  
(3.102) 
The first term Eloc is a local potential accounting for interactions between atoms separated by 
a few covalent bonds, such as the electrostatic interaction between adjacent peptide units along the 
chain. The other three terms are non-local: Eev represents excluded-volume effects, Ehb is a 
hydrogen-bond potential, and Esc represents residue-specific, pairwise, additive approximations for 
hydrophobic attraction between nonpolar side chains and electrostatic interactions among charged 
side-chains. Energy parameters in Eq. (3.102) are given in entropy unit, eu (1 eu = 1 kcal/(mol'K)). 
The factor for conversion from eu to kcal/mol are determined by calibration against the 
experimental melting temperature for a peptide220. The exact forms of each term in Eq. (3.102) are 
given below. 
The local potential  can be divided into two backbone terms,   and 
E (2)loc , and one side-chain term, . Defining a so-called “peptide unit” to be composed of the 
backbone C"O group of one residue and the backbone NH group of the next residue, then 
represents interactions between partial charges of neighboring peptide units along the peptide chain: 
  
(3.103) 
where the outer sum runs over all pairs of nearest-neighbor peptide units, and each of the two inner 
sums runs over atoms in one peptide unit (except for proline for which the sum runs over only C" 
and O). The partial charges are given as qi = ±0.20 for H and N atoms and qi = ±0.42 for C" and O 
atoms, respectively221. The constant  has the value of 6 eu, corresponding to a dielectric constant 
of # % 41. Two peptide units that are not nearest neighbors along the chain interact through 
hydrogen bonding (see below) rather than through .  
The term  reads 
  (3.104) 
where =1.2 eu, = &0.15 eu, I is a residue index, and 
  
(3.105) 
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uI =min d H I ,N I+1( ),d N I ,H I+1( )!" #$% d H I ,H I+1( ),
vI =min d O I , &CI+1( ),d &CI ,O I+1( )!" #$% d O I ,O I+1( ),
f x( ) =max 0, tanh3x( ).
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The function f(uI) is positive if the HIHI+1 distance, d(HI,HI+1), is smaller than both the HINI+1 and 
NIHI+1 distances, and zero otherwise. This term thus provides an energy penalty when HI and HI+1 
are exposed to each other (it is omitted if residue I or I+1 is a proline). Similarly, f(vI) is positive 
when OI and OI+1 are exposed to each other. The first sum in Eq. (3.104) provides an additional OO 
and HH repulsion for neighboring peptide units, unless the residue flanked by the two peptide units 
is a glycine. This repulsion makes doubling of hydrogen bonds less likely. Glycine has markedly 
different backbone energetics compared to other residues. Therefore, the second sum in Eq. (3.104) 
provides an energy penalty for glycine backbone dihedral ( values around ±120°, which are 
sterically allowed but relatively rare in known protein structures222. 
 is an explicit torsion angle potential for side-chain angles, #i:  
  
(3.106) 
where  and ni are constants with different values that define four classes of side-chain angles in 
amino acids (Table 2.1).  
 
Table 2.1: Classification of side-chain angles, #i. The parameters of the torsion angle potential  
are ( , ni)= (0.6 eu, 3) for class I, ( , ni)= (0.3 eu, 3) for class II, ( , ni)= (0.4 eu, 3) for 
class III, and ( , ni)= (-0.4 eu, 3) for class IV.  
Residue #1 #2 #3 #4 
Ser, Cys, Thr, Val I    
Ile, Leu I I   
Asp, Asn I IV   
His, Phe, Tyr, Trp I III   
Met I I II  
Glu, Gln I I IV  
Lys I I I I 
Arg I I I III 
 




where )ev = 0.10 eu, and the summation is over pairs of atoms (i and j). The values of the radii, ,i, 
are given as 1.77, 1.75, 1.53, 1.42, and 1.00 Å for S, C, N, O, and H atoms, respectively.  
The ,i values agree reasonably well with the statistical analysis of standard radii and volumes in 
proteins223. The parameter -ij is a “reduction factor” with the value 0.75 for all pairs except for those 
E (3)loc




























connected by three covalent bonds, for which -ij = 1. A cutoff of 4.3-ij Å is employed in the 
evaluation of the pairs to be considered in the sum of Eev to speedup the calculations.  
The third term in Eq. (3.102), Ehb, describes hydrogen bonds between NH and CO groups. 
Two neighboring peptide units, which interact through the local potential Eloc, are excluded in the 
hydrogen-bond term. Ehb has the following form 
  
(3.108) 
where  = 3.0 eu and = 2.3 eu set the strengths of backbone-backbone and side-chain-
backbone bonds, respectively, rij is the HO distance, $ij is the NHO angle, and %ij is the HOC angle. 
The functions u(r) and v($, %) are given by 
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where ,hb = 2.0 Å. A cutoff of 4.5 Å is used for u(r), i.e. u(r) = 0 if r > 4.5 Å. 
The last term in Eq. (3.102), Esc, is formed by two terms, Esc = Ehp + Ech. Ech represents 
interactions among side-chain charges. Ehp accounts for the effects of all the other relevant 
interactions, especially effective hydrophobic attraction. Ehp and Ech have a similar form 
  
(3.110) 
where the sums run over residue pairs IJ,  and  are contact measures with values between 
0 and 1, and  and  are energy parameters. Details of the parameters , ,
 and  are given in ref. 220. 
PBC is applied in PROFASI. Since all the interactions in PROFASI are short-ranged, it is 
sufficient to use a periodic box length slightly larger than the maximum end-to-end distance of the 
peptide/protein being simulated18. 
3.4.2.2 The MC algorithm in PROFASI 
The simulation algorithms used in PROFASI are based on MC methods rather than MD. The 
conformational updates currently implemented in PROFASI include three different conformational 
updates: i) single-variable updates of side-chain and backbone angles, respectively, using simple 
Metropolis criteria 219 ii) backbone updates using biased Gaussian steps (BGS)224, and iii) rigid-body 
translations and rotations of whole chains, which are useful updates for multi-chain systems.  
Ehb = !hb
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The single-variable update, when applied to a backbone angle, tends to lead to a highly 
nonlocal deformation of the chain, thus, is likely to be rejected if the chain is compact. However, 
this update can be a very powerful method for simulating extended chains225; 226. The BGS are semi-
local updates that are less drastic than the single-variable updates. The BGS simultaneously update 
n (n & 8) adjacent torsion angles (*i,…, *n) along the backbone in a manner that keeps the ends of 
the segment approximately fixed. Given a backbone conformation , a tentative new 
conformation is generated with a bias toward local deformations. Specifically, using a 
conformation-dependent n $ n matrix G such that  for changes corresponding 
to local deformations,  is drawn from the Gaussian distribution 
  
(3.111) 
where 1 denotes the n $ n unit matrix, and a and b are tunable parameters controlling the acceptance 
rate and the degree of bias toward local deformations, respectively. Typical values for these 
parameters are a = 300(rad)&2 and b = (rad/Å)&2. The probability for accepting the new 
conformation  is   
P ! ! "!( ) =min 1,
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(3.112) 
where E and E( are the energy of  and , respectively.  
These updates are employed together in PROFASI for simulations in the canonical ensemble. 
In addition, improved sampling techniques such as simulated tempering227 and replica-exchange 
method228 are also implemented in PROFASI. The latter method is discussed in the next section. 
3.5 Replica-exchange method for improved sampling 
3.5.1 The sampling problem 
One of the major challenges in biomolecular simulations is the sampling229, because of the 
large number of degrees of freedom and the rugged energy landscape of biomolecules. 
Conformational transitions of proteins systems often occur orders-of-magnitude slower than the 
timescales accessible to standard simulation techniques230. Thus, methods that simply rely on the 
native sampling ability of the thermal motion of biomolecular systems at room temperature are 
often insufficient because of the far too short simulation time. Even with sufficiently accurate force 
fields it is still very difficult to simulate the folding processes or conformational transitions for 
proteins230; 231. Simulations may be trapped in local minima, thus they cannot achieve ergodicity. 
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Simulations of the same system starting from different initial conditions may give different 
results232. 
To improve sampling, a variety of advanced techniques have been developed, which have 
been discussed in several reviews229; 233; 234; 235. Most of the techniques could be grouped into three 
categories233: i) those that modify the potential energy; ii) those that reduce the degrees of freedom; 
and iii) variants of the replica-exchange (also known as parallel tempering) method228 (REM). Here, 
I will focus on the original REM, which was used to carry out the work presented in Chapter 5 of 
this thesis. 
3.5.2 Replica-exchange method 
The dynamic behavior of a system is intrinsically dictated by its free energy, and crossing 
energy barriers is often the first step leading to the conformational changes of proteins. Elevated 
temperature can significantly enhance the ability of a system to cross energy barriers. It is thus the 
most commonly used strategy to improve sampling in simulations. In this type of method, the 
entropic component of the free energy is exploited to enhance barrier crossing and sampling. Based 
on this idea, REM228 employs a set of replicated simulations at a range of temperatures. At regular 
intervals, the non-interacting simulation replicas are allowed to switch temperature with each other, 
thereby making it possible for low temperature replicas to gradually migrate up to higher 
temperatures and back again. The temperature range is chosen such that the low temperature values 
correspond to native conditions and the high values enable the system with sufficient energy to 
rapidly pass energy barriers. Originally developed for MC simulations228, REM has been adapted 
also for MD algorithms236. Below the basic technique of REM in MC simulations is described.  
Consider two replicas of the Metropolis MC simulation of a system, performed at 
temperature T1 and T2, respectively.  At a certain MC step, an update is made by exchanging the 
temperatures of the two replicas. The exchange is a stochastic process based on a Metropolis 
criterion. It occurs with a probability P(T1)T2) which depends on the reference temperatures of two 
replicas (T1, T2) and their instantaneous potential energies (U1, U2)237: 
  
(3.113) 
If the difference between the two temperatures, T1 and T2, is small enough, the energy histograms of 
the two simulation replicas should overlap. In other words, the system configurations sampled at 
temperature T1 are likely to appear during the simulation at T2. This gives the acceptance probability 
of exchanging temperatures between the two replicas. In practice, this update can be generalized to 
more than two systems. It is assumed that, in order to be efficient, each replica of the simulations 
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should spend equal amounts of time at each temperature and thereby facilitate the flux of 
configurations from low to high temperatures and back238. Therefore, the temperatures have to be 
chosen in a way that gives the same acceptance probability between all adjacent pairs of replicas 
over the entire temperature range. The exact choice of temperatures is crucial for optimal 
performance of the REM. The exchange frequency is determined by both the probability and the 
number of exchange trials. A simple geometric distribution of temperatures does not yield equal 
acceptance probabilities239. To determine an optimum set of temperatures is not straightforward. 
Recently, a “temperature predictor” has been developed to find the set of temperatures in a given 
range that give a desired exchange probability240. 
By a careful choice of temperatures and number of replicas, REM allows tunneling between 
metastable states of the system and improving convergence to a global optimum. This approach is 
successful in exploring energy landscapes of peptides and small proteins229. However, simulations 
of large systems or with explicit solvent are computationally expensive, and pose a challenge for 




 Common Structural Traits across Pathogenic Mutants of Chapter 4
the Human Prion Protein and Their Implications for 
Familial Prion Diseases 
Familial Hu TSE are associated with over 50 pathogenic mutations (PMs) in the gene coding 
for HuPrP (the PRNP gene). Most of the currently identified PMs are missense mutations (coding 
for a single-residue substitution) located in the folded globular domain of HuPrPC. We performed 
50 ns of molecular dynamics (MD) simulations in aqueous solution for HuPrPC globular domain 
containing each of these PMs in order to investigate their influence on the protein structure. Overall, 
1.6 's of MD data for these mutants are presented here. The calculations are based on the 
AMBER99 force field, which has been shown to reproduce very accurately the structural features of 
the wild-type (WT) HuPrPC and a few variants for which experimental structural information is 
available. The mutants exhibit structural traits different from those of WT HuPrP and of the 
protective polymorphism HuPrP(E219K-129M). These traits include the loss of salt bridges in the 
!2–!3 region and the loss of (-stacking interactions in the "2–!2 loop and between the loop and 
the C-terminal of !3 helix. In addition, in the majority of the mutants, the !3 helix is more flexible 
and residue Y169 in the "2–!2 loop is more solvent exposed than those in WT HuPrP and 
HuPrP(E219K-129M). The presence of similar traits in this large spectrum of PMs hints to a role of 
these fingerprints in their known disease-causing properties. Overall, the regions most affected by 
the PMs in terms of structure and/or flexibility are likely to be those involved in the conversion to 
PrPSc and in the interactions with cellular partners. These regions thus emerge as optimal targets for 
antibody- and ligand-binding studies. 
4.1 Introduction 
As introduced in Chapter 2, HuPrPC is mainly in $-helix conformation, while HuPrPSc is rich 
in !-structures241; 242; 243; 244; 245; 246; 247; 248. Solution-NMR studies249; 250 have established that HuPrPC 
features a largely disordered N-terminal tail (residues 23-124), a folded C-terminal globular domain 
(residues 125-230, denoted GD hereinafter), and two signal peptides (residues 1-22 and 231-253) 
(see Fig. 2.1D in Chapter 2). The GD structure has been resolved at pH 7250, which contains three $-
helices ($1, $2 and $3) and two short anti-parallel !-strands (!1 and !2) (Fig. 2.1D). A disulfide 
bond between residues C179 and C214 links the middle of the $2 and $3 helices. The $2-$3 region 
is believed to be crucial for HuPrPC!HuPrPSc conversion147; 249; 250; 251; 252; 253; 254; 255; 256; 257; 258; 259; 260; 261; 
262; 263; 264; 265; 266; 267; 268; 269; 270; 271; 272; 273. Familial types of Hu TSE are associated with over 50 PMs in 
the PRNP gene with broad chemical properties and diverse worldwide incidence154; 159; 274 (see Fig. 
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2.3 in Chapter 2). As many as 33 PMs are missense mutations located in the GD (Fig. 2.3) and they 
can lead to spontaneous formation of HuPrPSc in the brain275. These PMs may accelerate the kinetics 
of the misfolding process in vitro compared to WT HuPrP276 (HuPrP(WT), hereinafter). This may 
be caused, in part, by destabilization of the native HuPrP structure and/or by stabilization of the 
partially unfolded intermediate HuPrP species153; 267; 276; 277; 278 that are likely to be HuPrPSc 
precursors267; 276.  
NMR147; 259; 260 and X-ray studies279 have provided the underlying structural effects of several 
such PMs. MD simulations have given insights into the structural determinants and the plasticity of 
another 10 mutants containing PMs261; 262; 263; 264; 265; 266; 267; 269; 270; 271; 272; 273; 280; 281; 282; 283; 284; 285 with high 
incidences286, as well as those of the protective polymorphism HuPrP(E219K-129M) 263, l 
(HuPrP(PP), hereinafter). These studies have shown that the secondary and tertiary structural 
elements are similar across all these variants. In the MD simulations, Root Main Square Fluctuation 
(RMSF)263; 265; 266; 269; 272; 281, Root Main Square Deviation (RMSD)261; 287 and secondary-structure 
content270; 283 calculations lead to the suggestion that the $2-$3 region of the investigated mutants 
are more flexible than that of HuPrP(WT). This hints to the possible presence of structural 
fingerprints across the PMs that are relevant for the conversion to HuPrPSc. 
 Here we investigate the effect of PMs in HuPrPC GD by using a MD protocol based on the 
AMBER99 force field288; 289. This protocol has been validated against structural data of a few HuPrP 
mutants in a previous study of our lab263. In particular, thisstudy263 has found that the !2-$2 loop and 
the $2-$3 region in two PMs, HuPrP(Q212P-129M) and HuPrP(E200K-129M), differ significantly 
from those in HuPrP(WT) and HuPrP(PP), in full agreement with NMR structural information147; 260. 
In this work we extend this MD protocol to study 30 HuPrP mutantsm containing PMs located in 
GD (Fig. 4.1). Comparison is made with results of HuPrP(WT) and HuPrP(PP) obtained previously 
by applying the same protocol263 as well as with available NMR/X-ray structures of HuPrP 
variants147; 260; 279; 290. Overall, 1.6 µs MD simulations are performed here. The calculations point to 
the presence of several structural traits in all or most of the PMs. These traits hint to the molecular 
basis of the early stage of the HuPrPC!PrPSc conversion. 
                                                      
l Hereinafter, each variant is denoted by the mutation (the first five characters inside the parentheses) followed 
by the M/V polymorphisms at position 129 (last four characters inside the parentheses) associated with the 
mutation. 
m These include all the known PMs in the GD at the time of this study along with their associated 




Figure 4.1: The location of the PMs and polymorphisms in HuPrP GD studied in this work. The PMs are 
colored according to the associated Hu TSE phenotypes: blue, familial Creutzfeldt-Jakob’s disease (fCJD); 
red, Gerstmann-Sträussler-Scheinker disease (GSS); green, fatal familial insomnia (FFI); gray, unclassified 
phenotype. The polymorphisms are colored in black. Experimental structural information is available for the 
underlined variants (E200K-129M260, V210I-129M148, Q212P-129M147 and E219K-129M290 from NMR, 
F198S-129V279 and D178N-129M/V279 from X-ray crystallography). PMs with the highest worldwide 
incidence are boxed286.  
4.2 Computational details 
4.2.1 The simulation systems 
The structural models of the mutants were based on HuPrP(WT) GD NMR structure 
(residues 125-228, PDB entry 1HJN) at pH 7250. 1HJN is the only solution structure of HuPrP(WT) 
resolved at pH 7, which corresponds to the desired pH of our MD simulations. The best 
representative conformer of 1HJN is not indicated, whilst the minimized average structure, 
1HJM250, may not represent well the structure ensemble291. Therefore, a cluster analysis292 was 
performed on the 20 conformers in 1HJN to identify a representative as the initial structure for the 
MD simulations. Using the procedure validated previously263, the PMs and associated 
polymorphism were introduced into HuPrP(WT) using the Swiss-Pdb Viewer (also known as 
DeepView) 4.0293 to obtain the initial models of 30 mutants.  
Four histidines (H140, H155, H177, and H187) are present in the GD of HuPrP(WT). At pH 
7, the histidine side chains may be neutral or, to a smaller extent, positively charged. To assign their 
protonation state at pH 7, we noticed the following points. i) H140, H155, and H177 are solvent-
exposed, so that one or two of their side-chain nitrogen atoms could be protonated. ii) H187 forms a 
single intramolecular hydrogen bond (HB) which involves H187 N# atom and R156 backbone 
carbonyl. Hence, it is very likely that N# is protonated and the N#-H group acts as the HB donor. On 
the other hand, N) is solvent-exposed, thus it could be protonated or deprotonated. iii) Test 
calculations performed here (see Appendix 1.1 for details) along with an earlier study294 point to an 
 63 
instability of the structure featuring the charged, di-protonated states. Instead, by protonating all the 
histidine residues at N# atom only, the simulations could reproduce accurately the structural 
determinants of the NMR structure of HuPrP(WT) resolved at pH 7 (discussed in Appendix 1.1 and 
ref. 263). Inspection of all of the 30 mutant structures showed that point i) and point ii) hold true for 
them as well. Hence, we chose to protonate the four histidine residues at N# in all of the mutants 
considered here. With such a choice of the protonation state, the calculations turned out to 
reproduce fairly well the structural determinants of the available NMR structures of HuPrP variants 
including HuPrP(E200K-129M)260, HuPrP(V210I-129M)148, HuPrP(Q212P-129M)147 and 
HuPrP(PP)290 (discussed in section 4.3 and ref. 263).  
The aspartic acid, glutamic acid, lysine and arginine residues were considered in their ionized 
form. The N- and C-termini of the protein were considered charged, same as in the HuPrP(WT) 
NMR structure250. Following the protocol of ref. 263, we solvated each model in a box of explicit 
water, ensuring that the solvent shell extends for at least 16 Å around the protein. Thus, each system 
contained 10,140 to 10,160 water molecules and 2 to 4 Na+ counter ions. The total number of atoms 
ranged from 31,600 to 33,400. Periodic boundary conditions were applied. 
4.2.2 MD simulations 
 Same as in ref. 263, the AMBER99 force field288; 289 was used for the protein, while the Åqvist 
parameters295 and the TIP3P model296 were used for the counter ions and the water molecules, 
respectively. Long-range electrostatic interactions were treated with the particle mesh Ewald 
method297. A Fourier spacing of 1.2 Å combined with a fourth-order cubic spline interpolation was 
used. A 12 Å cutoff was used for van der Waals interactions as well as the real-space part of the 
electrostatic interactions298. All bond lengths were constrained with the LINCS algorithm and the 
time step was set to 2 fs. NPT ensemble (T=298K, P=1bar) MD simulations were carried out by 
coupling the systems with the Nosé-Hoover thermostat299 and the Parrinello-Rahman Barostat300; 301. 
The systems underwent 1000 steps of steepest-descent energy minimization with 5000 
kcal·mol-1·Å-2 harmonic position restraints on the protein, followed by 2500 steps of steepest-
descent and 2500 steps of conjugate-gradient minimization without restraints. For each system, the 
starting temperature of MD simulation was 2K. The system was then gradually heated in 12 steps of 
100-ps simulation (from 2K to 25K, 50K, 75K, 100K, 125K, 150K, 175K, 200K, 225K, 250K, 
275K and 298K). For each step, the velocity was generated consistent with a Maxwell-Boltzmann 
distribution at the corresponding temperature. After that, 200-ps equilibration simulations were 
performed. Finally, 50-ns production MD simulations were carried out. This exact protocol had 
already been validated in the previous study on HuPrP variants263, where four sets of 50-ns 
independent MD runs were carried out for HuPrP(WT), HuPrP(E200K-129M), HuPrP(Q212P-
129M) and HuPrP(E219K-129M). The results obtained turned out to be very similar in the four 
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sets. Moreover, they reproduced very accurately all of the available experimental information. Thus, 
here we performed one single 50-ns MD run for each mutant, since it had been shown to provide 
reliable insights into the structural determinants of PMs in ref. 263. All the simulations were carried 
out using GROMACS 4.0.7302 package. 
4.2.3 Data analyses 
Solvent-accessible surface area. The solvent-accessible surface area was calculated using the 
GROMACS g_sas module with a probe radius of 1.4 Å. The van der Waals radii used were 1.5 Å 
for C, 1.2 Å for F, 0.4 Å for H, 1.1 Å for N, 1.05 Å for O, and 1.6 Å for S.  
Salt bridge and .-stacking interactions. A distance cutoff of 5.0 Å was used as a geometry 
criterion for the presence of both salt bridge (SB) and (-stacking interactions between the 
interacting groups. For SB, the distance, dSB, was calculated between the center of mass of anionic 
carboxylate (RCOO-) of either aspartic acid or glutamic acid and that of the cationic ammonium 
(RNH3+) of lysine or the guanidinium [RNHC(NH2)2+] of arginine. Because these SBs were 
dynamically formed and broken during the simulations, an average dSB value over the entire 
trajectory did not describe well the presence/absence of the SBs. Therefore, we performed a cluster 
analysis on each trajectory for each SB using the GROMOS method303 implemented in the 
GROMACS g_cluster module with an RMSD cutoff of 1.0 Å. The main clusters were selected, 
which cover !80% of the overall trajectory. The SBs in the representative conformer of each 
cluster were analyzed according to the geometry criterion. For evaluating (-stacking interactions, 
the distance, d(, was calculated between the centers of mass of non-hydrogen atoms belonging to 
the aromatic rings.  
HB interactions. HBs were examined using the geometry criterion including a cutoff of 3.5 Å 
for the distance between the HB donor and acceptor and a cutoff of 30° for the acceptor–donor–
hydrogen angle.  
Protein flexibility. We used directional statistics in one-dimension space304 to calculate the 
spread of N values of the Ramachandran angles, ($1,… $j,…$N) and ((1,…(j,…(N), during the 
simulations. In this method305, each angle value is represented as a vector in a complex space: , 
where /j is the angle formed with the real axis. / = $ or (. The vector is completely defined by its 
direction, which depends on /j, because the modulus is one. The spread of the set of /j values is 
























Within this definition, the spread is minimum when ADI/= 0: all N unit vectors are aligned on the 
same direction and the vector from N data points has the length . The spread is maximum 
and , if ADI* tends to infinity. The ADI of the residue is then defined as the geometrical 
mean of the angular dispersion of the $ and ( dihedral angles: 
 (4.2) 
It is a measure of the backbone local fluctuations: the larger the ADI, the larger the local flexibility 
and/or the local rearrangements. It has the following advantages over RMSF (see Appendix 1.2 for 
more details): i) it requires no alignment of the different configurations along the trajectory to a 
reference structure; ii) it does not suffer for edge effects, i.e. it does not increase systematically in 
the terminus regions; iii) the value for each residue is strictly dependent on the residue itself.  
ADI may be used to characterize the flexibility of a secondary-structure element by 
averaging its values over the residues belonging to this element. We defined ADI_$i (i = 1, 2, 3) as 
the mean value of the ADI calculated for all the residues belonging to each of the three helices in 
HuPrP. The error assciated to ADI_$i is the standard error of the mean , where n is the 
number of residues belonging to $1, $2 or $3 and + is the standard deviation of the corresponding 
ADI values.  
The ADI calculations have been implemented into a tcl script, which can be utilized with 
VMD306. 
4.3 Results 
Our MD simulations show that the secondary-structure elements present in HuPrP(WT) are 
largely preserved in all the 30 PMs in the 50-ns timescale. The RMSD of C! atoms relative to 











ADI= ADI! !ADI" .
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Table 4.1: RMSDi of C! atoms during the simulations of HuPrP variants with respect to the NMR 
structure of HuPrP(WT). 
HuPrP variant RMSD (Å) HuPrP variant RMSD (Å) 
WT 2.4±0.3 E196K-129M 2.8±0.4 
G131V-129M 2.3±0.1 F198S-129V 2.3±0.3 
S132I-129M 2.3±0.4 E200K-129M 2.0±0.2 
A133V-129M 2.2±0.3 E200K-129V 2.3±0.4 
R148H-129M 3.0±0.3 D202N-129M 2.7±0.4 
D178N-129M 2.4±0.3 D202N-129V 2.7±0.4 
D178N-129V 2.3±0.4 V203I-129M 2.8±0.4 
V180I-129M 2.5±0.3 R208H-129M 2.3±0.3 
T183A-129M 3.1±0.2 R208H-129V 2.9±0.2 
T183A-129V 3.1±0.4 V210I-129M 2.7±0.2 
H187R-129V 2.4±0.3 V210I-129V 2.8±0.2 
T188K-129M 3.1±0.2 E211Q-129M 2.4±0.3 
T188A-129M 2.7±0.3 Q212P-129M 2.0±0.2 
T188A-129V 2.4±0.3 Q217R-129V 2.5±0.6 
T188R-129V 2.6±0.3 Y218N-129V 3.9±0.4 
T193I-129M 3.2±0.3 PP 2.0±0.2 
i Standard deviations (SDs) are indicated by “±”. 
 
The 30 PMs lose completely or partly a SB network which embraces the !2-!3 region and 
the !1 helix (see Appendix 1.3 for detailed data). This network is stably present in the simulations 
of HuPrP(WT) and in HuPrP(PP) (Fig. 4.2 and Table 4.2), consistent with the NMR structures250; 290. 
It involves five residues in !3 (E200, K204, E207, R208, and E211), two residues in !1 (E146 and 
R156) and one residue in the !2–!3 loop (E196) (Fig. 4.2 and Table 4.2). The disruption of the SB 
network has been observed also in the available NMR structures of the PMs, namely 
HuPrP(E200K-129M)260, HuPrP(V210I-129M)148 and HuPrP(Q212P-129M)147. In particular, the 
R156-E196 and the E146-K204 SBs play a role in preserving the tertiary structure of the GD252; 265; 
266; 269. The former connects the !2-!3 region to the C-terminal part of !1 (C-!1, hereinafter), and 
the latter connects !3 to !1, respectively. These SBs are lost in the majority of the 30 PMs (Fig. 4.2 
and Table 4.2). The disruption of the SB network is accompanied by the formation, in most but not 
all the PMs, of a SB between K204 and E207 in the !3 helix, whereas this SB is absent in 












Figure 4.2: Schematic representation of the SB network 
embracing the $2-$3 region and the $1 helix. Each SB is 
indicated with dotted line and a corresponding number: 1, 
E211-R208 SB; 2, E207-R208 SB; 3, E207-K204; 4, E200-
K204 SB; 5, E146-K204 SB; 6, E196-R156 SB. 
HuPrP(WT) and HuPrP(PP) feature the SBs 1, 2, 4, 5 and 6. 
Most of these SBs are lost in the PMs, whilst a new SB, 3, 
is formed. The SBs are identified using a cluster analysis 
(see 3.2.2 for the method). Helices and !-strands are 
indicated with cylinders and arrows respectively. The 
C179-C214 disulfide bond is shown with a solid line. 
 
 
Table 4.2: The presence of SBs in the SB networki embracing the $2-$3 region and the $1 helix in 
the main clusters of each HuPrP variant.  
HuPrP variant $3 $1 with 
$3 
!1 with the 
!2-!3 loop HuPrP variant $3 
$1 with 
$3 
!1 with the 
!2-!3 loop 
WT 1, 2, 4 5 6 E196K-129M 3 – – 
G131V-129M 3 – 6 F198S-129V – – 6 
S132I-129M 1 – 6 E200K-129M 3 – 6 
A133V-129M 1, 2 5 6 E200K-129V 1 5 6 
R148H-129M 3 – – D202N-129M – – – 
D178N-129M – – – D202N-129V 3 – 6 
D178N-129V – – – V203I-129M – – – 
V180I-129M – – – R208H-129M – – – 
T183A-129M – – – R208H-129V – – 6 
T183A-129V 4 – – V210-129M 1, 2 – – 
H187R-129V – – – V210I-129V 1, 2 – – 
T188K-129M – – – E211Q-129M – – - 
T188A-129M – 5 – Q212P-129M 1, 2 – – 
T188A-129V – 5 6 Q217R-129V – – – 
T188R-129V 3 – 6 Y218N-129V – – 6 
T193I-129M – 5 – PP 1, 2, 4 5 6 
ii The numbers represent different SBs, same as those used in Fig. 4.2 (1, E211-R208; 2, E207-R208; 3, E207-
K204; 4, E200-K204; 5, E146-K204; 6, E196-R156). 
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In the "2–!2 loop, hydrophobic intramolecular interactions between the loop and C-!3 (Fig. 
4.3A) are undermined in the PMs compared to those in HuPrP(WT) and HuPrP(PP) (Table 4.3). 
These interactions include the Y169-F175-Y218 (already reported in ref. 263 for HuPrP(E200K-
129M) and HuPrP(Q212P-129M)) and the M166-Y225 (-stacking interactions (Fig. 4.3B). The 
latter appear stable in the NMR structures of HuPrP(WT)250 and HuPrP(PP)290 (Table 4.5). These 
results reproduce the features observed in the NMR and X-ray structures of HuPrP(E200K-
129M)260, HuPrP(V210I-129M)148, HuPrP(Q212P-129M)147, HuPrP(F198S-129V)279, and 
HuPrP(D178N-129M/V)279 (Table 4.4). 
 
Table 4.3: *-stacking interactions in the "2-!2 loop and C-!3 region described as average d( values 
(defined in section 4.2.3).  
HuPrP variant Y169-F175i d( (Å) F175-Y218i d( (Å) M166-Y225ii d( (Å) 
WT 4.5±0.2 4.6±0.03 4.9±0.7 
G131V-129M 5.2±0.2 6.0±0.03 7.9±0.5 
S132I-129M 5.7±0.7 5.2±0.03 4.7±0.8 
A133V-129M 4.8±0.3 5.3±0.02 7.7±2.9 
R148H-129M 4.8±0.2 5.4±0.02 6.1±2.0 
D178N-129M 7.2±0.6 5.3±0.03 5.6±2.0 
D178N-129V 6.6±1.0 5.2±0.03 5.2±1.5 
V180I-129M 6.8±0.8 5.2±0.03 10.3±2.3 
T183A-129M 7.4±0.3 5.5±0.03 10.8±1.3 
T183A-129V 4.8±0.3 5.3±0.02 6.6±1.4 
H187R-129V 10.7±1.6 5.1±0.02 6.8±1.7 
T188K-129M 5.1±0.3 5.4±0.03 9.6±2.3 
T188A-129M 7.3±0.4 5.4±0.03 9.8±2.7 
T188A-129V 6.5±0.3 5.0±0.03 4.5±0.5 
T188R-129V 5.4±0.3 5.4±0.03 9.6±3.2 
T193I-129M 5.4±1.0 5.3±0.03 5.6±1.6 
E196K-129M 4.9±0.3 5.3±0.03 10.4±3.0 
F198S-129V 9.6±2.8 5.3±0.03 6.2±2.0 
E200K-129M 8.4±0.7 5.0±0.04 6.0±2.0 
E200K-129V 4.9±0.3 5.1±0.03 6.0±1.3 
D202N-129M 5.4±0.9 5.3±0.03 6.3±3.0 
D202N-129V 5.1±0.2 5.3±0.03 5.3±0.9 
V203I-129M 5.6±0.6 5.3±0.03 8.3±4.4 
R208H-129M 4.8±0.3 5.3±0.02 6.2±0.7 
R208H-129V 6.0±0.9 5.2±0.03 6.7±2.9 
V210I-129M 10.9±1.0 5.1±0.02 5.9±1.0 
V210I-129V 10.5±1.0 5.1±0.02 7.0±2.0 
E211Q-129M 7.3±0.3 5.4±0.03 10.3±2.5 
Q212P-129M 8.6±0.5 4.7±0.03 5.5±3.0 
Q217R-129V 5.5±0.9 5.1±0.03 4.9±0.5 
Y218N-129V 6.4±0.10 — 6.3±1.5 
PP 4.4±0.4 4.3±0.02 4.9±0.8 
i Centroid distance between the aromatic rings (only carbon atoms considered).  





Figure 4.3: Selected properties emerging from the MD simulations. A) Y169-F175, F175-Y218, and M166-
Y225 (-stacking interactions. The values in HuPrP(WT) and HuPrP(PP) are highlighted with black and red 
bars, respectively. The interactions are described here in terms of distances between the centers of mass of the 
aromatic rings. The cartoon represents the interactions in HuPrP(WT). B) Y169 solvent exposure. The values 
in HuPrP(WT) and HuPrP(PP) are highlighted with black and red bars, respectively. The red dotted line 
underlines the value for HuPrP(WT). The PMs in which Y169 is totally outside the loop and completely 
solvent-exposed are boxed in blue and green for the calculated and experimental structures147; 260; 279, 
respectively. These PMs feature a large cavity formed by the "2-!2 loop and C-!3, which is indicated with a 





Table 4.4: Calculated and experimental *-stacking interactions in the "2-!2 loop and C-!3 region.  
HuPrP variant Y169-F175 (Å) F175-Y218 (Å) M166-Y225 (Å) Experimentali Calculated Experimental Calculated Experimental Calculated 
WT250 5.3 4.5±0.2 5.3 4.6±0.3 4.9 4.9±0.7 
D178N-129M279, ii 14.1 7.2±0.6 5.3 5.3±0.3 5.6 5.6±2.0 
D178N-129V279 10.7 6.6±1.0 5.2 5.2±0.3 —iii 5.2±1.5 
F198S-129V279, ii 14.2 9.6±2.8 5.6 5.3±0.3 5.8 6.2±2.0 
E200K-129M260 14.2 8.4±0.7 5.5 5.0±0.4 6.0 6.0±2.0 
Q212P-129M 32 13.2 8.6±0.5 7.7 4.7±0.3 15.0 5.5±3.0 
V210I-129M148 14.6 10.9±1.0 8.5 5.1±0.2 17.1 5.9±1.0 
PP290 9.6 4.4±0.4 4.8 4.3±0.2 5.9 4.9±0.8 
i Measured as the d( values (defined in section 4.2.3) in the X-ray structure or the best representative 
conformer in the NMR structure. 
ii Crystallized as a dimer279. 
iii Missing side chain. 
 
The Y169 residue in the "2-!2 loop turns out to be more solvent-exposed in most PMs than 
in HuPrP(WT) and HuPrP(PP). This is evaluated by calculating the solvent-accessible surface area 
of Y169 along the trajectory of each HuPrP variant (Table 4.5). Remarkably, Y169 has been found 
completely outside the loop in HuPrP(T183A-129M), HuPrP(E200K-129M), HuPrP(H187R-129V), 
HuPrP(F198S-129V), HuPrP(V210I-129M/V), HuPrP (E211Q-129M), HuPrP(Q212P-129M), and 
HuPrP (Y218N-129V). As already noted in ref. 263, the predicted conformational change reproduces 
what is found in the available NMR structures of HuPrP(Q212P-129M) and HuPrP(E200K-
129M)147; 260. Here, it is shown to also reproduce this feature in the X-ray structures of 
HuPrP(F198S-129V)279 and the NMR structure of HuPrP(V210I-129M)148. It is worth noting that in 
the recently published NMR structure of HuPrP(PP)290, the "2–!2 loop appears flexible and in some 
of the conformers Y169 is solvent-exposed. However, as the structure was resolved at pH 5.5, it 
may differ from that at pH 7. Indeed, acidic pH has been shown to decrease the stability and affect 
the structure of HuPrP250. 
The flexibility of helices $2 and $3 has been suggested to increase on passing from 
HuPrP(WT) to some PMs261; 263; 265; 266; 269; 270; 272; 281; 283; 287. The flexibility was evaluated mainly by 
calculating RMSF263; 265; 266; 269; 272; 281. Here we use ADI_$2 and ADI_$3 for characterizing the 
flexibility (as described in section 4.2.2). In most of the PMs, ADI_$3 turns out to be larger than 
that of HuPrP(PP) and of HuPrP(WT) (Fig. 4.4A)n. This is caused, at least in part, by the loss of the 
SBs involving !3 on passing from HuPrP(WT) and HuPrP(PP) to the PMs. RMSD calculations 
(data not shown) and simple visual inspection of the investigated systems suggest that no significant 
                                                      
n The only exceptions are HuPrP(E200K-129V) and HuPrP(F198S-129V), whose ADI_$3 are smaller than 
that of HuPrP(WT). 
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rearrangements of the helix take place. Hence, !3 appear to be more flexible in most of the PMs 
than in HuPrP(PP) (and HuPrP(WT)).  
 
Table 4.5: Solvent-accessible surface area (SASA) of residue Y169 calculated over the MD 
trajectory of each HuPrP variant.  
HuPrP variant Y169 SASA (Å2)i HuPrP variant Y169 SASA (Å2)a 
WT NE 4.9±1.3 E196K-129M E 5.2±1.1 
G131V-129M E 4.6±0.8 F198S-129V O 13.5±3.3 
S132I-129M VE 6.0±1.1 E200K-129M O 12.3±1.1 
A133V-129M E 5.5±1.1 E200K-129V VE 6.0±1.3 
R148H-129M NE 4.9±0.9 D202N-129M VE 6.8±1.1 
D178N-129M VE 6.4±1.1 D202N-129V NE 4.6±0.8 
D178N-129V VE 6.7±1.2 V203I-129M E 5.6±1.3 
V180I-129M VE 6.4±1.5 R208H-129M E 5.3±0.9 
T183A-129M O 10.2±0.9 R208H-129V VE 7.1±1.3 
T183A-129V E 5.2±0.8 V210I-129M O 15.3±2.8 
H187R-129V O 15.0±2.5 V210I-129V O 16.4±2.4 
T188K-129M NE 4.0±0.9 E211Q-129M O 10.2±1.0 
T188A-129M VE 9.6±1.5 Q212P-129M O 12.9±1.6 
T188A-129V VE 8.4±1.0 Q217R-129V VE 6.4±1.6 
T188R-129V VE 6.6±1.3 Y218N-129V O 12.9±1.3 
T193I-129M E 5.8±1.0 PP NE 5.0±1.2 
i Not Exposed (NE): SASA& 5.0 Å2, Exposed (E): SASA > 5.0 Å2, Very Exposed (VE): SASA + 5.0 Å2, 
Outside (O): SASA + 10.0 Å2. SDs are indicated by “±”. 
 
The ADI_!2 values of HuPrP(WT) are smaller than those of the PMs, but those of 
HuPrP(PP) are not (Fig. 4.4B). A large rearrangement of C-!2 (T193-K194) is likely to 
significantly contribute to the relatively large value of ADI_!2 in HuPrP(PP). This rearrangement is 
accompanied by the formation of a HB between H155 and E196, as well as by an increase of 
intramolecular contacts in the protein (Fig. 4.4C). This HB is only partially formed in 
HuPrP(F198S-129V) and HuPrP(T193I-129M) and is not present in HuPrP(WT) and in the other 28 
PMs (Table 4.6). At the speculative level, this might increase the stability of the protein in this 
variant. Interestingly, in the NMR structure of HuPrP(PP) at pH 5.5 (which was resolved after this 
study had been carried out), the conformation at C-!2 turn out very similar to that in our 
simulations. C-!2 is in shorter distance to the !1 helix than those in HuPrP(WT), which enhances 





Figure 4.4: Flexibility analysis of !2 and !3 helices. A) ADI_!3 and B) ADI_!2 for all the HuPrP variants; 
HuPrP(WT) and HuPrP (PP) are highlighted with black and red bars, respectively; error bars indicate the 
standard error of the mean (see 3.2.2 for the definition). C) The observed conformational rearrangement in 
HuPrP(PP) at C-!2. Selected conformations of HuPrP(WT) and HuPrP(PP) are shown in cartoon 
representation. Residues H155 and E196 (in licorice) form a HB between in HuPrP(PP). The intramolecular 
contacts counted over the whole trajectories are plotted per residue for HuPrP(WT) (black line) and 
HuPrP(PP) (red line). HuPrP(PP) shows an increase of contacts in the region of the !2-!3 loop and the N-




Table 4.6: Hydrogen bond (HB) between residues H155 and E196 during the MD simulations of 
each HuPrP variant, calculated as number of HB per frame.  
HuPrP variant H155-E196 HBi HuPrP variant H155-E196 HB HuPrP variant H155-E196 HB 
WT 0.00 T188K-129M 0.00 V203I-129M 0.00 
G131V-129M 0.00 T188A-129M 0.00 R208H-129M 0.00 
S132I-129M 0.00 T188A-129V 0.00 R208H-129V 0.00 
A133V-129M 0.01 T188R-129V 0.00 V210I-129M 0.30 
R148H-129M 0.14 T193I-129M 0.84 V210I-129V 0.00 
D178N-129M 0.00 E196K-129M — E211Q-129M 0.00 
D178N-129V 0.00 F198S-129V 0.75 Q212P-129M 0.20 
V180I-129M 0.00 E200K-129M 0.00 Q217R-129V 0.12 
T183A-129M 0.00 E200K-129V 0.14 Y218N-129V 0.00 
T183A-129V 0.26 D202N-129M 0.00 PP 1.00 
H187R-129V 0.28 D202N-129V 0.00   
i Calculated as average number of HB per frame. 
 
4.4 Discussion 
In this study, we have carried out 1.6 µs MD simulations in explicit solvent for 30 HuPrP 
mutants containing known PMs in the GD. Along with the previous study on HuPrP(WT), 
HuPrP(PP), HuPrP(E200K-129M) and HuPrP(Q212P-129M), the simulations have been compared 
with experimental data263 and other MD studies reported earlier261; 262; 264; 265; 266; 267; 268; 269; 270; 271; 272; 281; 
307. The results point to common structural traits in the mutants independent of the position and the 
chemical nature of the PMs. These common traits include: i) the disruption of a specific SB network 
present in HuPrP(WT) and HuPrP(PP) in all PMs, with consequent increase in flexibility of $3 in 
most PMs; ii) the loss or the weakening of hydrophobic interactions present in HuPrP(WT) and 
HuPrP(PP) in all PMs; iii) an increased solvent-exposure of Y169 in the !2-$2 loop relative to 
HuPrP(WT) and HuPrP(PP) in most PMs. These findings may have biological relevance as 
discussed below. 
i) The partial or complete loss of the SB network in the $2–$3 region in all PMs may lead to 
a destabilization of the PrP fold in those regions. Indeed, according to in silico studies, the PrP fold 
of $2 and $3 is assisted by intramolecular interactions with the rest of the protein308; 309; 310 rather 
than those of the $-helices themselves (as it has been already observed in other proteins with a 
significant content of $-helices310; 311; 312). The $2-$3 region is per se highly fibrillogenic249; 255; 256; 257; 
258; 310; 313, hence the disruption of intramolecular interactions (such as SBs) may play a key role in 
the PrPC!PrPSc conversion. Most importantly, the residues involved in the SB interactions (Fig. 
4.2, Table 4.2) are highly conserved258 and their absence is linked with pathogenic mutants258. 
Possibly due to the loss of SBs, $3 is more flexible in most PMs.  
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ii) The weakening of hydrophobic interactions between the !2-$2 loop and C-$3 in the PMs 
is consistent with in vitro and in vivo studies10; 11; 137; 138; 141; 142, which indicate that the long-range 
interactions involving these regions play a role in prion disease susceptibility. As already mentioned 
in Chapter 2, the !2-$2 loop could be highly flexible (same as in HuPrP55; 56) or well structured in 
some other mammalian species135 136; 137; 138; 139; 140. Linking the !2-$2 loop to C-!3 can partially 
inhibit oligomerization in ovine PrP314. Single-residue mutations in the !2-$2 loop and C-$3 can 
cause the otherwise flexible "2-!2 loop to adopt rigid structures137; 138; 141. Such mutations, when 
expressed in transgenic mice, could lead to spontaneous and progressive prion-like disease11 or alter 
the susceptibility to different PrPSc strains10; 142.  
(iii) The larger solvent-exposure of Y169 in the majority of PMs than in HuPrP(WT) and 
HuPrP(PP) is consistent with the fact that this residue, along with the rest of the !2-$2 loop and C-
$3, forms a disease-linked epitope for a monoclonal antibody315, a hypothetical facilitator of prion 
conversion involved in the development of TSE316. Therefore, the PMs are expected to interact 
differently with this antibody relative to HuPrP(WT). At the speculative level, we expect that this in 
turn may affect the HuPrPC!HuPrPSc conversion. We further noticed that the rearrangement of 
Y169 creates a cavity (Fig. 4.3B), which might accommodate planar compounds that are able to 
inhibit prion fibrillization317; 318; 319; 320.  
4.5 Conclusion 
Our calculations based on AMBER99 force field288; 289 identify key structural features (few of 
which have already been reported for some PMs147; 260; 261; 263; 270) that emerge as common traits 
among most or all of the PMs concerning HuPrP GD.  
From a physiological point of view, the altered conformation observed in the PMs might 
cause a different affinity for cellular membranes and, consequently, an aberrant localization of 
HuPrP in cellular compartments, favoring the formation of altered endoplasmic reticulum 
topologies43; 321. Independent evidence derived from cell-line assays on some of the PMs studied 
here shows that these mutations affect folding and maturation of PrPC in the secretory pathway of 
neuronal cells322; 323.  
The structure-function relationships suggested in this work may contribute to understanding 
the molecular basis of familial Hu TSE. They may also serve to provide a molecular explanation for 
PrPSc formation in the more common sporadic forms of TSE. 
Finally, the highlighted “hot spot” regions identified here correspond to the optimal targets 
proposed in several antibody- and ligand-binding studies324; 325; 326; 327 as the key regions for 
PrPC!PrPSc conversion or for interactions with cofactors.  
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We close this section by pointing out that our MD calculations are subject to limitations, as in 
any modeling study. In particular, the timescale of the simulations is several orders of magnitude 
shorter than that of the NMR experiments with which comparison has been made. However, in this 
specific case, the AMBER99-based MD protocol used here had been shown to reproduce strikingly 
well the available NMR structures263. Importantly, the predictions turned out to be rather 
independent of the initial conditions of the MD simulations263. Thus, for this specific system, one 
may be confident about the predictive power of the simulations as far as the NMR structural 
determinants are concerned. 
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 Dominant-negative Effects in Prion Diseases: Insights from Chapter 5
MD Simulations on Mouse Prion Protein Chimeras 
In Chapter 4, it has been shown that pathogenic mutations in HuPrP affect the protein 
structure in a common manner, which hints to the underlying mechanism of familial Hu TSE. In 
transgenic mice, mutations in mouse (Mo) PrP can determine the susceptibility of the mice to the 
infection of different PrPSc strains. Some of these mutations also show a dominant-negative effect, 
thus halting the replication process through which endogenous wild-type MoPrP is converted into 
MoPrPSc. Using all-atom MD simulations in explicit solvent, here we study and compare the 
structures of HuPrP, MoPrP, 10 Hu/Mo PrP chimeras and 1 Mo/sheep PrP chimera. Overall, ~2 µs 
of MD simulations are carried out. The simulations reveal distinct structural features in these PrP 
variants, which are related to the different responses to PrPSc infection. Our findings suggest that the 
interactions between !1 helix and the N-terminal of !3 helix in PrPC are critical in the PrPC!PrPSc 
conversion, whereas the "2-!2 loop conformation plays a role in the dominant-negative effect. 
5.1 Introduction 
The link between mutations in PrP and TSE has been further verified using transgenic (Tg) 
mice expressing mutations in the MoPrP gene328; 329; 330. When mutations associated with familial Hu 
TSE were expressed in Tg mice, these mice could spontaneously develop TSE-like 
neurodegenerative diseases328; 329; 330. Tg mice expressing both MoPrP and HuPrP did not exhibit 
abbreviated incubation times when infected with HuPrPSc. However, Tg mice expressing chimeric 
PrP in which a 9-residue segment was replaced with HuPrP sequence were found highly susceptible 
to HuPrPSc and exhibited abbreviated incubation times129. Recently, Tg mice expressing MoPrP 
chimeras (CMPrP) containing residues from other species have been reported to exhibit either 
transmission barriers against certain PrPSc strains10 or spontaneous generation of PrPSc11; 12. 
Interestingly, a variety of CMPrP investigated in scrapie-infected Mo neuroblastoma (ScN2a) cells 
showed diverse susceptibility or resistance to MoPrPSc infection13. Some of these CMPrP also acted 
as “dominant-negatives” to inhibit the endogenous wild-type (WT) MoPrP from being converted 
into PrPSc. The dominant-negative effects of residue substitutions in PrP have been reported and 
deeply investigated in humans and in sheep. Naturally occurring polymorphisms in PrP have been 
known to influence the etiology and neuropathology of TSE both in humans8 and in sheep9. In 
humans, the polymorphism E219K was found to be protective against sporadic CJD when 
expressed in heterozygosis130; 131. In sheep, three polymorphisms are acutely linked to the occurrence 
of sheep scrapie: A136V, R154H and Q171R/H. These generate five commonly observed alleles: 
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ARQ, ARR, AHQ, ARH and VRQ. ARR and AHQ are associated with resistance to scrapie, 
whereas ARQ, ARH and VRQ are linked with susceptibility to scrapie132; 133. 
 Taken together, these experimental data suggest that subtle changes in PrPC structure can 
alter PrPSc propagation, possibly by (de)stabilizing the physiological folding of PrPC and/or 
affecting its interactions with some yet unknown factors. Here, we apply our well-established MD 
protocol (used in Chapter 4) to study the atomistic structures of 11 CMPrP globular domain (GD) 
(Table 5.1), which are then compared with the GD structures of WT MoPrP and HuPrP. Among 
these 11 CMPrP, 10 CMPrP are Hu/Mo chimeras that contain 1 or 2 mutations corresponding to the 
Hu codons. Another CMPrP, CMPrP(Q172R)o, corresponds to a natural ovine dominant-negative 
polymorphism331; 332. All these 11 CMPrP have been previously investigated in ScNa2 cells for their 
response to MoPrPSc infection13. We include CMPrP(Q172R) in this study because the mutation is 
located in the PrPC "2-!2 loop which composes an epitope crucial for prion susceptibility10; 12. 
Although CMPrP(Q172R) may not have the same significance as the Hu/Mo CMPrP, studying it 
provides additional information and confirms our findings with Hu/Mo CMPrP. The origin of these 
mutations as well as their in vivo and in vitro effects are listed in Table 5.1. This study may explain 
the transmission barrier between Hu and Mo PrPSc strains, as well as the dominant-negative effects 
of certain PrP polymorphisms.  
 
  
                                                      
o Hereinafter, each CMPrP is denoted (in parenthesis) with the mutation(s) in MoPrP numbering according to 
the equivalent residue(s) in HuPrP. This is to keep a coherent numbering throughout the thesis. 
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Origin of the 
mutation(s) 
Q168E ScN2a cells13 # - Hu codon 
N171S ScN2a cells13 - - Hu mutation linked to prion-like disorders333 
Q172R ScN2a cells13 + + Sheep protective polymorphism331; 332 
V215I ScN2a cells13 # + Hu codon 
V215I_Q219E ScN2a cells13 + - Hu codons 
Q217R ScN2a cells13 + + Hu GSS-linked mutation156 
Q217R_Q219E ScN2a cells13 + - 
R217: Hu GSS-linked 
mutation156 
E219: Hu codon 
Q219K ScN2a cells
13, 
Tg mice334 + + 
Hu protective 
polymorphism335 
Q219E ScN2a cells13 + - Hu codon 
K220R ScN2a cells13 - - Hu codon 
K220R_Q219E ScN2a cells13 + - Hu codons 
i All the experiments were performed in vitro except for Q219K where the same findings have been reported 
also in Tg mice. 
ii “+” indicates the CMPrP is NOT converted into PrPSc. “#” indicates the CMPrP is less efficiently converted 
than the control (WT MoPrP). “-” indicates the CMPrP shows no resistance to MoPrPSc.  
iii “+” indicates the CMPrP inhibits the co-expressed MoPrP from being converted to PrPSc (the dominant-
negative effect). “-”indicates the CMPrP shows no dominant-negative effect. 
 
5.2 Computational details 
5.2.1 The simulation Systems  
The structural models of MoPrP and the CMPrP GD were based on the NMR structure of 
MoPrP GD (PDB entry 1XYX) resolved at pH 4.558, the only solution structure available so far for 
MoPrP. Note that 1XYX is the refined structure of an earlier PDB entry 1AG2336 resolved at the 
same pH. The best representative conformer (model 1) of the 1XYX ensemble58 was used. 
Following the same procedure used in Chapter 4 (section 4.2.1), the mutations in CMPrP were 
introduced into WT MoPrP using Swiss-PdbViewer (DeepView 4.0)293. The structural model of 
HuPrP was the one used in Chapter 4 (section 4.2.1). 
The aspartic acid, glutamic acid, lysine and arginine residues were considered in their ionized 
form at pH 7. Three histidine residues, H140, H177, and H187, are present in the GD of MoPrP and 
CMPrP. They have the same local environment as the corresponding histidines in HuPrP (already 
described in Chapter 4, section 4.2.1). Same as in Chapter 4, test simulations were carried out to 
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determine the protonation states of H140, H177, and H187 in these simulation systems. The test 
calculations suggest that H140, H177, and H187 adopt the same N#-protonation neutral state as 
those in HuPrP (see Appendix 2.1 for details). Other protonation states introduced instability to the 
protein structure (Appendix 2.1).  
5.2.2 MD Simulations 
The simulations were performed using the same protocol described in Chapter 4 (section 
4.2.2). Each system contained 9,540 to 10,720 water molecules and 0 to 2 Na+ counter ions. The 
total number of atoms ranged from 29,700 to 33,240. However, the latest AMBER99SBidln 
(instead of AMBER99) force field337 was used to treat the protein. A newer GROMACS version 
4.5338 was used to perform the simulations. Because our initial structural models are based on the 
PDB 1XYX resolved at pH 4.5, these models may differ considerably from the structures at pH 7. 
Therefore, we performed three independent MD runs on each system, starting from different 
random seeds for the initial velocity generation. 
5.2.3 Data analyses 
All the analyses were carried out with GROMACS 4.5 modules and VMD339 except for the 
secondary-structure analysis which was performed using DSSP software340. 
5.3 Results 
Three independent MD runs are carried out on HuPrP, MoPrP and each of the 11 CMPrP 
(Table 5.1). During all the MD runs the systems appear to reach equilibrium within 10 ns, as 
indicated by the RMSD of C! atoms as a function of simulation time (Fig. A2.1 in Appendix 2). 
Thus, the last 50 ns of equilibrated trajectory are taken from each MD run for analysis, which yield 
1.95 µs of dynamics data.  
All CMPrP maintain the 3D fold in GD similar to MoPrP and HuPrP during the simulations. 
Large fluctuations are observed in the "2-!2 loop (residues 167-171) and the C-terminal of !3 helix 
(C-!3, residues 219-231) (Fig. 5.1). Indeed, these two fragments were poorly defined in MoPrP 
NMR structure, indicating structural disorder or increased mobility341. Excluding the flexible 
terminal residues (125-127 and 220-231), the GD of CMPrP during our simulations show RMSD of 
C! atoms no more than 2.7±0.4 Å from the MoPrP NMR structure341 or 2.8±0.7 Å from the HuPrP 
NMR structure55 (Table 5.2). Consistently, the radius of gyrations (Rg) of C! atoms averaged along 
the x, y and z axes ranges from 13.3±0.1 Å to 13.6±0.2 Å for residues 128-219 of each CMPrP 
(Table 5.2). All CMPrP except CMPrP(K220R) show smaller RMSF of C! atoms than those of 
MoPrP. These fluctuations are similar to those of HuPrP (Fig. 5.1). CMPrP(K220R) exhibits large 
fluctuations in residues 133-157 which contain the "1-!1 loop and the !1 helix, as well as in 
residues 190-199 which correspond to the N-terminal of !3 (N-!3) (Fig. 5.1). These fluctuations 
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Figure 5.1: A-D) RMSF of C! atoms in GD averaged over three independent 50-ns MD trajectories of each 
CMPrP, in comparison with those of MoPrP and HuPrP. The plot of each CMPrP is labeled with the 
mutation(s) in the CMPrP. E) The final conformation during the MD of MoPrP, of HuPrP and of all the 
CMPrP are superimposed on the HuPrP NMR structure56. The "2-!2 loop (residues 167-171) and C-!3 




Table 5.2: RMSD of C? atoms and Rg of residues 128-219 of MoPrP, HuPrP and all the CMPrP 
during MD. The RMSD are calculated relative to the NMR structures of MoPrP (PDB code: 1XYX) 



















1 1.8±0.4 2.4±0.2 13.6±0.2 CMPrP 
(V215I_Q219E) 
1 1.7±0.1 2.0 ±0.2 13.4±0.1 
2 1.8±0.2 2.1±0.2 13.3±0.1 2 1.9±0.2 2.1±0.2 13.4±0.1 
3 1.8±0.2 1.9±0.1 13.3±0.1 3 1.6±0.2 2.2±0.2 13.4±0.1 
HuPrP 
1 1.9±0.2 1.7±0.2 13.5±0.2 CMPrP 
(Q217R) 
1 1.7±0.2 2.2±0.2 13.3±0.1 
2 1.7±0.2 2.2±0.2 13.2±0.1 2 1.3±0.1 2.2±0.2 13.3±0.1 
3 1.8±0.2 2.0±0.2 13.3±0.1 3 2.4±0.2 2.1±0.2 13.6±0.1 
CMPrP 
(Q168E) 
1 1.8±0.2 2.0 ±0.2 13.5±0.1 CMPrP 
(Q217R_Q219E) 
1 1.8±0.6 2.0±0.2 13.3±0.1 
2 2.4±0.2 2.1±0.2 13.7±0.1 2 1.7±0.2 2.1±0.6 13.5±0.1 
3 1.7±0.2 2.0±0.2 13.3±0.1 3 1.7±0.2 1.8±0.2 13.5±0.1 
CMPrP 
(N171S) 
1 1.8±0.2 2.0±0.2 13.5±0.1 CMPrP 
(Q219K) 
1 1.7±0.3 2.0 ±0.2 13.6±0.2 
2 2.1±0.2 2.3±0.2 13.5±0.1 2 1.4±0.2 2.3±0.2 13.3±0.1 
3 2.2±0.2 2.1±0.2 13.3±0.1 3 1.6±0.2 2.1±0.2 13.4±0.1 
CMPrP 
(Q172R) 
1 1.4±0.2 2.2±0.2 13.4±0.1 CMPrP 
(Q219E) 
1 1.9±0.2 2.2±0.2 13.6±0.2 
2 1.5±0.2 1.9±0.2 13.4±0.1 2 1.6±0.2 2.0±0.2 13.4±0.1 
3 1.6±0.2 2.6±0.2 13.2±0.1 3 1.8±0.2 2.1±0.3 13.4±0.2 
CMPrP 
(V215I) 
1 1.6±0.2 2.0±0.2 13.4±0.1 CMPrP 
(K220R) 
1 2.6±0.4 2.8±0.6 13.5±0.2 
2 1.7±0.2 2.0 ±0.2 13.5±0.1 2 1.8±0.2 2.4±0.2 13.3±0.1 
3 1.7±0.2 2.1±0.2 13.3±0.1 3 1.9±0.3 1.9±0.2 13.5±0.1 
 CMPrP (K220R_Q219E) 
1 1.4±0.2 2.1±0.2 13.3±0.1 
2 1.5±0.2 2.1±0.2 13.3±0.1 
3 1.6±0.2 2.3±0.2 13.3±0.1 
 
 
We analyzed the interactions between !1 and N-!3 in all simulated systems. Strikingly, 8 
CMPrP (Q168E, Q172R, V215I_Q219E, Q217R, Q217R_Q219E, Q219K, Q219E, K220R_Q219E) 
exhibit stable HB interactions between residues Y149 and D202, Y157 and D202 (Table 5.3, Fig. 
5.2A). These HBs appear less stable in MoPrP and HuPrP (Table 5.3). A salt bridge (SB) between 
R156 and E196 is observed in these 8 CMPrP as well as MoPrP and HuPrP (Table 3, Fig. 5.2B). 
These HB and SB interactions keep the !1 helix in close contact with N-!3, conserving the 
hydrophobic interactions among residues F141, Y149, Y157, M205 and M206 at this interface. The 
same interactions are observed also in CMPrP(V215I), albeit less pronounced than in the above 8 
CMPrP. By contrast, CMPrP(N171S) and CMPrP(K220R) lack these HB and SB interactions 
during most of the simulation time (Table 5.3, Fig. 2C and D). Without them, the hydrophobic 
interactions are undermined and the !1 helix shifts apart from N-!3 (Fig. 2E). Correspondingly, the 
average C!-distance between residue D144 (at C-!1) and residue D202 (at N-!3) increases 
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significantly in CMPrP(N171S) and CMPrP(K220R) (17.7±1.0 Å and 17.5±1.5 Å, respectively). In 
sharp contrast, this distance is below 16.0 Å in 7 CMPrP (Q172R, V215I_Q219E, Q217R, 
Q217R_Q219E, Q219K, Q219E, K220R_Q219E). In CMPrP(Q168E), CMPrP(V215I), MoPrP and 
HuPrP this distance is between 16.0 and 17.0 Å (Table 5.3).  
Next we examined the "2-!2 loop where all CMPrP and HuPrP exhibited smaller RMSF 
than MoPrP. We analyzed the secondary-structure elements of this loop during each simulation. 
Residues 169-171 showed an exchange between coil and bend conformations in all the systems. 
Residues 166-168, however, exhibited distinct exchange patterns in different PrP variants. In 
MoPrP, residues 166-168 feature an exchange pattern mainly between 310-helix (68.9%) and turn 
(29.6%) conformations, whereas in HuPrP an exchange pattern among bend (48.2%), turn (35.5%) 
and coil (16.2%) is observed. Out of the 11 CMPrP studied here, seven (N171S, Q172R, V215I, 
Q217R, Q219K, K220R and K220R_Q219E) show the ‘310-helix/turn’-exchange pattern at residues 
166-168, similar to that of MoPrP (Table 5.4). In such a Mo-like pattern, 310-helix covers over 45% 
of the simulation time while coil occurs in less than 3%. The 310-helix conformation is stabilized by 
two HBs: one is formed between the backbone of Q168 N atom and P165 O atom, the other is 
between the backbone of Y169 N atom and V166 O atom. The other 4 CMPrP (Q168E, 
V215I_Q219E, Q217R_Q219E and Q219E) manifested a more Hu-like pattern: the ‘bend/turn’-
exchange dominates the loop conformation, whereas 310-helix covers less than 20% and coil 
accounts for over 10% (Table 5.4). A HB formed between D167 backbone N atom and S170 
sidechain O atom stabilizes the bend conformation. Alternatively, a HB between the E168 backbone 
N atom and M166 backbone O atom contributes to the turn conformation. Our analyses did not 





Table 5.3: Selected intramolecular interactions between !1 and N-!3 of MoPrP, of HuPrP and of 





























1XYX 16/20 7/20 1/20 14.8±0.8 
- - 1 0.3 0.3 0.0 16.7±1.1 2 0.8 0.6 0.3 
3 0.4 0.8 0.7 
HuPrP 
1HJN 5/20 9/20 2/20 15.0±1.0 
N/A N/A 1 0.9 0.8 0.7 16.5±1.0 2 0.5 0.3 0.9 
3 1.0 0.3 0.5 
CMPrP 
(Q168E) 
1 1.0 0.9 0.6 
17.0±1.5 # - 2 1.1 1.0 0.7 
3 0.9 1.0 0.9 
CMPrP 
(N171S) 
1 0.0 0.0 0.0 
17.7±1.0 - - 2 0.0 0.0 0.1 
3 0.1 0.0 0.0 
CMPrP 
(Q172R) 
1 1.0 1.0 0.7 
15.8 ±0.4 + + 2 1.0 1.0 1.0 
3 1.0 0.9 0.2 
CMPrP 
(V215I) 
1 1.1 1.0 0.5 
16.5±1.0 # + 2 0.7 0.5 0.0 
3 0.5 0.4 0.2 
CMPrP 
(V215I_Q219E) 
1 1.0 1.0 0.8 
15.7±0.4 + - 2 1.1 0.9 0.5 
3 1.0 0.9 0.6 
CMPrP 
(Q217R) 
1 1.0 1.0 0.7 
15.6±0.4 + + 2 1.0 1.0 0.9 
3 1.1 1.0 0.4 
CMPrP 
(Q217R_Q219E) 
1 1.1 0.9 0.4 
15.8±0.4 + - 2 1.1 1.0 0.5 
3 1.0 0.8 0.3 
CMPrP 
(Q219K) 
1 1.1 1.0 0.5 
15.9±0.4 + + 2 1.1 1.0 0.5 
3 1.1 1.0 0.5 
CMPrP 
(Q219E) 
1 1.0 0.9 0.9 
15.9±0.4 + - 2 1.1 1.0 0.5 
3 1.0 1.0 0.9 
CMPrP 
(K220R) 
1 0.0 0.0 0.0 
17.5±1.5 - - 2 0.8 0.3 0.0 
3 0.1 0.1 0.4 
CMPrP 
(K220R_Q219E) 
1 1.0 1.0 0.7 
15.9±0.4 + N/A 2 1.1 0.9 0.7 
3 1.0 0.9 0.3 
i Calculated as the average number per frame in the MD run, or the number of conformers out of the total 
number of conformers in the NMR structure. The value of HB Y149-D202 can be slightly >1, because in a 
small number of frames D202 has the chance to form two HBs with Y149.  
ii Averaged over 3 runs.  
iii, iv The symbols have the same indications as those in Table 5.1. 
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Figure 5.2: Selected HB and SB interactions between !1 helix and N-!3 are formed during 98% and 67%, 
respectively, of the simulation time of CMPrP(Q172R) which is resistant to MoPrPSc replication in vitro13 (A 
and B). These interactions are absent in the non-resistant CMPrP(N171S) (C and D). E) The !1 helix shifts 
apart from N-!3 in CMPrP(N171S) (blue), relative to that in CMPrP(Q172R) (yellow). These features are 
common across the other resistant and non-resistant CMPrP. 
 
Table 5.4: Percentage content of secondary-structure elements in residues 166-168 of MoPrP, of 
HuPrP and of all the CMPrP during the MD (average over three runs of each system). 
PrP variant 310-helix (%) Turn (%) Bend (%) Coil (%) 
MoPrP 68.9 29.6 4.2 2.9 
HuPrP 0 35.5 48.2 16.2 
CMPrP(Q168E) 14.4 54.9 16.8 13.2 
CMPrP(N171S) 49.0 37.5 10.4 1.4 
CMPrP(Q172R) 62.2 30.0 6.3 1.5 
CMPrP(V215I) 45.6 42.9 8.9 2.1 
CMPrP(V215I_Q219E) 8.9 21.1 42.3 27.7 
CMPrP(Q217R) 57.0 27.2 10.8 5.1 
CMPrP(Q217R_Q219E) 14.1 31.2 29.4 25.3 
CMPrP(Q219K) 62.8 24.3 5.7 1.5 
CMPrP(Q219E) 20.0 38.5 18.6 22.2 
CMPrP(K220R) 45.1 42.5 11.2 1.1 
CMPrP(K220R_Q219E) 67.2 25.4 5.9 1.6 
 
5.4 Discussion 
Our simulations highlight stronger interactions between !1 helix and N-!3 in 7 CMPrP 
(Q172R, V215I_Q219E, Q217R, Q217R_Q219E, Q219K, Q219E, and K220R_Q219E) than those 
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in MoPrP and HuPrP. Indeed, the average distance between C-!1 and N-!3 appears shorter in the 7 
CMPrP than that in MoPrP and HuPrP. Notably, all these 7 CMPrP were reported to highly resist 
the MoPrPSc replication in ScN2a cells13 (Table 5.1). Although less pronounced, these features are 
also observed in the MD of CMPrP(Q168E) and CMPrP(V215I). The latter two CMPrP were 
reported with only mild resistance in ScN2a cells13. By contrast, CMPrP(N171S) and 
CMPrP(K220R) lack these interactions during the MD. They exhibit longer distances between C-!1 
and N-!3 than those in MoPrP and HuPrP. Correspondingly, these 2 CMPrP are both susceptible to 
MoPrPSc infection. These data indicate that the resistance to MoPrPSc is related to stronger 
intramolecular interactions between !1 helix and N-!3 in CMPrP. Our previous study in Chapter 
4150 suggests that a loss of SB interactions between !1 and N-!3 plays a role in the spontaneous 
conversion of Hu pathogenic mutants to PrPSc. Recently. a solution-NMR study on Hu protective 
polymorphism E219K has discovered stronger interactions between N-!3 and !1 as well as a few 
residues proceeding !1342. Interestingly, a number of MD studies suggest that the region from C-!2 
to N-!3 is more flexible in HuPrP pathogenic mutants than in WT HuPrP16; 150; 151; 343; 344; 345; 346; 347; 348. 
Many other studies have pointed out that the !2-!3 region is per se highly fibrillogenic255; 256; 349; 350; 
351; 352. Hence, the !2-!3 region is likely to be stabilized by interactions with !1 and its flanking 
residues. This hypothesis is in line with several investigations on the hydrophobic core of PrP 
amyloid fibrils. Hydrogen exchange, site-directed spin labeling, electron paramagnetic resonance 
spectroscopy and solid-state NMR studies have suggested that the core of PrP amyloid fibrils is 
composed of the region spanning the !2 helix, the !2-!3 loop and a major part of !3 helix of 
PrPC353; 354; 355. These studies indicate a dissociation of the !2-!3 region from the rest of PrP during 
the conversion. Therefore, enhanced interactions between !1 and N-!3 might inhibit the 
dissociation and the conversion, such as seen in our simulations of the MoPrPSc-resistant CMPrP. 
However, some other studies suggest that amyloid fibrils can be formed by the structured regions 
preceding the !1 helix, likely via an extended "-structure involving residues 102-124. This 
hypothesis is supported by the extensive studies356; 357; 358 on the pathogenic HuPrP mutation 
Y145stop, which contains only residues 23-144. These studies indicate that in the absence of the C-
terminal residues 145-230, the fibril core is composed mostly of residues 102–139. While the 
misfolding mechanism of PrP remains obscure, a growing body of evidence suggests that distinct 
aggregate structures can be formed through multiple pathways by different PrPSc strains359; 360; 361; 362; 
363. This may explain the discrepancy between our findings and some others derived from different 
PrP variants or PrPSc strains. 
The "2-!2 loop of PrP conformation has been deeply investigated in various mammalian 
PrPs136; 137; 364. As already introduced in Chapter 2, it has been suggested that the loop plasticity is 
related to the transmissible barrier across PrPSc strains58; 60; 137; 138; 140; 365; 366; 367; 368. Solution-NMR 
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studies on MoPrP and HuPrP structures found that at room temperature (293-298K) a line 
broadening of NMR signals was reported for the "2-!2 loop in all the Mo and Hu PrP constructs 
due to local conformational exchanges55; 56; 58; 369. A recent solution-NMR study discovered that at 
310K, the "2-!2 loop of MoPrP was characterized by 310-helix, while Y169A/G mutations resulted 
in "-turn conformation370. This study suggests that at room temperature the "2-!2 loop of MoPrP is 
disordered, likely due to conformational exchange between 310-helix and other conformations. 
These findings imply that the loop conformation may play an essential role by binding to an 
unknown factor required for prion propagation. Consistently, previous studies on pathogenic HuPrP 
mutants (including ours in Chapter 4)17; 150; 152 indicate that the conformation of the "2-!2 loop is 
related to the familial Hu TSE. In this study, we identify a ‘310-helix/turn’ conformational exchange 
pattern of the "2-!2 loop in MoPrP and a ‘bend/turn/coil’ pattern in HuPrP. The intramolecular 
interactions that contribute to the 310-helix turn out to be the same HBs as those observed in the 
MoPrP NMR structure at 310K, which involve residues P165, V166, Q168 and Y169370. Another 2 
HBs are identified to control the bend and turn conformations, which involve residues M166, D167, 
E168 and S170. These specific interactions in the "2-!2 loop may be the determinants of the loop 
conformation. Seven CMPrP (N171S, Q172R, V215I, Q217R, Q219K, K220R and K220R_Q219E) 
exhibit the Mo-like pattern during the MD. Among these, two of them (CMPrP(N171S) and 
CMPrP(K220R)) have been shown to be susceptible to MoPrPSc in ScN2a cells, whereas the other 
four (CMPrP(Q172R), CMPrP(V215I), CMPrP(Q217R), and CMPrP(Q219K)) showed the 
dominant-negative effect13. CMPrP(K220R_Q219E) was resistant to MoPrPSc13 but no data have 
been reported about the dominant-negative effect. The other four CMPrP studied here 
(CMPrP(Q168E), CMPrP(V215I_Q219E), CMPrP(Q217R_Q219E) and CMPrP(Q219E)) show a 
more Hu-like pattern. They turn out to be the ones resistant to MoPrPSc but not to have dominant-
negative effect13. Our results indicate that the Mo-like conformational exchange pattern in the "2-
!2 loop is necessary for the dominant-negative effect if the CMPrP is also resistant to MoPrPSc.  
Based on these findings, we propose the following mechanism for the dominant-negative 
effect: the Mo-like conformation at the "2-!2 loop can bind to an unknown factor that facilitates 
PrPSc propagation. When the resistant CMPrP have the Mo-like "2-!2 loop conformation, they can 
bind to this factor but cannot be converted to PrPSc. They stay bound with the factor and keep its 
binding site inaccessible for the WT MoPrP. Therefore, WT MoPrP is not converted to PrPSc. In the 
case of non-resistant CMPrP, such as CMPrP(N171S) and CMPrP(K220R), they can bind to the 
factor but are easily converted to PrPSc and released from it. The binding site is then free again to 
bind new CMPrP or WT MoPrP. Therefore, WT MoPrP is also converted to PrPSc and no dominant-
negative effect is observed.  
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Evidence exists that PrPSc propagation requires an accessory cofactor371; 372; 373. Recently, 
Deleault et al. demonstrated that a small-molecule cofactor can regulate the conformation, strains 
and infectivity of PrPSc in vivo 374. However, some other studies argue against the intervention of 
any ancillary components375 and suggest that the dominant-negative effect is only due to the 
heterozygosis of PRNP (in humans) or Prnp (in other species) genes376; 377; 378. This alternative 
model, denoted as the “stone fence model”, suggests that human individuals heterozygous for E/K 
at codon 219 are protected by sporadic CJD because the PrPs deriving from two allelic variants 
interfere with each other in the conversion process due to their incompatible structures. The in vivo 
and in vitro evidence supporting this model is reviewed in379. However, an ultimate structural 
explanation of the dominant-negative effect is still missing in prion biology.  
Considering the previous findings on CMPrP13; 129, which have inspired this work, we propose 
the above possible mechanism of the dominant-negative effect. Nevertheless, further investigations 
are needed to verify this hypothesis. In particular, the alternative hypothesis that the dominant-
negative effects are due to PRNP or Prnp heterozygosis may suggest novel rationally designed MD 
experiments aimed to investigate the interaction between the two different allelic variants to mimic 
the heterozygosis condition. 
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 Role of prion disease-linked mutations in the intrinsically Chapter 6
disordered N-terminal domain of the prion protein 
Among the currently identified PMs in the human PRNP gene, seven missense mutations are 
located in the naturally unfolded N-term of HuPrP. Intriguingly, and in sharp contrast to many PMs 
in the GD, these seven PMs do not affect the in vitro misfolding kinetics of the protein. Here we 
hypothesize that the neurotoxicity of these PMs arises from changes in structural determinants of 
the N-term, which affect the protein binding with its cellular partners and/or the co-translational 
translocation during the biosynthesis of the protein. We test this idea by predicting the 
conformational ensemble of WT and mutated MoPrP N-term, whose sequence is almost identical to 
that of the human one and for which the largest number of in vivo data is available. The 
conformational properties of the WT are consistent with those inferred experimentally. Importantly, 
the PMs turn out to affect in a subtle manner the intra-molecular contacts in the N-term at the 
putative binding sites for Cu2+ ions, sulphated glycosaminoglycans and other known prion protein’s 
cellular partners in vivo. The PMs also alter the local structural features of the transmembrane 
domain and adjacent stop transfer effector, which act together to regulate the protein topology. 
These results corroborate the hypothesis that PMs affect the prion protein binding to its functional 
interactors and/or the translocation. 
6.1 Introduction 
Numerous studies have shown that PMs in the HuPrP GD can alter the GD's secondary-
structure (SS) elements and structure flexibility16; 147; 148; 150; 152 and accelerate the misfolding process 
in vitro156. Our previous work in Chapter 4 suggests that PMs and chimeric mutations in HuPrP or 
MoPrP GD affect common regions in the GD structure that are crucial for the protein’s stability and 
interactions with cellular partners.  
Seven missense PMs have been identified in the N-term of HuPrP (N-term_HuPrP 
hereinafter, Fig. 6.1A): Q52P has been recently found and it is likely associated with familial 
Creutzfeldt–Jakob disease (fCJD)154, G114V has been reported with both fCJD155 and Gerstmann-
Sträussler-Scheinker syndrome (GSS)156, whereas P102L, P105L/S/T, and A117V are associated 
with GSS156. The correspondent mutation of P102L in Mo PrPC alters the incubation time in 
transgenic mice upon infection by PrPSc from human, hamster, sheep or murine sources in a strain-
dependent manner157; 158. Intriguingly, these PMs may cause the disease without affecting the 
kinetics of the HuPrPC to HuPrPSc conversion in vitro156. This hints at the presence of processes in 
vivo that lead these PMs indirectly to pathogenic forms of HuPrP, the hallmark of all Hu TSE, 
although structural information on the effects of these PMs is currently lacking. 
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Figure 6.1: A) Molecular structure of HuPrPC. The GD NMR structure56 is shown in cartoon. The disordered 
N-term and three C-terminal residues, not present in the NMR structure, are sketched in dashed lines. Red 
arrows indicate the PMs studied in this work. B) Alignment of HuPrPC and MoPrPC sequences, obtained using 
BLAST380. The distinct residues in each of the two proteins are shadowed in orange. Those belonging to OR, 
STE, and TM1 are colored in blue, green and red, respectively. Residues at putative binding-sites for Cu2+, 
sulphated GAG, vitronectin and STI1 (Table 6.1) are underlined in red, green, black and blue, respectively.  
 
On the one hand, N-term_HuPrP, along with the equivalent domain in MoPrP (N-
term_MoPrP, featuring 93% sequence identity with N-term_HuPrP, see Fig. 6.1B), contains a major 
part of the so-called transmembrane domain (termed TM1, comprising roughly residues 112–135) 
and the preceding “stop transfer effector” (STE, a hydrophilic region containing roughly residues 
104–111)43 (Fig. 6.1B). STE and TM1 act in concert to control the co-translational translocation at 
the endoplasmic reticulum (ER) during the biosynthesis of HuPrPC and of Mo and Syrian hamster 
(SHa) PrPC38; 42. Four topological forms of the protein can be generated during the translocation38 
(Fig. 2.1 in Chapter 2): SecPrP, NtmPrP, CtmPrP and cyPrP (see Chapter 2 section 2.2.1 for details). 
Modified structural features of TM1 and STE can increase the proportion of the atypical forms 
NtmPrP, CtmPrP and cyPrP, which can be detrimental in vivo38; 43; 47. It is worth noting that 5 out of the 7 
PMs in this study are located in the STE and TM1 regions (‘STE/TM1’, hereinafter). 
On the other hand, N-term_HuPrP is a broad-spectrum molecular sensor14. Indeed, along with 
N-term_MoPrP, it interacts with chemicals including: i) sulphated glycosaminoglycans (GAG)381, 
which bind to the four histidines in the so-called octapeptide-repeat region (OR, residues 51-91, see 
Fig. 6.1A and B), as well as several lysines at the N-terminus70 (Table 6.1); ii) Cu2+ ions382, which 
may bind at six histidine residues383, including those located in the OR (Table 6.1). In addition, the 
Mo protein has been shown to interact with vitronectin103, the stress-inducible protein 1 (STI1)105 
and amyloid-! (A!) multimers106; 107; 108, which may bind N-term_MoPrP at residues 104–118, 114–
127and 96-111, respectively, as well as with the lipoprotein receptor-related protein 1 (LRP1)109 and 
the neural cell adhesion molecule (NCAM)32 (Table 6.1).  
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Table 6.1: Binding partners of Hu/Mo/SHa PrPC N-term so far identified by in vivo studies. The 
affinity and the binding site identified in vitro for these partners are also reported. 
Binding 
partner Proposed role(s) in vivo 
PrPC interacting 
residues (in vitro) Affinity (in vitro) References 
Sulphated 
GAG 
In the formation of 
Hu/Mo/SHa PrPSc381; 384 
In Hu/Mo/SHa PrPC: 
K23, K24, K27, H61, 









signaling, in the progression 
of the disease382 
In Hu/Mo/SHa PrPC 








in ref. 382; 
383 In Hu/Mo/SHa PrPC 
outside ORa: H96, 
H111 
Nanomolar range 
Vitronectin Supporting axonal growth103 In MoPrP
C: residues 
105–119103 12 nM
103 Ref. 103 
STI1 Triggering neuroprotection105 In MoPrP
C: residues 
115–128105 140 nM
105 Ref. 105 
A! 
multimers 
Suppression of long-term 
potentiation106; 107; 108 
In MoPrPC: residues 
96–111106; 107; 108 N/A 
Ref. 106; 107; 
108 
LRP1 In a clathrin-dependent internalization mechanism109 N/A Nanomolar range
109 Ref. 109 
NCAM In the cell adhesion process110 N/A N/A Ref. 
32; 110 
a A few studies using N-terminally truncated murine PrPC GD have also detected a weak binding site in the 
GD with affinity ~10 µM 91; 92. 
 
On these premises, here we make the plausible hypothesis that the PMs in the N-term of the 
HuPrP cause prion diseases by (i) modifying the conformational properties of the STE/TM1 region 
and its interactions with trans-acting factors in the ER membrane and in the cytosol385, and/or (ii) by 
affecting the interactions of N-term_HuPrP with chemicals and/or with protein partners in vivo. We 
tested this hypothesis by biocomputing methods. We focused on MoPrPC because of its high 
sequence identity (particularly in the N-term) to HuPrPC, and because experiments of protein 
binding have been so far reported mainly for this species. Our calculations p  predict the 
conformational ensemble of WT N-term_MoPrP and that of N-term_MoPrP containing the 7 Hu 
PMs using replica-exchange (RE) Monte Carlo (MC) simulations227 based on an implicit-solvent 
                                                      
p We do not consider: i) the PMs present in MoPrP but not in HuPrP and artificial mutations386; 387 because 
their effect in humans is currently unknown; ii) the PMs in the signal peptides which are cleaved off during 
the biosynthesis of the protein388; iii) the interactions with metal ions other than Cu2+ (e.g. Zn2+) because their 
relevance in vivo has not been firmly established382. 
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all-atom potential18. The latter has been shown to be effective in investigating the folding of 
structurally diverse sets of proteins, as well as in studying the conformational properties of naturally 
unfolded proteins19; 220; 389.  
We found that N-term_MoPrP is composed of several regions characterized by different SS, 
in agreement with biophysical data56; 390; 391; 392; 393. The PMs do not change dramatically the 
conformational ensemble of N-term_MoPrP. Rather, they affect in a subtle manner the intra-
molecular contacts in regions responsible for interactions with cellular partners, as well as the local 
structural features of STE/TM1. These in turn may alter the protein function14 and biosynthesis38. 
6.2 Computational details 
6.2.1 Bioinformatics 
A structural model of the full-length MoPrPC was first constructed by homology modeling. 
HHpred web server394 was used to select homologous templates (Table 6.2) from structured proteins 
in RCSB Protein Data Bank (www.pdb.org). These templates were provided to MODELLER 
9.10395 for multi-template homology modeling. Firstly, 100 preliminary models were constructed. 
The best model was then selected which had the best DOPE score (calculated in Modeller 9.10) and 
high stereochemical quality (analyzed using the PROCHECK program396). The full-length model 
was truncated at residue 128 to obtain the N-term_MoPrP. The Swiss-PdbViewer (DeepView) 4.0293 
was used to introduce the 7 mutations (Q52P, P102L, P105L/T/S, G114V and A117V) into the N-
term_MoPrP for generating initial models of the 7 PMs. These 8 models were used as educated 
guesses for the subsequent molecular simulations and by no means represented a structural 
prediction.  
The bioinformatics tool PONDR-FIT397 was used to predict the intrinsic disorder disposition 
of N-term_MoPrP. SS prediction tools including PSIPRED398, Jpred3399, Porter400, RaptorX401 and 





Table 6.2: Structure templates for homology modeling of the full-length MoPrP.  













MoPrP (121-232) NMR 1XYX (A) 121-128 120-127 100 Ref. 341 






88 Ref. 56 
HuPrP pathogenic mutant 
Q212P (90-231) NMR 2KUN (A) 90-121 89-120 88 Ref. 
403 
HuPrP pathogenic mutant 
V210I (90-231) NMR 2LEJ (A) 85-121 84-120 92 Ref. 
148 
The Thermus thermophilus 
protein TTHA0988 X-ray 3OEP (A) 163-169 27-32 83 Ref. 
404 
Bovine angiogenin X-ray 1AGI (A) 85-91 33-39 57 Ref. 405 
Hu Ribonuclease 1, R31L, 
R32L mutant X-ray 2E0J (A) 87-93 33-39 86 Ref. 
406 
The malonyl coenzyme A-
acyl carrier protein 
transacylase 
X-ray 2QC3 (A) 6-11 38-43 83 Ref. 407 
Phycocyanin X-ray 2VML (B) 69-75 44-50 86 N/A 
 
6.2.2 Molecular simulations 
REMC simulations227 using the PROFASI (PROtein Folding and Aggregation Simulator) 
code18 were carried out for WT N-term_MoPrP and each of the 7 PMs. PROFASI uses an all-atom 
model for the protein including hydrogen atoms, and implicit water solvent. The model assumes 
fixed bond lengths, bond angles, and peptide torsion angles (180°), so that each amino acid has the 
Ramachandran dihedral angles $ and ( as well as a number of side-chain torsion angles as its 
degrees of freedom. The interaction potential is composed of four terms: ! ! !!"# ! !!" ! !!! !!!". The term!!"# !is a local potential which accounts for interactions between atoms separated by a 
few covalent bonds, such as the electrostatic interaction between adjacent peptide units along the 
chain. The other three terms are nonlocal in sequence. The excluded volume term !!" is a
repulsion between pairs of atoms. !!! represents two kinds of hydrogen bonds: backbone-backbone 
bonds, and bonds between charged side chains and the backbone. The last term!!" represents 
simple pairwise additive approximations for hydrophobic attraction between nonpolar side chains 
and electrostatic interactions among charged side-chains. The interaction potential assumes the 
presence of a solvent environment for the proteins although solvent molecules are not explicitly 
represented in the simulations. To explore the conformation space, we used a Markov Chain MC 
procedure. At any step, a conformation update involving a change in one or more backbone and 
121/ r
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side-chain torsion angles is proposed, and is either accepted or rejected using a Metropolis219 
criterion. A semi-local backbone update, called Biased Gaussian Steps224 producing smooth local 
deformations of the chains was used at the lower temperatures to improve the sampling of compact 
structures. 
In each case studied here, the system was enclosed in a periodic cubic box of size (300 Å)3. 
We used a replica exchange (also known as parallel tempering) procedure408 to enhance the 
sampling in our simulations. Simultaneous MC simulations were performed at 8 temperatures: 
293.0 K, 299.7 K, 306.5 K, 313.5 K, 320.6 K, 327.9 K, 335.4 K and 343.0 K. Periodically, 
conformations of replicas at consecutive temperatures were swapped with a probability !!"#$!" !!"# !!!!! ! !!!!! !! ! !! , where Tk is the temperature and Ek is the energy of replica k, and 
kB is the Boltzmann constant. The exchange procedure improves sampling at the lower temperatures 
by stochastically seeding them with independent states obtained at high temperatures, and the above 
exchange probability ensures equillibrium is maintained at each temperature even for the replica 
exchange step.  
In order to assess the reliability of the statistics obtained in these simulations, we examined 
the random walk of the replicas in temperature space (see Fig. A3.1 in Appendix 3). Since, at the 
higher temperatures the conformation of the system decorrelates fast by jumping over energy 
barriers, the statistics collected at the lower temperatures consists of uncorrelated samples, if the 
replica has visited a high temperature in between. The histogram of energy at different temperatures 
(see Fig. A3.2 in Appendix 3) demonstrates a massive overlap between each consecutive pair of 
temperatures. This shows that there were no sharp transitions in temperature in our system. The 
length of the simulations was chosen to allow our replicas to reach both ends of the temperature 
range repeatedly, so that our histograms received data from uncorrelated sample conformations 
from different parts of the energy landscape. We calculated the cumulative averages409 of the the 
radius of gyration (Rg) and of the SS contents over the sampled trajectory. The cumulative average 
was defined by !! !!!!! , where N was the total number of frames sampled, i was the frame 
number and !! was the property of interest (the Rg or the SS contents) calculated for each frame. 
The cumulative averages appeared to converge rather than systematically drifting (see Fig. A3.3 in 
Appendix 3). This combined with the fact that the simulations continued to explore uncorrelated 
states by moving back and forth across temperatures gives us reasonable confidence that our 
simulations have captured the statistical properties of these systems to the accuracy of the force 
field. In order to further reduce the effect of auto-correlation in our statistics, the conformations 
were sampled every 104 cycles (3.7 106 MC steps). We performed 1.8%108 cycles (or 6.7%1010 MC 
 94 
steps) of simulations for each system and the first 10% of each run was discarded for 
thermalization. Production trajectories obtained at 293K were extracted, which yielded 2000 frames 
per protein for analysis. 
6.2.3 Data analyses 
The following properties were calculated with the production trajectory obtained for each N-
term_MoPrP variant. i) The average Rg was calculated using the g_gyrate module in Gromacs 4.5338. 
ii) The SS in each frame, as well as the average SS content in the trajectory, was calculated with the 
DSSP software340. iii) The intra-molecular contact map for each frame, which was a distance matrix 
consisting of the smallest distance within 6 Å between residue pairs, was calculated using the 
g_mdmat module in Gromacs 4.5. The total number of contacts per residue was also calculated over 
the entire production trajectory. Every time two residues approached each other within 6-Å 
distance, this was counted as one contact for each residue. iv) The backbone flexibility during the 
trajectory was calculated using the angular dispersion index (ADI) analysis305 described in Chapter 
4, section 4.2.3. 
A clustering analysis was carried out on the contact map data in order to characterize the 
intra-molecular contacts in each trajectory. The contact map of each frame was converted into an 
array of length M$M by concatenating matrix rows, where M was the number of residues in the 
protein. Distances between frames were computed using the Euclidean distance (Eq. (6.1)) as metric 
and stored in a proximity matrix. This distance indicated the similarity between two frames 
regarding their intra-molecular contacts: the shorter the distance, the more similar the two frames. 
Finally, a hierarchical clustering410 was performed by using an average linkage method411. In this 
method, the distance between two clusters is the average distance between pairs of observations, 
one in each cluster. Main clusters were obtained using a distance cutoff on the hierarchical tree so 
that the 10 most populated clusters cover about 70% of the entire data set. An average contact map 
in each cluster was computed to represent the intra-molecular contacts in the cluster members. 
d p,q( ) = p1 ! q1( )2 + p2 ! q2( )2 +... pn ! qn( )2 .  (6.1) 
6.3 Results 
A total of 5.4%1011 MC steps of simulations were performed on bioinformatics-based 
structural models of N-term_MoPrP and the 7 PMs (6.7%1010 MC steps for each protein). The 
number of MC steps performed is expected to be sufficient for the naturally unfolded proteins 
studied here. The simulations obtained at 293 K are chosen for analyses in this work because most 
of the in vitro experiments with which we compare our results have been carried out at room 
temperature56; 390; 391; 392; 393. We also calculated the SS contents (in %) for the wild-type N-
term_MoPrPC simulated at 306.5 K and 313.5 K in this work. These are the nearest to the 
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physiological temperature. As it might be expected, the !-helix content decreases and the coil 
structure increases with respect to the results of 293 K (see Table A3.1 in Appendix 3). However, 
the changes are in the range of the standard deviation along the simulations. Hereafter we describe 
the structural determinants of the resulting proteins' conformational ensembles at 293 K. 
N-term_MoPrP WT. The equilibrated trajectory of N-term_MoPrP provides an ensemble of 
conformations containing transient SS elements (Fig. 6.2A) with Rg of 18.5±2.9 Å. On average, it 
contains 19±8% $-helix, 8±5% !-sheet, 7±3% !-bridge, 27±5% !-turn, 12±4% bend, 4±3% 310-
helix and 1±1% *-helix. However, different regions appear to adopt different SS. According to the 
occurrence of diverse SS, N-term_MoPrP can be roughly divided into 6 sub-regions (Table 6.3). 
Notably at residues 99-117 and 118-125 we observe relatively high occurrence of $-helix (64±9% 
and 33±8%, respectively), which is in line with the prediction by PONDR-FIT that this region has 
relatively low intrinsic disorder disposition (Fig. A3.4 in Appendix 3). Consistently, commonly 
used bioinformatic tools for SS prediction (such as PSIPRED, Jpred, Porter, Raporx and CABS-
fold) also indicate that residues ~104-120 have the propensity to form $-helix (Fig. A3.4). 
Our results are consistent with the finding by solution NMR that the OR peptide comprising 
residues 61-68 in N-term_HuPrP acquires a stable loop/!-turn conformation at pH ~6393. In our 
simulations indeed we find the loop/!-turn conformations in the OR region resembling the NMR 
structure. These conformations show backbone RMSD of less than 2.5 Å from the NMR structure, 
which composes 8%, 11%, 3%, 9% and 13% of the five sequential OR peptide in the OR region, 
respectively. We also find antiparallel !-sheets/!-bridges formed between adjacent OR peptides.  
 
 
Figure 6.2: Selected conformations of A) WT N-term_MoPrP and B) one PM (N-term_MoPrP_Q52P) from 
our simulations. These contain transient !-helix (in violet), "-sheet (yellow), "-bridge (orange), "-turn (cyan), 
310-helix (blue) and *-helix (red) elements. 
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Table 6.3: Content of transient SS elements (in %i) in each region of N-term_MoPrP averaged over 
the trajectory. According to the occurrence of different SS, we identify 6 sub-regions: i) residues 
23-30, mainly in coil/!-turn/bend conformation; ii) residues 31-50, mainly in !-turn/coil/bend/!-
bridge conformations; iii) residues 51-91 (OR) mainly in !-turn/coil/bend/!-sheet conformations; 
iv) residues 90-99 mainly in coil/!-turn/bend/!-sheet conformations; v) residues 100-118 which 
contain the highest percentage of $-helix among all 6 sub-regions and vi) residues 119-126 which 
display a comparable percentage of $-helix and !-turn. 
Residues $-helix !-sheet !-bridge "-turn Bend 310-helix *-helix Coil 
23-128 19±8 8±5 7±3 27±5 12±4 4±3 1±1 25±5 
23-30 3±2 3±3 6±2 22±5 10±4 2±2 0±1 55±9 
31-50 7±4 8±5 12±4 33±6 13±4 5±3 0±1 22±5 
51-91 (OR) 6±2 12±5 9±4 36±7 13±5 6±3 1±1 18±4 
90-99 5±2 12±5 5±3 23±5 16±4 4±2 0±2 35±7 
100-118 64±9 1±2 0±1 7±3 8±3 2±2 0±1 16±6 
119-126 33±8 3±6 2±3 33±5 9±3 5±3 1±1 15±4 
i Standard deviations (SD) are indicated by “±”. 
 
In residues 106–126 (known as the amyloidogenic region), we observe transient helical 
conformation spanning all over this region. However, the first part (residues 106–118) shows 
mainly $-helix motif, while residues 119–126 display a comparable percentage of $-helix and !-
turn. These results are consistent with the reported CD, NMR and FTIR studies on HuPrPC 
fragments390; 391; 392. Together, these studies indicate that the equivalent region in HuPrPC may adopt 
$-helix, !-sheet or coil structures under different experimental conditions390; 391; 392. We notice that 
this region roughly corresponds to the STE/TM1 in N-term_MoPrP, which comprises residues 104–
128.  
N-term_MoPrP PMs. The Rg of the 7 PMs studied here is comparable to that of the WT 
(Table 6.4). This indicates that the mutations do not alter the compactness of the N-term_MoPrP. 
The average SS contents in the PMs are also mostly similar to those of the WT (Table 6.4, Fig. 
6.2B).  
Differences between the WT and PMs are mainly in the !-sheet and $-helix contents in 
residues 100–128 (Table 6.4). Among these, N-term_MoPrP_P102L has 11% more !-sheet content 
and 11% less $-helix content in this region than those in the WT. This result is consistent with the 
in vitro data of MoPrPC containing the P102L mutation412. N-term_MoPrP_P105L/T/S mutations 
lead to an increase in $-helix content by 9%, 11% and 8%, respectively. The PMs feature different 
backbone's conformational flexibility (calculated here with the T-PAD analysis305, Fig. A3.2) from 
that of N-term_MoPrP WT. In particular, the flexibility of STE/TM1 increases in N-
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term_MoPrP_Q52P, N-term_MoPrP_P102L and N-term_MoPrP_A117V. It decreases in N-
term_MoPrP_G114V and N-term_MoPrP_P105L/T/S with respect to the WT (Fig. 6.3). 
 
Table 6.4: Rg and content of transient SS elements (in %i) of the entire systems studied (top) and of 
residues 100-128 (bottom).  
Variant Rg (Å) $-helix !-sheet !-bridge Bend !-turn 310-helix *-helix Coil 
 N-term 
N-term_MoPrP 18.5±2.9 19±8 8±5 7±3 12±4 27±5 4±3 1±1 24±5 
N-term_MoPrP _Q52P 17.1±2.5 17±8 14±7 7±3 12±4 29±5 3±3 1±2 22±6 
N-term_MoPrP _P102L 19.6±3.0 16±10 12±10 7±3 11±4 29±5 4±3 0±1 24±6 
N-term_MoPrP _P105L 19.3±2.9 23±8 9±7 7±3 11±4 29±5 4±3 0±1 22±6 
N-term_MoPrP _P105S 20.1±2.9 21±7 8±5 7±5 11±3 27±5 5±4 0±1 23±5 
N-term_MoPrP _P105T 19.7±3.0 22±8 8±7 7±3 11±4 28±5 4±4 0±1 24±6 
N-term_MoPrP _G114V 18.7±2.9 20±7 9±5 7±7 12±3 28±4 4±3 0±1 25±5 
N-term_MoPrP _A117V 18.8±2.9 17±8 10±7 7±3 11±4 29±5 4±3 0±1 25±5 
 Residues 100-128 
N-term_MoPrP 12.3±1.4 52±10 2±2 1±1 8±5 15±4 3±3 1±1 20±4 
N-term_MoPrP _Q52P 12.2±1.4 48±10 4±4 2±2 9±4 15±5 3±3 0±1 19±5 
N-term_MoPrP _P102L 11.9±1.2 41±11 13±4 1±2 6±4 17±5 3±3 0±1 19±4 
N-term_MoPrP _P105L 12.2±1.4 61±12 3±2 1±1 4±4 14±5 2±3 0±1 14±5 
N-term_MoPrP _P105S 12.4±1.2 63±13 2±2 1±2 4±4 14±4 2±2 0±1 14±4 
N-term_MoPrP _P105T 12.3±1.3 60±11 3±2 1±1 14±6 14±4 2±3 0±1 15±4 
N-term_MoPrP _G114V 11.9±1.2 53±10 2±3 1±2 7±4 14±6 2±2 1±1 19±5 
N-term_MoPrP _A117V 11.8±1.4 46±10 4±3 1±1 8±5 16±4 3±3 0±1 21±5 




Figure 6.3: Flexibility of backbone units of residues 100-128. The higher the ADI value305, the more flexible 
the backbone. The SDs in the 10 simulation runs of the WT N-term_MoPrP are indicated with vertical bars, 
whereas those of the PMs are shown in Appendix 3 Fig. A3.6. 
 
6.4 Discussion  
Our calculations suggest that N-term_MoPrP WT features a large ensemble of conformations 
containing transient SS, rather than completely disordered ones. The result is consistent with 
experimental data56; 390; 391; 392; 393. 
While many PMs in the GD are known to modify significantly the folded structure and to 
increase its flexibility16; 147; 150; 156, our calculations suggest that those in the N-term do not impact 
significantly the global structural properties of the N-term. This is consistent with in vitro 
experiments, which have shown that PMs in N-term_HuPrP do not affect the thermostability or 
misfolding kinetics of the protein molecule156. However, the PMs at the N-term do modify local 
features from those of the WT at the binding sites for known cellular partners. This might affect the 
interactions with these partners and interfere with the related physiological functions. 
Specifically, (i) the intra-molecular contacts of residues binding Cu2+ and sulphated GAG 
(Table 6.1) decrease on passing from the WT to the PMs, as shown by the total number of contacts 
per residue during the simulations of each system (Fig. 6.4). A cluster analysis on the intra-
molecular contact maps of each system (described in “Materials and Methods”) result in ten main 
clusters that characterize the intra-molecular contacts during the simulations. These contact maps of 
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the most populated cluster for each system  (Fig. 6.5) demonstrate that the major differences 
between N-term_MoPrP WT and the PMs are in the residues binding Cu2+ and sulphated GAG (i.e. 
the OR region and the H111 Cu2+-binding site (Table 6.1)).  In the less populated clusters of contact 
maps (Appendix 3.1), minor differences between N-term_MoPrP WT and the PMs are observed 
also in other regions, which vary from one PM to another. These minor differences are not 
statistically significant, thus they are not discussed here.  Alteration of the Cu2+-PrPC binding 
process has been suggested to play a role for Hu/Mo PrPC aggregation and for the progression of the 
disease382. Interestingly, a recent study in our lab shows that the PM Q212P in the HuPrPC GD can 
influence the Cu2+ binding mode at H96 and H111413, implicating a role of abnormal Cu2+ binding in 
the pathology of PMs in HuPrPC. Sulphated GAG binding to PrPC is likely involved in the 
formation of PrPSc in vivo, although its role remains to be established381. In addition, ii) the PMs 
affect the SS, the flexibility and increase the hydrophobicity of STE/TM1 (Table A3.2 in Appendix 
3). The latter contains the putative binding sites for in vivo binding partner proteins such as 
vitronectin103 and STI1105. This might affect the biological function of these interactions, which 
involves the signaling for axonal growth103 and that for neuroprotection105, respectively. 
The PM Q52P in the OR region affects the flexibility of STE/TM1 (Fig. 6.3), while the other 
6 PMs in STE/TM1 also alter the intra-molecular contacts in the OR region (Fig. 6.4 and 6.5). This 
suggests that the PMs may affect the transient interactions between the OR region and STE/TM1. 
However, these observed alternations on passing from the WT to the PMs in (i) the intra-molecular 
contacts and (ii) the backbone flexibility turn out not to be quantitatively correlated. The number of 
contacts takes into account the backbone and side-chain atoms and is related to the 3D fold of the 
protein conformations sampled in the simulations. The PAD index, instead, measures the 
fluctuations of the backbone dihedral angles of the residues during the simulations. Therefore, the 
local backbone flexibility might not be directly related to the protein’s 3D fold. 
Growing evidence point to the role of PrPC in mediating the memory impairment by A! 
multimers in vivo106; 107. On the one hand, A! oligomers have been found to bind PrPC N-term, 
which is required for the suppression of long-term potentiation by A! oligomers in vivo106; 108. On 
the other hand, in vitro experiments suggest a Cu2+-dependent mechanism that links the 
neurotoxicity of A! oligomers to PrPC414. The fact that MoPrPC residues 96-111 in the N-term are 
essential for the binding of both A! oligomers106 and Cu2+ suggests the significance of this region in 
the yet undefined role of PrPC in Alzheimer’s disease. Our findings that PMs affect the structural 
features of this region are in line with the hypothesis that a Cu2+-dependent mechanism may unify 
the pathogenesis of neurodegenerative diseases such as TSE, Alzheimer’s disease and Parkinson’s 
disease415.  
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The altered local features in STE/TM1 might also impact on the protein's interactions with 
trans-acting factors in the cytosol and in the ER membrane385. This result is consistent with the in 
vitro data that PMs P102L, P105L and A117V increase the interactions between MoPrPC STE/TM1 
and a membrane mimetic at pH 7416. These changes may affect the relative proportions of the SecPrP, 
NtmPrP, CtmPrP and CyPrP topological variants in human and mice38. This in turn could have 
repercussions on the disease, as elevated CtmPrP level has been related to both familial (in GSS 
patients) and infectious (in transgenic mice) prion diseases43; 47. 
 
Figure 6.4: Total number of intra-molecular contacts per residue in the WT and mutated N-term_MoPrP. A) 
Total number of contacts between residues in the entire N-term over the trajectory. The SDs of the 10 
simulation runs of each system are shown in Appendix 3 Fig. A3.7. B) Total number of contacts in the OR 
over the trajectory where the four histidine residues are indicated with vertical dashed lines. The SDs in the 10 
simulation runs of the WT N-term_MoPrP are indicated with vertical bars, whereas those of the PMs are in 
the similar range (Fig. A3.7). 
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Figure 6.5: Contact maps illustrating the intra-molecular interactions in WT and mutated N-term_MoPrP. 
Contacts within 6 Å are plotted in gray scale according to the distances as shown at the bottom. Residue 
numbers are labeled for the N-term_MoPrP and are the same for all the PMs. For each protein, only the most 
populated cluster is shown (see Appendix 3.1 for the rest of the clusters and the detailed data of each cluster). 
Major differences between the WT and the PMs are highlighted in the lower half of the (diagonally 
symmetric) maps with yellow boxes. 
 
Implications for PrPC's molecular recognition. Experimental structural information is 
available for several fragments of PrPC N-term in complex with antibodies. These include: residues 
119-122 from HuPrPC in !-strand (Abskharon et al., unpublished data), residues 104–113 from 
SHaPrP (equivalent to HuPrP 104–113) in bend conformation417, residues 107–115 from bovine 
(Bo) PrPq (equivalent to HuPrP 96–104) in bend conformation418 and a MoPrP 2-OR peptide 
(residues 68–83) in an extended conformation419. In addition, herapin binds to N-term from SHaPrP 
and stabilizes a repeated loop/!-turn conformation encompassing 4 OR70. Interestingly, the former 
three are present in our calculated ensemble. This indicates a possible “conformational selection” 
mechanism420 upon binding in these cases. The extended conformation of the MoPrP 2-OR peptide 
                                                      
q SHaPrP and BoPrP both share high (>85%) sequence identity with HuPrP and MoPrP (Table A3.3 in 
Appendix 3). The N-term and OR region are highly conserved in these PrP species (Table A3.3). 
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is embedded in a groove of its cognate antibody (named POM2 Fab)419 which prevents the 
formation of the loop/!-turn seen by NMR393 and by our simulation. Similarly, the 4-OR 
conformation in N-term from SHaPrP bound with herapin is absent in our simulation, although, as 
discussed in the Results section, the conformation of each single OR is similar to that of the NMR 
structure393 and it is present in our simulation. Hence, we suggest that the binding of the POM2 Fab 
antibody and herapin to the OR involves an “induced fit” mechanism420, since the resulting OR 
conformations are not formed before binding. 
Our test simulations on full-length WT MoPrPC (discussed below), the above-mentioned !-
strand structure in residues 119-122 (denoted !0, hereinafter) extends the two-strand !-sheet in the 
GD into a three-strand antiparallel !-sheet. Such extension has been reported previously in the 
crystal structure of HuPrPC bound with an antibody (Abskharon et al., unpublished data) and in the 
all-atom MD simulations on truncated SHaPrPC at acidic pH348 or upon the G131V or M129V 
mutations in truncated SHaPrPC345. Our simulations on full-length WT MoPrPC and N-term_MoPrP 
show that !0 can be formed with or without the GD (Table 6.3 and Table A3.4 in Appendix 3), 
suggesting the propensity of residues 119-126 to form transient !-strand. The occurrence of !0 
along with other !-sheet structures within residues 100-128 (Table 6.4) is higher in the P102L 
mutant than that in the other mutants and the WT, which appears to be accompanied by a decrease 
of $-helix in this mutant, consistent with the in vitro data of full-length MoPrPC_P10L412. This was 
not observed in the all-atom MD simulations of a truncated SHaPrPC (90-231) containing this 
PM346, in which, however, the authors pointed out that the discrepancy might be explained by the 
relatively short timescale (4-8 ns) of their MD simulations. 
 
Limitations. As any modeling study, this work has limitations. Firstly, we did not include 
the GD in the calculations. Test calculations on full-length WT MoPrP show that its N-term 
conformational ensemble exhibits very similar features to those of the N-term_MoPrP (Table A3.4 
in Appendix 3). On the one hand, this suggests that the absence of GD does not notably influence 
the conformational ensemble of the N-term. On the other, simulating the full-length MoPrP 
(containing 208 residues) for all of the systems investigated here might face issues of convergence 
and limitations of the accuracy of the force field used. The latter is calibrated for systems much 
smaller than the full-length MoPrP18; 421; 422. Secondly, without explicit water molecules, some 
potentially important questions cannot be addressed, such as the effect of ionic strength. Here, 
however, we stress that the full agreement between available experimental data and our findings 
does validate the computational approach, which has been successfully applied to a variety of 
intrinsically disordered proteins19; 389. 
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6.5 Conclusion 
The seven PMs do not dramatically impact the conformational ensemble. However, they do 
alter the local conformational features in STE/TM1, which are in control of PrP topology during its 
biosynthesis38; 43. This region also contains the estimated binding sites for cellular partners such as 
vitronectin and STI1103; 105. Furthermore, the PMs specifically affect the intra-molecular contacts in 
the OR at the putative binding sites for Cu2+ 383 and sulphated GAG70, as well as in the Cu2+-binding 
site around residue H11190 (Table 6.1). Hence, unlike most of the PMs in the GD, which affect 
HuPrP thermostability and misfolding kinetics156, the PMs at the N-term induce local structural 
modifications in key regions for HuPrP biosynthesis38; 43, for metal binding383 and for interactions 
with other cellular partners14.  
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 Conclusions Chapter 7
Pathogenic mutations in the PrP gene (PRNP in humans or Prnp in other mammalian 
species) are associated with spontaneous generation of TSE328; 329; 330. Polymorphisms (i.e. non-
pathogenic, naturally occurring mutations) in the PrP gene are found to influence the etiology and 
neuropathology of the disease both in humans8 and in sheep9. In transgenic mice, artificial 
mutations could determine the susceptibility to the infection of different prion strains10; 11; 12. In vitro, 
chimeric MoPrP variants (denoted MoPrP chimeras) which contain artificial mutations react very 
differently to PrPSc infection13: some were resistant to the PrPC!PrPSc conversion and others were 
not; some of the resistant mutants even showed dominant-negative effect to protect the endogenous 
WT MoPrPC from the conversion. 
The intriguing roles of these various mutations likely lie in their impact on the molecular 
structure of PrPC, which affects the PrPC!PrPSc conversion and the disease development. 
Understanding the underlining molecular mechanism can revolutionize the research on many other 
neurodegenerative diseases that are major concerns for public health. Structural biology approaches 
such as NMR spectroscopy, although very powerful in studying the structures of PrP variants, are 
relatively slow, and this hampers the progress in probing the roles of different mutations. Moreover, 
experimental methods currently face immense difficulties in studying the intrinsically disordered N-
term of PrP. In this thesis, we addressed these challenging issues by using extensive molecular 
simulation approaches. We investigated the structural features of more than 37 PrPC variants, and 
characterized the impact of pathogenic mutations, polymorphisms and artificial mutations on the 
structural determinants in PrPC. 
First, we investigated the pathogenic missense mutations (point mutations coding for single-
amino acid substitutions) in the HuPrPC GD, aiming to identify their impact on the folded structure 
of HuPrPC. MD simulations were carried out on 30 variants of HuPrPC GD containing pathogenic 
missense mutations (Fig. 4.1 in Chapter 4), using our well-established MD protocol17 that had been 
validated against available NMR structures of HuPrPC WT and mutants. Remarkably, despite the 
diverse location and chemical nature of the mutations, all the mutants turned out to feature common 
structural traits in the GD, distinct from those of the WT and of the protective polymorphism. These 
common traits (relative to the WT) include: i) increased flexibility of the !2-!3 region due to a loss 
of specific intramolecular interactions in this region and between this region and the !1 helix; ii) 
weakened intramolecular contacts in the "2-!2 loop and between the "2-!2 loop and the !3 helix; 
iii) larger solvent exposure of residue Y169 in the "2-!2 loop, especially in the mutants with high 
worldwide incidence. The findings suggest that these regions are the hot spots in HuPrPC structure 
vulnerable to the destabilizing effect of mutations. Altered structural features in these spots may be 
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involved in the early stage of the PrPC!PrPSc conversion. Consistently, a number of other studies 
suggest that the !2-!3 region is metastable under acidic pH256 or high pressure255, and it has high 
tendency to form oligomers352, amyloids351 or fibrils349; 350. The "2-!2 loop and its long-range 
interactions with the C-terminal of !3 helix are likely responsible for the transmission barrier across 
PrPSc strains, as indicated by in vitro and in vivo studies10; 11; 137; 138; 141; 142. Therefore, the "2-!2 loop 
and the C-terminal of !3 helix may form an epitope for molecular recognition by PrPSc and/or other 
interaction partners.  
Encouraged by the above findings, we have then applied the same approach to study the GD 
structure of a group of 11 MoPrP chimeras. Our findings are as follows. i) The specific interactions 
between the N-terminal of !3 helix and the !1 helix are stronger in the resistant chimeras than 
those in the non-resistant chimeras and in the WT MoPrPC. This suggests that strong intramolecular 
interactions in this region are crucial for maintaining the folded GD structure and preventing the 
conformational conversion upon PrPSc infection. This is consistent with the finding in our previous 
study that human pathogenic mutations remarkably deteriorate the intramolecular interactions in 
this region and increase the flexibility of the !2-!3. ii) The chimeras show exchanges between 
different secondary structures in the "2-!2 loop, which can be categorized into two distinct 
patterns, a 310-helix/turn pattern like in MoPrPC and a bend/turn pattern like in HuPrPC. All the non-
resistant chimeras adopt the Mo-like pattern, same as the dominant-negative chimeras. The other 
resistant (non-dominant-negative) chimeras show the Hu-like pattern. Thus, the dominant-negative 
effect occurs when the resistant chimeras adopt the Mo-like pattern in the "2-!2 loop conformation. 
These indicate that the PrPC!PrPSc conversion process requires specific conformation in the PrPC 
"2-!2 loop that is compatible with the PrPSc strain or with some unknown factor. This in turn 
allows the dominant-negative chimeras to interfere with the conversion of the endogenous MoPrPC 
into PrPSc. This agrees with our previous study, which suggests that the "2-!2 loop serves as (part 
of) a recognition site in the disease development.  
Lastly, we investigated the impact of all the 7 Hu TSE-linked missense mutations on the 
structure of the disordered N-term of MoPrP. Using replica-exchange MC simulations and an 
effective all-atom potential for proteins, we were able to obtain the large conformational ensemble 
of the N-term of WT MoPrP and that of the 7 mutants. The N-term turns out to feature an ensemble 
of transient secondary structures, instead of completely disordered conformations. The mutations in 
the N-term do not alter dramatically the conformational ensemble. Unlike the missense mutations in 
the GD that have global impact on the GD structure, these in the N-term cause subtle, local 
structural changes. The changes are mainly in the regions that control PrP topology during its 
biosynthesis and in the residues involved in binding with putative cellular partners. Therefore, these 
mutations may not affect the thermostability of PrPC, which is consistent with in vitro 
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experiments156. Rather, they may cause the diseases by leading to detrimental amount of atypical 
topological species of the protein and/or malfunction of the protein and its partners. 
In conclusion, we have shown that biocomputing is instrumental to provide hints to possible 





Appendix 1 Supplementary materials for Chapter 4 
Appendix 1.1 Test simulations on the histidine protonation state  
We performed 10-ns test MD simulations based on AMBER99 force field423; 424 force field for 
HuPrP(WT) in which either H140, or H155, or H177 or H187 side chain was in the charged state 
(denoted HuPrP(WT_140HIP), HuPrP(WT_155HIP), HuPrP(WT_177HIP) and 
HuPrP(WT_187HIP), respectively). We used the same computational protocol as described in 
Chapter 4, section 4.2.2. Comparison was made with the first 10 ns of MD of HuPrP(WT), in which 
the four histidines are in the neutral state and they are protonated at the N, atom.  
The RMSD of HuPrP(WT) turned out to be slightly smaller than that of 
HuPrP(WT_140HIP), HuPrP(WT_155HIP), HuPrP(WT_177HIP) and HuPrP(WT_187HIP), for 
most of the dynamics (Fig. A1.1.1). A comparison between initial and final MD structures suggests 
that the presence of any positively charged histidine residues affects the conformation of nearby 
segments as well as that of other regions of the proteins (Fig. A1.1.2). Consistently, other MD 
simulations of HuPrP(WT) using the GROMOS96 53 A6 force field425 have shown that the 
fluctuations of HuPrP(WT) along the dynamics are smaller when all the histidines are at their 
neutral state than when they are positively charged294.  
We conclude that the presence of the positively charged histidines causes instability in the 





Figure A1.1.1: RMSD of C! atoms of HuPrP(WT), HuPrP(WT_140HIP), HuPrP(WT_155HIP), 
HuPrP(WT_177HIP) and HuPrP(WT_187HIP) with respect to the initial conformations, plotted as a function 
of simulation time. 
 
 
Figure A1.1.2: Superimposition between initial (blue) and final (red) MD structures of HuPrP(WT), 
HuPrP(WT_140HIP), HuPrP(WT_155HIP), HuPrP(WT_177HIP) and HuPrP(WT_187HIP). The proteins are 
represented in cartoons. Charged histidine residues are shown in ball-and-sticks. 
 
Appendix 1.2 ADI versus RMSF 
In Chapter 4, section 4.2.3, we state that ADI has three advantages over RMSF. In the 
following paragraph we discuss each of these points. 
-i) ADI needs no fitting of the different configurations along the trajectory to a reference 
structure. Two different conformations of the same protein, sampled with MD, may be compared: a) 
by using atomic coordinates (for example by calculating their RMSF)-, b) by using internal 
coordinates, specifically the dihedral angles of each residue. 
By using atomic coordinates it is necessary to eliminate (or minimize) the effects of rigid 
body movements of one conformation with respect to the other (roto-translations), in order to 
highlight only the effects due to protein rearrangements. This is usually accomplished by fitting one 
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configuration over the other. By using dihedrals angles, instead, roto-translations effects are 
intrinsically removed. Indeed the dihedral angles $ and ( (involving respectively the (C, N, C!, C) 
and (N, C!, C, N) atoms) depend on the position of the last atom with respect to the other three in 
each set of four atoms. Thus they allow to define univocally the residues' internal coordinates. - 
ii) ADI does not suffer for edge effects. 0 The RMSF calculation is preceded by a fitting of the 
different protein configurations. However this is not a straightforward operation, especially when 
the flexibility of the protein is relevant. The standard fitting procedures tend indeed to minimize the 
overlap of most of the protein atoms, leading to a systematic increase of the deviations of the atoms 
in the terminus regions, usually more flexible. So the RMSF exhibits a steady increase for residues 
belonging to these regions. By using the dihedral angles to calculate the residue-by-residue 
flexibility this issue can be overcome: the fitting procedure is avoided and the movements of each 
residue are treated independently from those of the neighboring residues. This can be appreciated 
by analyzing Figure A1.2.1, where the residue-by-residue RMSF (in Å) and ADI calculated from 
MD simulation of HuPrP(PP) are reported. 
 
Figure A1.2.1: Values of RMSF (blue bars, in Å) and ADI (red bars) for HuPrP(PP).  
 
iii) The ADI value for each residue is strictly dependent on the single residue. Figure A1.2.2 
plots the ( values of two residues as a function of simulation time for HuPrP(Q212P-129M). 
A) The residue experiences a transition between two Ramachandran regions. 
B) The residue remains in the same Ramachandran region along the whole trajectory with slight 
fluctuations. 
The corresponding values of ADI and RMSF of C? atoms are reported in Table A1.2.1. The 
values of ADI allow distinguishing between these very different cases: S170 exhibits the largest 










conformational transition. E200 has a lower ADI. It indeed samples only one Ramachandran region 
and remains in the same conformation for the whole simulation. The RMSF values do follow the 
opposite trend (Table A1.2.1).  
 
Table A1.2.1: Measure of flexibility values of ADI and RMSF for selected residues of 
HuPrP(Q212P-129M).  
Residue ADI RMSF (Å) 
S170 0.63 1.20 




Figure A1.2.2: Values of dihedral angle . evolved in residue S170 (top) and E200 (bottom) during the MD 
trajectory of HuPrP(Q212P-129M). 
 
The reason for such discrepancy can be explained by Fig. A1.2.3, where the values of RMSF 
and ADI for all the residues of the considered mutant are compared. Arrowheads point to the above-
mentioned residues S170 and E200: they both fall in the more flexible loop regions (the "2-!2 and 
the !2-!3 loops respectively). As a consequence, their RMSF values, being influenced by those of 
the neighboring residues, are larger, while their ADI values are specific of these residues and very 








Appendix 1.3 The SB network in the HuPrP variants 
Table A1.3.1: The dSB (nm) values (defined in Chapter 4, section 4.2.3) calculated for the main 
clusters extracted from the MD trajectory of each HuPrP variant, which covered ~80% of the entire 
conformer population in the trajectory. The cluster configurations of E207-K204 and E200-K204 in 
HuPrP(WT) and HuPrP(PP) correspond to SBs alternatively formed and broken: K204 side chain 
switched indeed from a conformation closed to E200 to another closed to E146. Consistently, K204 
is in a middle position between both in the most populated cluster, close to E200 in the second and 

















61.2 21.7 17.1 72.7 12.4 9.7 5.1 32.4 25.4 22.4 19.7 57.1 28.1 14.8 
Cluster 1 2 3 1 2 3 4 1 2 3 4 1 2 3 
E211-R208 3.9 4.0 3.8 7.0 3.8 4.0 3.9 5.0 7.2 4.7 10.7 4.0 8.1 3.9 
E207-R208 3.9 4.4 4.5 8.8 4.2 4.6 4.8 11.3 8.6 9.9 9.4 4.4 9.6 4.4 
E207-K204 10.1 9.7 10.5 3.5 5.7 3.4 9.4 3.5 9.7 6.6 4.5 9.9 3.3 9.5 
E200-K204 9.3 3.7 9.2 11.1 11.6 10.9 5.1 12.7 11.0 4.0 10.3 5.7 8.8 3.7 
E146-K204 7.8 8.4 3.5 13.2 10.9 11.7 12.5 13.1 5.0 14.0 11.8 4.6 13.2 11.4 















55.9 30.4 13.7 74.1 14.9 11.0 53.9 25.3 20.8 72.9 15.4 11.6 58.3 27.6 14.1 
Cluster 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
E211-R208 9.1 4.0 3.9 8.3 8.9 8.7 10.3 9.5 9.5 7.6 4.4 4.0 8.6 8.0 7.8 
E207-R208 10.0 4.2 4.3 10.3 10.7 10.0 9.5 9.3 8.3 10.1 8.7 4.2 12.4 10.3 10.3 
E207-K204 3.2 9.0 3.5 8.5 3.7 3.2 7.9 3.2 3.3 10.9 10.7 6.6 9.5 11.0 8.2 
E200-K204 9.1 6.3 10.3 7.6 10.4 9.6 9.5 17.4 9.2 8.5 4.6 6.9 7.0 4.9 5.0 
E146-K204 13.6 13.8 12.0 9.5 12.6 16.3 9.1 11.8 10.6 6.3 7.3 12.6 11.9 9.3 10.7 

















59.2 16.9 15.1 8.8 62.7 16.0 15.2 6.1 57.7 37.0 5.3 83.2 11.0 5.8 
Cluster 1 2 3 4 1 2 3 4 1 2 3 1 2 3 
E211-R208 8.9 6.9 4.5 9.4 9.5 9.3 4.8 10.0 9.7 10.0 9.2 8.8 3.9 3.8 
E207-R208 10.0 9.6 9.9 9.3 8.9 9.8 8.7 7.8 8.4 9.9 9.1 11.6 4.3 6.4 
E207-K204 8.7 8.6 3.5 8.3 8.0 9.7 5.9 3.6 8.0 8.3 9.9 14.1 10.7 9.5 
E200-K204 3.6 3.9 10.3 10.2 5.7 5.2 10.5 8.1 7.0 3.7 4.4 14.5 9.6 10.1 
E146-K204 14.4 11.6 11.9 8.8 6.4 6.3 9.3 9.0 14.0 13.4 15.3 3.3 7.4 3.7 














66.8 23.3 9.9 54.5 23.0 22.4 63.5 24.3 12.2 40.4 36.0 23.4 80.1 11.2 8.7 
Cluster 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
E211-R208 9.4 10.2 4.9 10.8 10.5 10.7 7.8 4.6 4.8 8.9 9.2 4.0 8.5 8.7 3.7 
E207-R208 8.7 8.9 11.5 9.9 10.8 9.1 12.3 11.1 10.4 7.0 9.1 8.0 9.5 8.7 4.4 
E207-K204 9.5 3.5 14.8 3.9 6.0 3.8 15.6 14.3 9.3 3.6 3.8 8.2 8.8 9.9 7.5 
E200-K204 10.1 9.0 13.0 11.5 8.6 9.5 12.0 14.5 12.5 12.4 10.8 8.6 8.2 5.6 9.1 
E146-K204 3.7 12.6 3.4 12.0 11.2 13.3 3.7 6.8 13.7 11.7 11.6 9.2 5.9 7.2 7.1 













59.5 25.5 15.0 60.1 23.1 9.6 7.3 68.9 23.0 8.2 55.7 36.8 7.5 58.9 37.5 13.6 
Cluster 1 2 3 1 2 3 4 1 2 3 1 2 3 1 2 3 
E211-R208 9.4 3.8 4.3 4.6 4.1 4.5 4.9 10.3 7.0 8.4 8.3 10.0 7.0 9.5 8.9 10.1 
E207-R208 9.7 4.5 6.9 9.5 8.7 8.1 9.4 9.8 6.2 9.5 10.3 10.1 9.0 9.4 8.1 9.1 
E207-K204 3.6 9.8 9.4 10.2 8.7 9.4 10.3 8.2 3.5 3.5 3.7 8.3 9.3 3.6 9.6 9.1 
E200-K204 8.2 7.0 9.6 - - - - 14.8 13.7 11.6 9.0 3.6 4.7 8.8 7.0 6.4 
E146-K204 3.5 10.6 6.6 3.5 7.7 5.4 5.6 7.3 14.0 12.9 13.3 14.1 11.3 11.8 8.0 8.6 














45.3 29.6 25.1 69.4 18.5 12.1 52.6 24.6 22.8 60.3 29.3 10.4 47.8 20.8 18.7 
Cluster 1 2 3 1 2 3 1 2 3 1 2 3 1 2 3 
E211-R208 - - - - - - 4.8 10.2 8.2 3.8 3.9 7.8 - - - 
E207-R208 - - - - - - 4.4 8.1 7.2 4.4 4.3 9.8 9.4 4.9 9.0 
E207-K204 6.6 11.0 8.5 8.2 8.4 7.2 3.9 3.5 3.4 8.6 8.8 3.7 3.4 11.2 3.3 
E200-K204 9.9 10.4 11.3 6.9 6.8 5.5 10.1 10.7 9.4 7.6 3.5 9.7 7.4 10.1 7.0 
E146-K204 10.6 6.8 10.5 11.5 11.8 11.8 12.3 9.5 12.3 8.6 11.3 10.4 13.5 4.0 10.7 
















76.0 14.2 9.8 72.2 13.3 7.9 6.6 61.2 25.8 13.0 60.6 29.4 10.0 
Cluster 1 2 3 1 2 3 4 1 2 3 1 2 3 
E211-R208 3.8 9.7 7.1 8.5 4.6 3.8 9.8 9.6 9.7 10.5 5.1 5.0 5.1 
E207-R208 3.9 7.4 11.1 10.0 9.2 4.0 8.2 10.9 9.6 9.3 3.5 3.6 3.6 
E207-K204 9.7 9.8 4.0 8.6 5.4 11.5 8.1 6.9 3.9 7.5 9.7 9.9 8.8 
E200-K204 6.4 3.8 9.5 8.9 10.8 4.4 8.8 9.5 12.1 10.1 5.9 3.5 9.4 
E146-K204 10.8 11.3 11.4 5.2 10.0 9.1 4.7 10.9 10.9 8.9 4.6 11.1 4.7 




Appendix 2 Supplementary materials for Chapter 5 
  
 
Figure A2.1: RMSD of the C! atoms of MoPrP, HuPrP and all the CMPrP with respect to the initial models, 
plotted as a function of simulation time. Three independent MD runs in each system are shown in black, red 
and green, respectively. 
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Appendix 2.1 Test simulations on the histidine protonation state 
 We carried out 20-ns MD simulations on 7 forms of the WT MoPrP in explicit solvent. These 
forms differed from each other in the protonation state of the 3 histidines (H140, H177 and H187) 
present in MoPrP GD (Table A2.1.1). The simulation method was the same as that described in 
Chapter 5, section 5.2.2. All the systems appeared to reach equilibrium within 10 ns of MD, as 
indicated by the RMSD of C! atoms as a function of simulation time (data not shown). The RMSF 
of C! atoms in each system (Fig. A2.1.1) were then calculated from the last 10 ns of the 
simulations. 
 MoPrP_HIE, in which all the 3 histidines were in neutral state and protonated at the N, 
atoms (Table A2.1.1) turned out to have the smallest RMSF (Fig. A2.1.1a). The other systems 
showed much larger RMSF (Fig. A2.1.1b-e) than MoPrP_HIE. We concluded that MoPrP is likely 
to exist in the HIE form in solution at pH 7. This is the same protonation state as that of HuPrP at 
pH 7. This result was not unexpected since these histidines have the same local environment as 
those in HuPrP. 
 
Table A2.1.1: Protonation statei of the 3 histidines in the 7 forms of MoPrP considered here in 
Appendix 2.1.  
Form HIE 140HID 177HID 187HID 140HIP 177HIP 187HIP 
H140 N, N, N, N, N,, N, N, N, 
H177 N, N, N, N, N, N,, N, N, 
H187 N, N, N, N, N, N, N,, N, 





Figure A2.1.1: RMSF of C! atoms of the 7 forms of MoPrP in different histidine protonation states during 10 
ns of equilibrated test simulations. a-d) Three independent runs were carried out on each neutral state. On 
average, the HIE state gave the smallest RMSF. e) Three charged states showed apparent larger RMSF 
compared to the HIE state, therefore only one run was performed on these charged states. 
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Appendix 3 Supplementary materials for Chapter 6 
 
Figure A3.1: Combined histogram of energy at different temperatures during a typical run of our simulations. 
The observed energy distribution is unimodal at each temperature and there is a substantial overlap in the 
energy histogram at any pair of consecutive temperatures, leading to a high acceptance probability for the 
replica exchange move. In the systems examined in this study, there were no observed bottle-necks 
complicating the flow of replicas across the temperatures. 
 
 
Figure A3.2: The random walk of a representative replica (in a typical run) in the temperature space of our 
simulations. Our simulation runs are long enough to permit several round trips of each replica from one 





Figure A3.3: Cumulative averages of a) Rg and b) selected SS contents as a function of the MC frames of N-
term_MoPrP and the PMs at 293 K. The color code in b) is: $-helix (blue), !-sheet (green), !-turn (red) and 
bend (cyan). 
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Table A3.1: Content of transient secondary structure (SS) elements (in %i) in N-term_MoPrP averaged over 
the REMC simulation trajectory at 293 K, 306.5 K and 313.5 K, respectively. 
REMC $-helix !-sheet !-bridge "-turn Bend 310-helix *-helix Coil 
293 K 19±8 8±5 7±3 27±5 12±4 4±3 1±1 25±5 
306.5 K 14±8 6±6 6±3 28±4 15±3 5±4 0±2 31±6 
313.5 K 11±8 5±6 6±5 28±6 16±5 5±4 0±1 34±6 









Figure A3.4: a) The intrinsic disorder disposition of MoPrPC N-terminal residues (23-128, here in Mo 
numbering) predicted by PONDR-FIT. b) Predictions of SS in N-term_MoPrP using five different 
bioinformatics tools, PSIPRED398, Jpred3399, Porter400, RaptorX401 and CABS-fold402. The letter code for 




Figure A3.5: Backbone flexibility per residue in WT and mutated N-term_MoPrP calculated using the ADI 
analysis305 over the frames sampled from the production trajectories. The higher the ADI value, the more 
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Figure A3.6: Flexibility of backbone units of residues 100-128 measured by the ADI analysis 305. The SDs in the 10 simulation runs of each system are indicated with 
vertical bars. 
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Figure A3.7: Total number of intra-molecular contacts per residue in the WT and mutated N-term_MoPrP. The SDs in the 10 simulation runs of each system are indicated 









Appendix 3.1 Intra-molecular contacts in the WT and mutated N-term_MoPrP 
Figure A3.1.1: Contact maps illustrating the intra-molecular interactions in the N-term_MoPrP and PMs. For each protein, the 10 most populated clusters are shown. 
Contacts within 6 Å are plotted in white. Residue numbers are labeled in the contact map of N-term_MoPrP cluster 1 and are the same for all the other contact maps.  
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   Figure A3.1.1-1: Contact maps of N-term_MoPrP.  
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Figure A3.1.1-3: Contact maps of N-term_MoPrP_P102L.  
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Figure A3.1.1-4: Contact maps of N-term_MoPrP_P105L.  
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Figure A3.1.1-5: Contact maps of N-term_MoPrP_P105S.  
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Figure A3.1.1-6: Contact maps of N-term_MoPrP_P105T.  
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Figure A3.1.1-7: Contact maps of N-term_MoPrP_G114V.  
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Figure A3.1.1-8: Contact maps of N-term_MoPrP_A117V.    
 
     
 135 
Table A3.1.1: Clustering based on contact maps of N-term_MoPrP and PMs conformations 
sampled from the production trajectories.  
Cluster Population Rg (Å)i Population Rg (Å) Population Rg (Å) Population Rg (Å) 
 N-term_MoPrP N-term_MoPrP_Q52P N-term_MoPrP_P102L N-term_MoPrP_P105L 
1 17.1% 19.8±3.0 34.3% 16.5±1.3 19.0% 19.8±2.7 19.7% 17.8±2.5 
2 13.1% 19.3±3.0 7.6% 19.6±2.7 13.5% 19.8±2.8 13.9% 20.2±2.9 
3 12.2% 16.0±1.3 6.1% 15.8±0.8 11.7% 17.2±2.5 8.5% 20.29±3.10 
4 5.6% 15.7±1.2 5.4% 20.1±2.6 10.1% 20.5±2.8 6.7% 20.0±2.4 
5 5.5% 19.2±2.8 4.8% 19.4±2.9 5.4% 21.0±3.2 5.8% 20.2±2.9 
6 5.4% 18.8±2.4 4.3% 14.7±1.5 3.0% 20.1±3.0 4.3% 20.0±3.0 
7 3.7% 19.2±2.8 3.2% 16.8±2.2 2.2% 20.5±2.5 3.6% 20.0±2.9 
8 2.9% 19.1±3.0 2.9% 16.0±1.7 2.1% 20.2±3.2 3.6% 18.6±2.6 
9 2.6% 18.2±2.3 2.7% 16.6±1.4 2.0% 20.0±2.6 3.5% 17.0±1.3 
10 2.6% 18.9±2.5 2.0% 16.1±1.2 1.8% 19.6±2.8 3.3% 20.9±2.7 
Total 70.5%  73.1%  70.7%  72.7%  
 N-term_MoPrP_P105S N-term_MoPrP_P105T N-term_MoPrP_G114V N-term_MoPrP_A117V 
1 42.4% 20.6±2.5 22.6% 20.1±3.0 16.0% 19.0±3.2 21.8% 19.8±3.0 
2 5.0% 16.6±1.1 18.8% 19.9±3.0 10.7% 19.6±3.0 10.0% 18.4±2.4 
3 3.9% 20.9±2.5 7.0% 19.9±3.1 9.2% 19.9±3.1 8.7% 19.7±3.2 
4 3.7% 20.3±2.8 5.6% 18.6±2.4 8.2% 17.9±2.5 6.8% 19.5±3.2 
5 3.5% 20.8±2.8 4.1% 19.7±3.0 7.9% 18.9±2.4 6.0% 17.2±1.4 
6 3.3% 19.7±2.6 3.4% 20.0±2.8 5.6% 19.9±2.8 4.9% 19.2±3.5 
7 3.0% 21.0±3.0 3.0% 19.0±2.2 4.1% 18.4±3.4 4.2% 17.7±2.2 
8 20.% 21.2±2.5 2.4% 19.6±2.5 3.5% 16.4±1.2 3.6% 19.1±2.9 
9 1.9% 19.1±1.9 2.2% 18.8±3.0 2.7% 19.6±2.7 2.8% 19.8±3.1 
10 1.9% 20.8±2.5 2.0% 17.4±1.4 2.6% 17.3±3.1 2.7% 17.2±2.2 
Total 70.5%  71.0%  70.3%  71.2%  
i Standard deviations (SDs) of Rg are indicated by “±”. 
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Table A3.2: Four different hydrophobicity scales for amino acid residues in proteins.  From the top 
to the bottom the hydrophobicity decreases gradually.  














































































































Table A3.3: Sequence Identity (in %) between HuPrP and PrP of Mo, SHa and bovine (Bv) 
species. The residues involved in PMs in the N-term are fully conserved.  
 Domain (residues in HuPrP) 
 Full-length (23-230) N-term (23-124) OR (51-91) 
MoPrP 90 93 90 
SHaPrP 90 98 98 
BoPrP 90 89 100i 





Table A3.4: Average content of transient SS elements (in %i) in the N-term obtained by our 
simulation of the full-length MoPrP.  
Residues !-helix "-sheet "-bridge "-turn Bend 310-helix #-helix Coil 
N-term (23-128) 19±8 8±6 7±3 27±5 11±4 4±3 0±2 24±5 
23-30 4±3 3±2 6±3 17±5 10±3 2±2 1±1 56±9 
31-50 8±4 7±6 12±5 32±6 12±4 5±3 0±1 24±5 
51-91 (OR) 6±2 13±6 9±3 38±6 12±3 5±3 0±2 18±5 
90-99 4±2 15±6 5±3 22±4 17±5 3±2 0±2 34±8 
100-118 65±10 2±2 1±0 6±3 7±3 2±4 0±1 17±6 
119-126 32±8 4±6 2±3 32±8 9±4 4±3 1±1 16±5 
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